march shareholders alex gorsky chairman board director chief executive officer ask lead work well proof health care chose spend success johnson johnson achieve company career johnson johnson deliver solid financial result fullyear well job janssen flagship company sale billion adjust net position pharmaceutical segment current earning billion continue help meet role company chairman ceo investment accelerate growth urgent year later answer begin long term need credo johnson please performance johnson simple powerful document pen know rest general robert wood johnson son provide sustainable highquality health care founder company chairman society great challenge credo outline company commitment responsibility people unprecedented era human history community touch day historic aging rate world population product service year grow middle class serve moral compass world bring dramatically great demand johnson johnson ensure lose high quality health care government sight strong value important health system manage need stakeholder serve increasingly strain resource consider credo johnson johnson credo compel visionary statement corporate purpose innovate area unmet write medical need overcome barrier advance chairmans letter ihealth care corner world world today require good involve prevent spread deadly johnson johnson offer infectious disease solve twin challenge constantly strive come way overnutrition undernutrition lead innovate lead deliberate breakthrough medical research empower choice portfolio focus citizen responsibility manage energy capture great opportunity health wellness advance patient care confident future company well position johnson johnson reason help meet urgent need johnson johnson core business strong position continue expand give progress business leadership past year evolve exciting deep product approach place great emphasis pipeline entire enterprise innovation accelerate growth continue change way interact commitment excellence execution non customer negotiable process evolve structure effective efficient drive growth succeed clear goal priority approximately grow pipeline interconnect global society people come year pharmaceutical pipeline live business come realize work poised yield consistent flow new product travel world filing allow bring new medicine johnson johnson health care local operating technology patient continue personal approximately company build pipeline order stay people work operating company country forefront country broad range medical specialty community health need lead consumer health care market unique insight capability aim expand leadership target help address formidable challenge market holistically address criticalneed proud colleague state overthecounter medicine globe focus oral care baby skin care market single day care world person time strengthen position medical device focus accelerate growth large diversified health innovative product transform care company world gotomarket model well serve opportunity responsibility help meet customer patient challenge boldness vision drive chairmans lettersense purpose acknowledge value come life way credo embrace responsibility way company endure competitive advantage constant significantly effort reminder address ebola epidemic believe work health care work exceptional collaboration global honor privilege think health community substantially accelerate well place carry incredible work value production ebola vaccine regimen johnson johnson thank commit goal bring vaccine approve small legacy general robert wood uphold family frontline health care johnson credo professional risk quickly possible thank continue support credo constant reminder work investment johnson johnson value commit uphold value strive sincerely real energy passion care hard work single day join longterm driver growth create value innovation expand alex gorsky global reach local focus maintain laser chairman board director focus excellence execution lead chief executive officer purpose difference world chairman letter iiiour credo action year review dar salaam tanzania johnson johnson partners ccbrt kupona foundation provide support rehabilitation people disability result childbirth injury obstetric fistula remove barrier medical care treatment power credo unite shortage million health care professional people johnson johnson world poor country step collaborate multinational coalition common set principle country develop new generation nurse mid helpful framework understand wife pharmacist community health worker fill approach drive growth meeting gap commitment support nurse give educational grant nursecom need stakeholder continue education resource ebola available please highlight key achievement nurse date nurse take virtual training alex gorsky chairman board director chief executive officer deliver new product offer significant advancement customer insight believe responsibility doctor drive approach innovation continuously nurse patient mother father adjust product brand portfolio meet use product service exceed expectation strong pipeline recognition important responsibility expect yield key consumer product launch johnson johnson support training protect globally new major medical device product health care worker line help filing major new people great need care service pharmaceutical filing line extension world health organization estimate photo mark tuschman credo actionwe responsible employee men johnson johnson innovation center woman work world locate major science technology hub care world person time unite london boston jolla shanghai keep inspire people johnson johnson include forefront new idea scientific breakthrough approximately employee globe jlab string attach incubator lead way manage health stimulate total innovation ecosystem help young wellness employee program forefront company pioneer idea ground industry decade research prove healthy company productive profitable final responsibility shareholder company health wellness program operate accord principle help employee reduce risk factor stockholder realize fair return key health measure half country gratifying shareholder support general population include area smoke year build worldwide high blood pressure high cholesterol inactivity business extend reach improve live people employee engagement johnson johnson alltime high continue measure rate strong performance enable meet external benchmark meet talent commitment shareholder engagement objective retain key talent strengthen talent pipeline improve employee engagement reputational standing measure credo survey employee responsible community consecutive year consecutive year live work world community dividend increase adjust earning commitment transform live patient increase community include contribution billion product cash year support aaa program address major healthrelate industrial issue local community country company hold aaa credit rating world great progress healthy future citizenship sustainability goal include effort global health environment responsible transparent business practice experiment new idea research development productivity leading industry approach design ensure continue lead year invest industry sale come brand platform lead billion execute global generate strategic partnership license acquisition market share position billion sale apiece pharmaceutical medical device consumer segment nongaap measure exclude special item credo action business highlight strong year johnson johnson deliver solid financial result continue investment accelerate growth long term build significant momentum pharmaceutical business realize benefit innovation scale breadth medical device business continue market leadership iconic brand consumer business achieve nearterm priority exceed financial target fullyear operational sale growth percent exclude net impact acquisition divestiture operational basis worldwide sale increase percent pharmaceutical golimumab remicade infliximab biologics worldwide pharmaceutical sale billion approve treatment number immune fullyear represent operational growth mediate inflammatory disease percent new medicine launch pharmaceutical segment fastest come innovation ensure grow pharmaceutical business continuous access new idea product europe japan medicines early stage expect good science prevail make dramatic impact regardless come source inside outside johnson johnson strong sale result drive new product significant acquisition add innovation strength core product new product portfolio alios biopharma inc privatelyheld clinical include olysiosovriad simeprevir stage biopharmaceutical company focus develop combination treatment chronic hepatitis adult therapy viral disease covagen privately patient xarelto rivaroxaban oral anticoagulant hold biopharmaceutical company specialize zytiga abiraterone acetate oral oncedaily development multispecific protein therapeutic medication use combination prednisone fynomab technology platform treatment metastatic castrationresistant prostate cancer invokana canagliflozin treatment medical device adult type diabete imbruvica ibrutinib worldwide medical device sale billion oral oncedaily therapy approve use treat fullyear represent operational decrease certain bcell malignancy blood cancer percent exclude net impact acquisition divestiture operational basis worldwide sale additional contributor operational sale growth increase percent stelara ustekinumab biologic approve treatment moderate severe plaque psoriasis medical device business hold strong leadership psoriatic arthritis invega sustennaxeplion position industry include platform paliperidone palmitate oncemonthly longacte billion sale launch major injectable atypical antipsychotic treatment new product major schizophrenia adult simponisimponi aria new filing plan end business highlightsprimary contributor operational growth broad year launch new product portfolio orthopaedic product biosense webster include women rogaine zyrtec dissolve tab electrophysiology product cardiovascular care new formulation listerine business biosurgical international sale relaunche brand tylenol energy product specialty surgery business insightdriven innovation consumer business sale result vision care diabete care focus address key consumer need state lead business negatively impact competitive megabrand new product launch pricing dynamic plan key approval launch year include citizenship sustainability food drug administration fda approval manage social environmental economic animas vibe insulin pump continuous impact locally globally important responsibility glucose monitoring system management citizenship sustainability strategic priority focus insulinrequiring diabete adult age old effort advance global health help safeguard incraft aaa stent graft system approve planet lead dynamic grow business launch treatment abdominal aortic responsibly aneurysm aaa europe canada saber pta dilatation catheter treatment patient continue progress healthy peripheral arterial disease receive fda future goal include leverage research european commission approval fda approve development ability innovate collaborate thermocool smarttouch catheter find solution global health issue response treatment patient suffer drugresistant ebola crisis collaboration national paroxysmal atrial fibrillation institutes health bavarian nordic committed accelerate vaccine program stop june company complete partnership global drug facility usaid divestiture orthoclinical diagnostic business expand access multidrugresistant carlyle group approximately billion tuberculosis compound sirturo expand collaboration international partnership consumer microbicide development commercialization worldwide consumer sale billion dapivirine prevention sexual transmission hiv year represent operational increase working viiv healthcare develop percent exclude net impact acquisition twodrug single tablet regimen maintenance treatment divestiture operational basis worldwide sale people live hiv increase percent legacy care environment protection positive contributor operational result sale natural resource continue work tylenol motrin analgesic zyrtec reduce energy consumption increase allergy overthecounter product aveeno proportion energy use renewable source neutrogena skin care product listerine reduce carbon dioxide emission oral care product continue look way reduce water consumption business highlight vii business highlight waste production product lifecycle health woman child include work support example continue integrate expand millennium development goal addition earthward approach drive continuous expand program mobile technology sustainability improvement innovation way disperse health information new expectant business date product mother south africa india announce gain earthward recognition ahead global partnership save child goal potential help improve survival healthy development million child age remain committed enhance transparency year engagement stakeholder serve improve health patient drive improve clinical outcome commitment transforming live patient announce extended agreement yale community include contribution open datum access yoda project provide access approximately billion product cash year clinical trial datum pharmaceutical medical device support program address major product set new industry standard healthrelate issue local community company ongoing effort improve country world nongaap measure reconciliation nongaap financial measure page annual report operational measure exclude impact currency translation ims midas datum growth versus previous year move annual total local currency dollar note forwardlooke statement chairman letter business highlight section contain forwardlooke statement relate thing business strategy performance expectation product development reader caution rely statement review section cautionary factor affect future result annual report important information statement include risk uncertainty factor cause actual result vary materially assumption expectation projection express forwardlooke statement johnson johnson undertake update forwardlooke statement result new information future event development viii business highlightstable content managementsdiscussionandanalysis ofresult ofoperationsandfinancialcondition organizationandbusinesssegment resultsofoperation analysisofsalesbybusinesssegment analysisofconsolidatedearningsbeforeprovisionfortaxesonincome liquidityandcapitalresource otherinformation cautionaryfactorsthatmayaffectfutureresult auditedconsolidatedfinancialstatement consolidatedbalancesheet consolidatedstatementsofearning consolidatedstatementsofcomprehensiveincome consolidatedstatementsofequity consolidatedstatementsofcashflow notestoconsolidatedfinancialstatement reportofindependentregisteredpublicaccountingfirm managementsreportoninternalcontroloverfinancialreporte supportingschedule summaryofoperationsandstatisticaldata shareholderreturnperformancegraph reconciliationofnongaapfinancialmeasure johnsonjohnsonannualreport management discussion analysis result operation financial condition organization business segment descriptionofthecompanyandbusinesssegment johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldthecompany conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand wellbee thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicespreviously referredtoasmedicaldevicesanddiagnosticstheconsumersegmentincludesabroadrangeofproductsusedinthe babycareoralcareskincareoverthecounterpharmaceuticalwomenshealthandwoundcaremarketsthese productsaremarketedtothegeneralpublicandsoldbothtoretailoutletsanddistributorsthroughouttheworldthe pharmaceuticalsegmentisfocusedonfivetherapeuticareasincludingimmunologyinfectiousdiseasesneuroscience oncologyandcardiovascularandmetabolicdiseasesproductsinthissegmentaredistributeddirectlytoretailers wholesalershospitalsandhealthcareprofessionalsforprescriptionusethemedicaldevicessegmentincludesabroad rangeofproductsusedintheorthopaedicsurgicalcarespecialtysurgerycardiovascularcarediagnosticsdiabete careandvisioncaremarketswhicharedistributedtowholesalershospitalsandretailersandusedprincipallyinthe professionalfieldsbyphysiciansnurseshospitalsandclinic thecompanysstructureisbasedupontheprincipleofdecentralizedmanagementtheexecutivecommitteeof johnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategicoperationsandallocationofthe resourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesoftheconsumerpharmaceuticaland medicaldevicesbusinesssegment inallofitsproductlinesthecompanycompeteswithcompaniesbothlocallyandgloballythroughouttheworld competitionexistsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolve competitioninresearchinvolvingthedevelopmentandtheimprovementofnewandexistingproductsandprocessesis particularlysignificantthedevelopmentofnewandinnovativeproductsisimportanttothecompanyssuccessinall areasofitsbusinessthisalsoincludesprotectingthecompanysportfolioofintellectualpropertythecompetitive environmentrequiressubstantialinvestmentsincontinuingresearchinadditionthedevelopmentandmaintenanceof customerdemandforthecompanysconsumerproductsinvolvessignificantexpendituresforadvertisingandpromotion managementsobjective thecompanymanageswithinastrategicframeworkwithourcredoasthefoundationthecompanybelievesthatour strategicoperatingprinciplesbeingbroadlybasedinhumanhealthcaremanagingthebusinessforthelongterma decentralizedmanagementapproachandcommitmenttoourpeopleandvaluesarerequiredtosuccessfullymeetthe demandsoftherapidlyevolvingmarketsinwhichwecompetetothisendmanagementisfocusedonourgrowthdriver creatingvaluethroughinnovationexpandingourglobalreachwithalocalfocusexcellenceinexecutionandleadingwith purpose thecompanyengagesinareasofhumanhealthcarewherethereisanopportunitytomakeameaningfuldifferenceand iscommittedtocreatingvaluebydevelopingbroadlyaccessiblehighqualityinnovativeproductsandservicesnew productsintroducedwithinthepastfiveyearsaccountedforapproximatelyofsalesinbillionor ofsaleswasinvestedinresearchanddevelopmentreflectingmanagementscommitmenttodeliveringnewand differentiatedproductsandservicestomeetevolvinghealthcareneedsandsustainthecompanyslongtermgrowth ourdiversebusinesseswithmorethanoperatingcompanieslocatedincountriesarethekeydriversofthe companyssuccessmaintainingthecompanysdecentralizedmanagementapproachwhileatthesametimeleveraging theextensiveresourcesoftheenterpriseuniquelypositionsthecompanytoinnovateexecuteandreachmarketsglobally whilefocusingontheneedsandchallengesofthelocalmarket johnsonjohnsonannualreportinordertoremainaleaderinhealthcarethecompanystrivestomaintainapurposedrivenorganizationandiscommitte todevelopingglobalbusinessleaderswhocanachievethesegrowthobjectivesbusinessesaremanagedforthe longterminordertosustainmarketleadershippositionsandenablegrowthwhichprovidesanenduringsourceofvalue toourshareholder ourcredounifiesalljohnsonjohnsonemployeesinachievingtheseobjectivesandprovidesacommonsetofvalue thatserveasthefoundationofthecompanysresponsibilitiestoitscustomersemployeescommunitiesandshareholders thecompanybelievesthatthesebasicprinciplesandgrowthdriversalongwithitsoverallmissionofimprovingthequality oflifeforpeopleacrosstheglobewillenablejohnsonjohnsontocontinuetobealeaderinthehealthcareindustry result operation analysisofconsolidatedsale inworldwidesalesincreasedtobillioncomparedtoincreasesofinandin thesesaleschangesconsistedofthefollowe salesincreasedecreasedueto volume price currency total insalesofthecompanyshepatitiscproductsolysiosovriadsimeprevirandincivotelaprevirhad apositiveimpactofandthedivestitureoftheorthoclinicaldiagnosticsbusinesshadanegativeimpactofon theworldwideoperationalgrowththeacquisitionofsynthesincnetoftherelateddivestitureincreasedworldwide operationalgrowthbyandinandrespectively salesbyuscompanieswerebillioninbillioninandbillioninthisrepresentsincrease ofininandinsalesbyinternationalcompanieswerebillioninbillion inandbillioninthisrepresentsincreasesofininandin thefiveyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectivelythetenyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectively salesineuropeachievedgrowthofascomparedtotheprioryearincludingoperationalgrowthofpartially offsetbyanegativecurrencyimpactofsalesinthewesternhemisphereexcludingtheusexperiencedadecline ofascomparedtotheprioryearincludingoperationalgrowthofoffsetbyanegativecurrencyimpactof salesintheasiapacificafricaregionachievedgrowthofascomparedtotheprioryearincludingoperational growthofandanegativecurrencyimpactof inthecompanyhadonewholesalerdistributingproductsforallthreesegmentsthatrepresentedapproximately ofthetotalconsolidatedrevenuesinandthecompanydidnothaveacustomerthatrepresente ormoreoftotalconsolidatedrevenue ushealthcarereform undertheprovisionsofthepatientprotectionandaffordablecareactandthehealthcareandeducationreconciliation actofbeginninginthecompanybeganpayingataxdeductibleexcisetaximposedonthesaleof certainmedicaldevicesthefullyearimpactoftheexcisetaxwasapproximatelymillioninandmillionin onjulytheinternalrevenueserviceissuedfinalregulationsforthebrandedprescriptiondrugfeeanannual nontaxdeductiblefeeimposedonentitiesengagedinthebusinessofmanufacturingorimportingbrandedprescription drugscoveredentitiesenactedbysectionofthepatientprotectionandaffordablecareactthefinalregulation acceleratedtheexpenserecognitioncriteriaforthefeeobligationbyoneyearfromtheyearinwhichthefeeispaidtothe yearinwhichthesalesusedtocalculatethefeeoccurthischangeimpactedcoveredentitiesandresultedintheneedfor allentitiestorecordanadditionalexpenseinforthefeethatwouldhaveotherwisebeenexpensedwhenpaidin thecompanyaccruedanadditionalmillioninthefiscalthirdquarterofduetothischangethefee associatedwiththisacceleratedexpensewillbepaidasscheduledinandthereforehadnocashimpactin johnsonjohnsonannualreport analysis sale business segment consumersegment consumersegmentsalesinwerebillionadecreaseoffromwhichincludedoperational growthoffsetbyanegativecurrencyimpactofusconsumersegmentsaleswerebillionadecreaseof internationalsaleswerebillionadecreaseofwhichincludedoperationalgrowthoffsetbya negativecurrencyimpactof majorconsumerfranchisesale change dollarsinmillion otc skincare babycare oralcare woundcareother womenshealth totalconsumersale theoverthecounterotcfranchiseachievedsalesofbillionanincreaseoffromstrongussale growthofwasdrivenbyanalgesicsandupperrespiratoryproductsprimarilyduetocontinuedprogressinreturne asupplyofproductstothemarketplace mcneilppcinccontinuestooperateunderaconsentdecreesignedinwiththeusfoodanddrug administrationfdawhichgovernscertainmcneilconsumerhealthcaremanufacturingoperationstheconsent decreetheconsentdecreerequiresmcneilppctoremediatethefacilitiesitoperatesinlancasterpennsylvaniafort washingtonpennsylvaniaandlaspiedraspuertoricothefortwashingtonfacilitywasvoluntarilyshutdownin aprilhowevermanyproductspreviouslymadeinfortwashingtonhavebeentransferredtoothermanufacture sitesandsuccessfullyreintroducedtothemarketthelancasterandlaspiedrasfacilitiescontinuetomanufactureand distributedrugswiththirdpartyoversightthirdpartyoversightwillceaseoncethefdahasdeterminedthatthefacilitie appeartobeincompliancewithapplicablelawinfebruarythethirdpartyoverseersubmittedwrittencertification tothefdaforallthreemanufacturingsitesthetimelineforcompletionofanyfdainspectioniswithinthefdas discretion theskincarefranchiseachievedsalesofbillionanincreaseofascomparedtotheprioryearprimarilydueto strongresultsfromtheaveenoneutrogenaanddabaoproductlinesthebabycarefranchisesaleswere billioninadecreaseoffromsalesgrowthinlatinamericaandasiapacificwasoffsetbythe impactofnegativecurrencyinalltheregionsoutsidetheustheoralcarefranchisesaleswerebillionanincrease ofascomparedtotheprioryearthegrowthwasdrivenbyincreasedsalesoflisterineproductsasaresultof newproductlaunchesandsuccessfulmarketingcampaignsthewoundcareotherfranchisesaleswerebillionin adecreaseoffromprimarilyduetolowersalesofnutritionalsoutsidetheusthewomenshealth franchisesaleswerebillionadecreaseofprimarilyduetothedivestitureofwomenssanitaryprotection productsintheuscanadaandcaribbeanwhichwascompletedinthefiscalfourthquarterof consumersegmentsalesinwerebillionanincreaseoffromwhichincludedoperational growthandanegativecurrencyimpactofusconsumersegmentsaleswerebillionanincreaseof internationalsaleswerebillionanincreaseofwhichincludedoperationalgrowthandanegative currencyimpactof johnsonjohnsonannualreportpharmaceutical segment thepharmaceuticalsegmentachievedsalesofbillioninrepresentinganincreaseofovertheprior yearwithstrongoperationalgrowthofandanegativecurrencyimpactofussaleswerebillionan increaseofinternationalsaleswerebillionanincreaseofwhichincludedoperationalgrowth andanegativecurrencyimpactofinpharmaceuticalsegmentsalesincludedapositiveadjustmentto previousestimatesformanagedmedicaidrebatesthisnegativelyimpactedpharmaceuticaloperationalsale growthbyascomparedtotheprioryearinsalesofthecompanyshepatitiscproduct olysiosovriadsimeprevirandincivotelaprevirhadapositiveimpactofontheoperationalgrowthof thepharmaceuticalsegment majorpharmaceutical therapeuticareasale change dollarsinmillion totalimmunology remicade simponisimponiaria stelara otherimmunology totalinfectiousdisease edurant incivo olysiosovriad prezista otherinfectiousdisease totalneuroscience concertamethylphenidate invega invegasustennaxeplion risperdalconsta otherneuroscience totaloncology velcade zytiga otheroncology totalother procriteprex xarelto totalpharmaceuticalsale prioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation percentagegreaterthan immunologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yeartheincreasedsalesofstelaraustekinumabandsimponisimponiariagolimumabwereprimarilydue tomarketgrowthandmarketsharegainsremicadeinfliximabgrowthwasprimarilyduetomarketgrowth thepatentsforremicadeincertaincountriesineuropegermanyspainunitedkingdomswedenaustriabelgium switzerlanddenmarkfrancegreeceitalyluxembourgandthenetherlandsexpireinfebruarylossofexclusivity willlikelyresultinareductioninsalesasbiosimilarversionsareintroducedtothemarketseenotetothe consolidatedfinancialstatementsforlegalmattersregardingtheremicadepatent johnsonjohnsonannualreport infectiousdiseaseproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtothe prioryearmajorcontributorstothegrowthwerethelaunchofolysiosovriadsimeprevirprezista darunavirduetomarketgrowthandsalesofedurantrilpivirinethiswaspartiallyoffsetbylowersalesof incivotelaprevirduetocompetitivepressuresandlowersalesofvaccineproductstheapprovalofcompetitive productstoolysiosovriadsimeprevirhadanegativeimpactinthefourthquarterofandisexpectedto continuetohaveasignificantnegativeimpactonfuturesalesofolysiosovriadsimeprevir neuroscienceproductssaleswerebillionadeclineofascomparedtotheprioryearstrongsalesof invegasustennaxeplionpaliperidonepalmitateandinvegapaliperidonepalmitatewerepartiallyoffset bylowersalesofrisperdalconstaadditionallyadeclineinsalesofconcertamethylphenidateand topamaxtopiramatewereduetocontinuedgenericcompetition oncologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yearmajorcontributorstothegrowthwerestrongsalesofzytigaabirateroneacetateaswellastherecentlaunchof imbruvicaibrutinibsalesgrowthofvelcadebortezomibwasmorethanoffsetbynegativecurrency otherpharmaceuticalsaleswerebillionanincreaseofascomparedtotheprioryearstrongsalesof xareltorivaroxabanandinvokanainvokametcanagliflozinwerepartiallyoffsetbylowersalesof aciphexparietrabeprazolesodiumandprocriteprexepoetinalfa duringthecompanyreceivedseveralregulatoryapprovalsincludingtheusfoodanddrugadministrationfda grantedapprovalofimbruvicaibrutinibcapsuleswhichisbeingjointlydevelopedandcommercializedby pharmacyclicsincforthetreatmentofpatientswithchroniclymphocyticleukemiacllwhohavereceivedatleastone priortherapytheeuropeancommissionecgrantedconditionalapprovalforsirturobedaquilineintheeuropean unionforuseaspartofanappropriatecombinationregimenforpulmonarymultidrugresistanttuberculosisinadult patientsthefdaandtheecgrantedapprovalofsylvantsiltuximabforthetreatmentofpatientswithmulticentric castlemansdiseasewhoarehumanimmunodeficiencyvirusnegativeandhumanherpesvirusnegativetheecgrante approvalforvokanametcanagliflozinmetforminhclafixeddosetherapycombiningcanagliflozinandimmediate releasemetforminhydrochlorideinasingletabletforthetreatmentofadultswithtypediabetesolysiosimeprevir forthetreatmentofadultpatientswithgenotypeorchronichepatitiscandforinvegapaliperidoneertoextend itsadultindicationofschizophreniatoincludeadolescentsagedyearsandolderthefdagrantedapprovalforathird indicationforimbruvicaibrutinibforthetreatmentofpatientswithcllwhohavethegeneticmutationpdeletion delpandalsograntedimbruvicaibrutinibfullapprovalforthetreatmentofpatientswithcllwhohavereceive atleastonepriortherapyfdagrantedapprovalforinvokametcanagliflozinmetforminhclforthetreatmentof adultswithtypediabetestheecapprovedimbruvicaibrutinibforthetreatmentofadultpatientswithrelapsedor refractorymantlecelllymphomaandadultpatientswithchroniclymphocyticleukemiawhohavereceivedatleastoneprior therapyorinfirstlineinthepresenceofpdeletionortpmutationinpatientsunsuitableforchemoimmunotherapy theecalsoapprovedrezolstadarunavircobicistatincombinationwithotherantiretroviralmedicinalproductsfor thetreatmentofhumanimmunodeficiencyvirusinfectioninadultsagedyearsorolder thecompanysubmittedseveralnewdrugapplicationsndastothefdaincludinganndaseekingapprovalfora oncedailyfixeddoseantiretroviralcombinationtabletcontainingdarunaviraproteaseinhibitordevelopedbyjanssen rdirelandandmarketedasprezistaintheuswithcobicistataninvestigationalpharmacokineticenhanceror boostingagentdevelopedbygileadsciencesincforuseincombinationwithotherhumanimmunodeficiencyvirus medicinesanndaforthreemonthatypicalantipsychoticpaliperidonepalmitateasatreatmentforschizophreniain adultsandanndaforyondelistrabectedinforthetreatmentofpatientswithadvancedsofttissuesarcoma includingliposarcomaandleiomyosarcomasubtypeswhohavereceivedpriorchemotherapyincludingananthracycline inadditionasupplementalnewdrugapplicationsndawasapprovedbythefdaforolysioincombinationwiththe nucleotideanalognsbpolymeraseinhibitorsofosbuvirdevelopedbygileadsciencesincforthetreatmentofchronic hepatitiscadditionalsndaswerealsosubmittedtothefdaforolysioforthetreatmentofadultpatientsin genotypechronichepatitiscandpatientscoinfectedwithhivoncemonthlyatypicallongactingantipsychotic invegasustennapaliperidonepalmitatewasapprovedtotreatschizoaffectivedisorderaseithermonotherapyor adjunctivetherapyandatypeiivariationapplicationwassubmittedtotheeuropeanmedicinesagencyemaforan additionalindicationofimbruvicaibrutinibforthetreatmentofpatientswithwaldenstrmsmacroglobulinemiaa raretypeofbcelllymphoma amarketingauthorizationapplicationwassubmittedtotheeuropeanmedicinesagencytoexpandthelabelfor velcadebortezomibtoincludeitsuseincombinationwithrituximabcyclophosphamidedoxorubicinandprednisone forthetreatmentofadultpatientswithpreviouslyuntreatedmantlecelllymphoma johnsonjohnsonannualreportpharmaceuticalsegmentsalesinwerebillionrepresentinganincreaseofovertheprioryearwith strongoperationalgrowthofandanegativecurrencyimpactofussaleswerebillionanincreaseof internationalsaleswerebillionanincreaseofwhichincludedoperationalgrowthanda negativecurrencyimpactofthepharmaceuticalsegmentoperationalgrowthwasimpactedbyindueto apositiveadjustmenttopreviousestimatesformanagedmedicaidrebate medicaldevicessegment themedicaldevicessegmentsalesinwerebillionadecreaseoffromwhichincludedan operationaldeclineofandanegativecurrencyimpactofussaleswerebillionadecreaseofas comparedtotheprioryearinternationalsaleswerebillionadeclineofascomparedtotheprioryearwith operationalgrowthofoffsetbyanegativecurrencyimpactofinthedivestitureoftheorthoclinical diagnosticsbusinesshadanegativeimpactofontheoperationalgrowthofthemedicaldevicessegment majormedicaldevicesfranchisesale change dollarsinmillion orthopaedic surgicalcare specialtysurgeryother visioncare cardiovascularcare diabetescare diagnostic totalmedicaldevicessale previouslyreferredtoasmedicaldevicesanddiagnosticsprioryearamountshavebeenreclassifiedtoconformtocurrentyear presentationinfectionpreventionisincludedinspecialtysurgeryother theorthopaedicsfranchiseachievedsalesofbillioninaincreaseovertheprioryeargrowthwa primarilydrivenbysalesoftraumasportsmedicinekneeandhipproductsgrowthwasnegativelyimpactedbycontinue pricingpressure thesurgicalcarefranchisesaleswerebillioninadecreaseoffromtheprioryearuspricingpressure lowersalesofwomenshealthandurologyproductsduetothecompanysdecisiontoexitfromcertainwomenshealth productsandtheimpactfromnegativecurrencywerepartiallyoffsetbyworldwidesalesgrowthofsuturesandthe successoftheechelonflexpoweredendopathstapleroutsidetheus thespecialtysurgeryotherfranchisesaleswerebillioninaincreaseovertheprioryearcontributor tothegrowthwerestrongsalesfrombiosurgicalproductssalesofenergyproductsoutsidetheusandmentorproduct duetonewproductlaunchesandmarketgrowth thevisioncarefranchisesaleswerebillioninadecreaseoffromtheprioryearthedeclinewas primarilyduetoincreasedcompetitionandpricingpressuresintheusandtheasiapacificregionpartiallyoffsetby salesgrowthineurope thecardiovascularcarefranchiseachievedsalesofbillionaincreaseovertheprioryeartheincreasedsale weredrivenbystronggrowthofbiosensewebsterproductsinallregion thediabetescarefranchisesaleswerebillionadecreaseofversustheprioryearintheuslowerprice werepartiallyoffsetbyvolumegrowth thediagnosticsfranchisesaleswerebillionadeclineofversustheprioryearthedeclinewasduetothe divestitureoftheorthoclinicaldiagnosticsbusinessthediagnosticsfranchisetothecarlylegrouponjune medicaldevicessegmentsalesinwerebillionrepresentinganincreaseofovertheprioryearwith operationalgrowthofandanegativecurrencyimpactofussaleswerebillionanincreaseofas comparedtotheprioryearinternationalsaleswerebillionanincreaseofovertheprioryearwithoperational johnsonjohnsonannualreport growthofandanegativecurrencyimpactoftheacquisitionofsynthesincnetoftherelatedtrauma businessdivestitureincreasedbothtotalsalesgrowthandoperationalgrowthforthemedicaldevicessegmentby andinandrespectively analysis consolidate earning provision taxis income consolidatedearningsbeforeprovisionfortaxesonincomeincreasedtobillioninascomparedto billioninanincreaseofearningsbeforeprovisionfortaxesonincomewerefavorableduetostrongsales volumegrowthparticularlysalesofolysiosovriadsimeprevirpositivemixfromhighersalesofhighermargin productsinthepharmaceuticalbusinessdivestituresoflowermarginbusinessesandcostreductioneffortsacrossmany ofthebusinessesadditionallyincludedhighernetgainsondivestituresofbillionprimarilythedivestitureof theorthoclinicaldiagnosticsbusinesslowerlitigationexpenseofbillionlowerinprocessresearchand developmentcostsofbillionandlowerexpensesofbillionrelatedtothedepuyasrhipprograma comparedtothefiscalyearthiswaspartiallyoffsetbytheinclusionofanadditionalyearofthebrande prescriptiondrugfeeofbillionandbillionofhighersynthesintegrationtransactioncostsinthefiscal yearincludedanetgainofbilliononequityinvestmenttransactionsprimarilythesaleofelanamerican depositaryshare consolidatedearningsbeforeprovisionfortaxesonincomeincreasedbybilliontobillionina comparedtobillioninanincreaseofearningsbeforeprovisionfortaxesonincomewerefavorable duetoincreasedgrossprofitofbillionresultingfromhighersalesofhighermarginproductsandcostcontainment initiativesandabillionnetgainonequityinvestmenttransactionsprimarilyfromthesaleofelanamericandepositary sharesthiswaspartiallyoffsetbyhigherlitigationexpensesofbillionandhigherexpensesofbillionrelatedto thedepuyasrhipprogramascomparedtothefiscalyearincludedbillionofhigherwritedownsof intangibleassetsandinprocessresearchanddevelopmentandhighercostsofbillionrelatedtothesynthe acquisitionpartiallyoffsetbyhighergainsofbillionrelatedtodivestiture asapercenttosalesconsolidatedearningsbeforeprovisionfortaxesonincomeinwasversusin costofproductssoldandsellingmarketingandadministrativeexpensescostofproductssoldandselle marketingandadministrativeexpensesasapercenttosaleswereasfollow ofsale costofproductssold percentpointdecreaseincreaseovertheprioryear sellingmarketingandadministrativeexpense percentpointdecreaseincreaseovertheprioryear incostofproductssoldasapercenttosalesdecreasedcomparedtotheprioryearthiswasprimarilytheresultof positivemixfromhighersalesofhighermarginproductsinthepharmaceuticalbusinessdivestituresoflowermargin businessesandcostimprovementsacrossmanyofthebusinessesthiswaspartiallyoffsetbypricingandtheimpactof negativetransactionalcurrencyinadditionincludedaninventorystepupchargeofbillionrelatedtothe synthesacquisitionintangibleassetamortizationexpenseincludedincostofproductssoldforbothandwas billiontherewasadecreaseinthepercenttosalesofsellingmarketingandadministrativeexpensesin comparedtotheprioryearprimarilyduetoleveragedcostsresultingfromgrowthinthepharmaceuticalbusiness particularlysalesofolysiosovriadsimeprevirandcostcontainmentinitiativesacrossmanyofthebusinesse thiswaspartiallyoffsetbytheinclusionofanadditionalyearofthebrandedprescriptiondrugfeeofmillioninthe fiscalthirdquarterof incostofproductssoldasapercenttosalesdecreasedcomparedtotheprioryearthiswasprimarilytheresultof positivemixresultingfromhighersalesofhighermarginproductslowercostsassociatedwithstrongvolumegrowthinthe pharmaceuticalbusinessandcostreductioneffortsacrossmanyofthebusinessesthedecreasewaspartiallyoffsetby incrementalintangibleassetamortizationexpenseprimarilyrelatedtosynthesthemedicaldeviceexcisetaxand increasedamortizationexpenseasaresultoftheroyaltybuyoutagreementwithvertexforincivointangibleasset amortizationexpenseforandwasbillionandbillionrespectivelyadditionallyinclude johnsonjohnsonannualreportbillionhigheramortizationoftheinventorystepupchargerelatedtothesynthesincacquisitiontherewasadecreasein thepercenttosalesofsellingmarketingandadministrativeexpensesincomparedtotheprioryearprimarilydueto costcontainmentinitiativesacrossmanyofthebusinesse researchanddevelopmentexpenseresearchanddevelopmentexpensebysegmentofbusinesswasasfollow dollarsinmillion ofsale ofsale ofsale consumer pharmaceutical medicaldevice totalresearchanddevelopmentexpense percentincreasedecreaseovertheprior year asapercenttosegmentsale researchanddevelopmentactivitiesrepresentasignificantpartofthecompanysbusinesstheseexpendituresrelateto theprocessesofdiscoveringtestinganddevelopingnewproductsimprovingexistingproductsaswellasensuring productefficacyandregulatorycompliancepriortolaunchthecompanyremainscommittedtoinvestinginresearchand developmentwiththeaimofdeliveringhighqualityandinnovativeproductsinworldwidecostsofresearchand developmentactivitiesincreasedbycomparedtothereductionasapercenttosaleswasprimarilydueto strongsalesgrowthinthepharmaceuticalbusinessresearchspendinginthepharmaceuticalsegmentincreasedin absolutedollarstobillionascomparedtobillionprimarilyduetohigherlevelsofspendingtoadvancethe companyspharmaceuticalpipelineinworldwidecostsofresearchanddevelopmentactivitiesincreasedby comparedtotheincreaseinthepharmaceuticalsegmentwasprimarilyduetohigherlevelsofspendingtoadvance thecompanyspharmaceuticalpipeline inprocessresearchanddevelopmentiprdinthecompanyrecordedchargesofbillionforthe impairmentofvariousiprdprojectsrelatedtorespivertcrucellmentorandsynthesforthedelayordiscontinuationof certaindevelopmentprojectsinthecompanyrecordedchargesofbillionprimarilyfortheimpairmentof variousiprdprojectsrelatedtocrucellcorimmunandacclarentforthedelayordiscontinuationofcertaindevelopment projectsinthecompanyrecordedchargesofbillionwhichincludedbillionfortheimpairmentofthe iprdrelatedtothediscontinuationofthephaseiiiclinicaldevelopmentofbapineuzumabivandthepartialimpairmentof theiprdrelatedtothecrucellvaccinebusinessintheamountofbillionofthebillionimpairmentofthe iprdrelatedtothediscontinuationofthephaseiiiclinicaldevelopmentofbapineuzumabivbillionisattributableto noncontrollinginterestthechargesrelatetodevelopmentprojectswhichhavebeendiscontinuedordelaye otherincomeexpensenetotherincomeexpensenetincludesroyaltyincomegainsandlossesrelatedtothe saleandwritedownofcertaininvestmentsinequitysecuritiesheldbyjohnsonjohnsondevelopmentcorporation gainsorlossesondivestiturescurrencygainsandlossesandlitigationaccrualsandsettlementsthechangeinother incomeexpensenetforthefiscalyearwasafavorablechangeofbillionascomparedtotheprioryearthe fiscalyearincludedhighernetgainsondivestituresofbillionprimarilythedivestitureoftheorthoclinical diagnosticsbusinesslowerlitigationexpenseofbillionandlowercostsofbillionrelatedtothedepuyasr hipprogramascomparedtothiswaspartiallyoffsetbyhighersynthesintegrationtransactioncostsofbillion andhigherintangibleassetwritedownsofbillionprimarilyrelatedtoincivotelaprevirinadditionallythe fiscalyearincludedahighernetgainofbillionascomparedtoonequityinvestmenttransaction primarilythesaleofelanamericandepositaryshare thechangeinotherincomeexpensenetforthefiscalyearwasanunfavorablechangeofbillionas comparedtotheprioryearthefiscalyearincludedanetgainofbilliononequityinvestmenttransaction primarilythesaleofelanamericandepositarysharesoffsetbyhigherlitigationexpensesofbillionhigherexpense ofbillionrelatedtothedepuyasrhipprogramandhighercurrencylossesofbillionthefiscalyear includedhigherwritedownsofintangibleassetsofbillionprimarilyrelatedtothecrucellvaccinebusinessand highercostsofbillionrelatedtothesynthesacquisitionadditionallyincludedhighergainsofbillion relatedtodivestiture interestincomeexpenseinterestincomeinwascomparabletotheprioryearahigherbalanceincashcash equivalentsandmarketablesecuritieswasoffsetbylowerinterestratescashcashequivalentsandmarketablesecuritie johnsonjohnsonannualreport totaledbillionattheendofandaveragedbillionascomparedtothebillionaveragecash balanceintheincreaseintheyearendcashbalancewasprimarilyduetocashgeneratedfromoperatingactivitie interestexpenseinincreasedbymillionascomparedtoduetoahigheraveragedebtbalancethe averagedebtbalancewasbillioninversusbillioninthetotaldebtbalanceattheendof wasbillionascomparedtobillionattheendofthehigherdebtbalanceofapproximatelybillion wasduetoincreasedborrowingsinnovemberthecompanyincreasedborrowingscapitalizingonfavorableterm inthecapitalmarketstheproceedsoftheborrowingswillbeusedforgeneralcorporatepurpose interestincomeinincreasedbymillionascomparedtotheprioryearcashcashequivalentsandmarketable securitiestotaledbillionattheendofandaveragedbillionascomparedtothebillionaverage cashbalanceintheincreaseintheyearendcashbalancewasduetocashgeneratedfromoperatingactivitie interestexpenseindecreasedbymillionascomparedtoduetoaloweraveragedebtbalancethe averagedebtbalancewasbillioninversusbillioninthetotaldebtbalanceattheendof wasbillionascomparedtobillionattheendofthehigherdebtbalanceofapproximatelybillion wasduetoincreasedborrowingsindecemberthecompanyincreasedborrowingscapitalizingonfavorableterm inthecapitalmarketstheproceedsoftheborrowingswereusedforgeneralcorporatepurpose segmentpretaxprofit pretaxprofitsbysegmentofbusinesswereasfollow percentof segmentsale dollarsinmillion consumer pharmaceutical medicaldevice total lessexpensesnotallocatedtosegment earningsbeforeprovisionfortaxesonincome seenotetotheconsolidatedfinancialstatementsformoredetail amountsnotallocatedtosegmentsincludeinterestincomeexpensenoncontrollinginterestsandgeneralcorporateincome expense consumersegmentinconsumersegmentpretaxprofitasapercenttosaleswasflattotheprioryear inconsumersegmentpretaxprofitasapercenttosaleswasversusinthefavorablepretax profitinversuswasprimarilyduetoagainofmilliononthesaleofintangibleandotherassetsaswella costcontainmentinitiativesincludedinwereintangibleassetwritedownsofbillioninadditioninclude highergainsondivestituresofbillion pharmaceuticalsegmentinpharmaceuticalsegmentpretaxprofitasapercenttosaleswasversus inthefavorablepretaxprofitwasattributabletostrongsalesvolumegrowthparticularlysalesofolysio sovriadsimeprevirpositivesalesmixofhighermarginproductsandcostcontainmentinitiativesrealizedinselle marketingandadministrativeexpensesthiswaspartiallyoffsetbybillionforanadditionalyearofthebrande prescriptiondrugfeeandabillionintangibleassetwritedownrelatedtoincivotelapreviradditionally includedanetgainofbilliononequityinvestmenttransactionsprimarilythesaleofelanamericandepositary sharesandapositiveadjustmentofbilliontopreviousestimatesformanagedmedicaidrebatespartiallyoffsetby higherwritedownsofbillionfortheimpairmentofiprdascomparedtoinpharmaceuticalsegment pretaxprofitasapercenttosaleswasversusinthefavorablepretaxprofitwasattributableto positivesalesmixofhighermarginproductslowercostsassociatedwithstrongvolumegrowthanetgainofbillion onequityinvestmenttransactionsprimarilythesaleofelanamericandepositarysharesapositiveadjustmentof billiontopreviousestimatesformanagedmedicaidrebatesandcostcontainmentinitiativesthiswaspartiallyoffsetby increasedamortizationexpenseasaresultoftheroyaltybuyoutagreementwithvertexforincivoadditionally includedhighernetlitigationexpenseofbillionandhigherwritedownsofintangibleassetsandinprocessresearch anddevelopmentofbillionthiswaspartiallyoffsetbyhighergainsondivestituresofbillion johnsonjohnsonannualreportmedicaldevicessegmentinmedicaldevicessegmentpretaxprofitasapercenttosaleswasversus inthefavorablepretaxprofitwasattributabletothenetgainofbilliononthedivestitureofthe orthoclinicaldiagnosticsbusinessinandlowerlitigationexpenseofbillionascomparedtoin medicaldevicessegmentpretaxprofitasapercenttosaleswasversusinthemedicaldevice segmentpretaxprofitwasunfavorablyimpactedbyhighercostsofbillionforlitigationexpenseandbillion relatedtothedepuyasrhipprogramaswellasthemedicaldeviceexcisetaxascomparedtoinaddition includedhighergainsofbillionondivestiturespartiallyoffsetbyhigherwritedownsofintangibleassetsand inprocessresearchanddevelopmentofbillionandhighercostsofbillionrelatedtothesynthesacquisition provisionfortaxesonincometheworldwideeffectiveincometaxratewasininand intheincreaseintheeffectivetaxrateascomparedtowasattributabletothefollowingthe divestitureoftheorthoclinicaldiagnosticsbusinessatanapproximateeffectivetaxratelitigationaccrualsatlow taxratesthemixofearningsintohighertaxjurisdictionsprimarilytheustheaccrualofanadditionalyearofthebrande prescriptiondrugfeewhichisnottaxdeductibleandadditionalustaxexpenserelatedtoaplannedincreasein dividendsfromcurrentyearforeignearningsascomparedtotheprioryeartheseincreasestotheeffectivetaxrate werepartiallyoffsetbyataxbenefitofbillionassociatedwiththeconormedsystemsdivestiture theeffectivetaxratewasreducedbyataxbenefitassociatedwiththewriteoffofassetsfortaxpurpose associatedwithsciosincandtheinclusionofboththeandbenefitfromtheresearchanddevelopmenttax creditandthecontrolledforeigncorporationlookthroughprovisionsbecausethoseprovisionswereenactedintolawin januaryandwereretroactivetojanuary theeffectivetaxratewasalsoreducedasthecompanyadjusteditsunrecognizedtaxbenefitsasaresultofithe federalappealscourtsdecisioninomjpharmaceuticalsincslitigationregardingcreditsunderformersectionof theinternalrevenuecodeseenotetotheconsolidatedfinancialstatementsforadditionalinformationandiia settlementofsubstantiallyallissuesrelatedtothecompanysusinternalrevenueserviceauditoftaxyear noncontrollinginterestinachargeofbillionwasrecordedfortheimpairmentoftheiprdrelatedtothe discontinuationofthephaseiiiclinicaldevelopmentofbapineuzumabivofthebillionimpairmentbillionwas attributabletononcontrollinginter liquidity capital resource liquiditycashflow cashandcashequivalentswerebillionattheendofascomparedwithbillionattheendofthe primarysourcesandusesofcashthatcontributedtothebilliondecreaseversustheprioryearwereapproximately billionofcashgeneratedfromoperatingactivitiesoffsetbybillionnetcashusedbyinvestingactivitiesand billionnetcashusedbyfinancingactivitiesseenotetotheconsolidatedfinancialstatementsforadditional detailsoncashinadditionthecompanyhadbillioninmarketablesecuritiesattheendofandbillionat theendof cashflowfromoperationsofbillionwastheresultofbillionofnetearningsandbillionofnoncash chargesandotheradjustmentsfordepreciationandamortizationstockbasedcompensationassetwritedown venezuelaadjustmentsandbillionrelatedtodeferredtaxesaccountspayableandaccruedliabilitiesandcurrentand noncurrentassetscashflowfromoperationswasreducedbybillionrelatedtocurrentandnoncurrentliabilitie inventoriesaccountsreceivableandnetgainsonsaleofassetsbusinesse investingactivitiesuseofbillionwasprimarilyfornetpurchasesofinvestmentsinmarketablesecuritiesof billionadditionstopropertyplantandequipmentofbillionacquisitionsnetofcashacquiredofbillionand otherprimarilyintangiblesofbillionpartiallyoffsetbybillionofproceedsfromthedisposalofasset business financingactivitiesuseofbillionwasprimarilyfordividendstoshareholdersofbillionandbillionforthe repurchaseofcommonstockfinancingactivitiesalsoincludedasourceofbillionfromnetproceedsofshortand longtermdebtandbillionofnetproceedsfromstockoptionsexercisedandassociatedtaxbenefit onjulythecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogramauthorize thecompanytopurchaseuptobillionofthecompanyssharesofcommonstockasofdecember johnsonjohnsonannualreport billionhasbeenrepurchasedundertheprogramsharerepurchaseswilltakeplaceontheopenmarketfromtimetotime basedonmarketconditionstherepurchaseprogramhasnotimelimitandmaybesuspendedforperiodsordiscontinue atanytimeanysharesacquiredwillbeavailableforgeneralcorporatepurposesthecompanyintendstofinancethe sharerepurchaseprogramthroughavailablecash inthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarketforadditionaldetail onborrowingsseenotetotheconsolidatedfinancialstatement thecompanyanticipatesthatoperatingcashflowsexistingcreditfacilitiesandaccesstothecommercialpapermarket willprovidesufficientresourcestofundoperatingneedsin concentrationofcreditrisk globalconcentrationofcreditriskwithrespecttotradeaccountsreceivablescontinuestobelimitedduetothelarge numberofcustomersgloballyandadherencetointernalcreditpoliciesandcreditlimitseconomicchallengesinitaly spaingreeceandportugalthesoutherneuropeanregionhaveimpactedcertainpaymentpatternswhichhave historicallybeenlongerthanthoseexperiencedintheusandotherinternationalmarketsthetotalnettradeaccount receivablebalanceinthesoutherneuropeanregionwasapproximatelybillionasofdecemberand billionasofdecemberapproximatelybillionasofdecemberandapproximatelybillionasof decemberofthesoutherneuropeanregionnettradeaccountsreceivablebalancerelatedtothecompany consumervisioncareanddiabetescarebusinessesaswellascertainpharmaceuticalandmedicaldevicescustomers whichareinlinewithhistoricalcollectionpatterns theremainingbalanceofnettradeaccountsreceivableinthesoutherneuropeanregionhasbeennegativelyimpacte bythetimingofpaymentsfromcertaingovernmentownedorsupportedhealthcarecustomersaswellascertain distributorsofthepharmaceuticalandmedicaldeviceslocalaffiliatesthetotalnettradeaccountsreceivablebalancefor thesecustomerswereapproximatelybillionatdecemberandbillionatdecemberthe companycontinuestoreceivepaymentsfromthesecustomersandinsomecaseslatepaymentpremiumsforcustomer wherepaymentisexpectedoverperiodsoftimelongerthanoneyearrevenueandtradereceivableshavebeen discountedovertheestimatedperiodoftimeforcollectionallowancesfordoubtfulaccountshavebeenincreasedfor thesecustomersbuthavebeenimmaterialtodatethecompanywillcontinuetoworkcloselywiththesecustomerson paymentplansmonitortheeconomicsituationandtakeappropriateactionsasnecessary financingandmarketrisk thecompanyusesfinancialinstrumentstomanagetheimpactofforeignexchangeratechangesoncashflow accordinglythecompanyentersintoforwardforeignexchangecontractstoprotectthevalueofcertainforeigncurrency assetsandliabilitiesandtohedgefutureforeigncurrencytransactionsprimarilyrelatedtoproductcostsgainsorlosse onthesecontractsareoffsetbythegainsorlossesontheunderlyingtransactionsaappreciationoftheusdollar fromthedecembermarketrateswouldincreasetheunrealizedvalueofthecompanysforwardcontractsby millionconverselyadepreciationoftheusdollarfromthedecembermarketrateswoulddecrease theunrealizedvalueofthecompanysforwardcontractsbymillionineitherscenariothegainorlossontheforward contractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhavenoimpactonfuture anticipatedearningsandcashflow thecompanyhedgestheexposuretofluctuationsincurrencyexchangeratesandtheeffectoncertainassetsand liabilitiesinforeigncurrencybyenteringintocurrencyswapcontractsachangeinthespreadbetweenusand foreigninterestratesonthecompanysinterestratesensitivefinancialinstrumentswouldeitherincreaseordecreasethe unrealizedvalueofthecompanysswapcontractsbyapproximatelymillionineitherscenarioatmaturitythegainor lossontheswapcontractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhaveno impactonfutureanticipatedcashflow thecompanydoesnotenterintofinancialinstrumentsfortradingorspeculativepurposesfurtherthecompanyhasa policyofonlyenteringintocontractswithpartiesthathaveatleastanaorequivalentcreditratingthecounterpartie tothesecontractsaremajorfinancialinstitutionsandthereisnosignificantconcentrationofexposurewithanyone counterpartymanagementbelievestheriskoflossisremote thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementisbasedoneitherbids providedbybankstheprimerateorlondoninterbankofferedratesliborplusapplicablemarginscommitmentfee undertheagreementarenotmaterial johnsonjohnsonannualreporttotalborrowingsattheendofandwerebillionandbillionrespectivelytheincreasein borrowingsbetweenandwasaresultoffinancingforgeneralcorporatepurposesinnetcashcash andcurrentmarketablesecuritiesnetofdebtwasbillioncomparedtonetcashofbillionintotaldebt representedoftotalcapitalshareholdersequityandtotaldebtinandoftotalcapitalin shareholdersequitypershareattheendofwascomparedtoatyearendadecreaseof asummaryofborrowingscanbefoundinnotetotheconsolidatedfinancialstatement contractualobligationsandcommitment thecompanyscontractualobligationsareprimarilyforleasesdebtandunfundedretirementplanstherearenoother significantobligationstosatisfytheseobligationsthecompanywillusecashfromoperationsthefollowingtable summarizesthecompanyscontractualobligationsandtheiraggregatematuritiesasofdecemberseenote andtotheconsolidatedfinancialstatementsforfurtherdetails longterm intereston unfunde debt debt retirement operating dollarsinmillion obligation obligation plan lease total total fortaxmattersseenotetotheconsolidatedfinancialstatement dividend thecompanyincreaseditsdividendinforthendconsecutiveyearcashdividendspaidwerepersharein comparedwithdividendsofpershareinandpershareinthedividendsweredistributed asfollow firstquarter secondquarter thirdquarter fourthquarter total onjanuarytheboardofdirectorsdeclaredaregularquarterlycashdividendofpersharepayableon marchtoshareholdersofrecordasoffebruarythecompanyexpectstocontinuethepracticeof payingregularcashdividend information criticalaccountingpoliciesandestimate managementsdiscussionandanalysisofresultsofoperationsandfinancialconditionarebasedonthecompany consolidatedfinancialstatementsthathavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedin theusgaapthepreparationofthesefinancialstatementsrequiresthatmanagementmakeestimatesand johnsonjohnsonannualreport assumptionsthataffecttheamountsreportedforrevenuesexpensesassetsliabilitiesandotherrelateddisclosures actualresultsmayormaynotdifferfromtheseestimatesthecompanybelievesthattheunderstandingofcertainkey accountingpoliciesandestimatesareessentialinachievingmoreinsightintothecompanysoperatingresultsand financialconditionthesekeyaccountingpoliciesincluderevenuerecognitionincometaxeslegalandselfinsurance contingenciesvaluationoflonglivedassetsassumptionsusedtodeterminetheamountsrecordedforpensionsandother employeebenefitplansandaccountingforstockbasedawards revenuerecognitionthecompanyrecognizesrevenuefromproductsaleswhengoodsareshippedordeliveredand titleandriskoflosspasstothecustomerprovisionsforcertainrebatessalesincentivestradepromotionscoupon productreturnsanddiscountstocustomersareaccountedforasreductionsinsalesinthesameperiodtherelatedsale arerecorde productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingpriceschargedbycompetitorsrebateswhichincludethemedicaidrebateprovision areestimatedbasedoncontractualtermshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarket conditionsinthevariousmarketsservedthecompanyevaluatesmarketconditionsforproductsorgroupsofproduct primarilythroughtheanalysisofwholesalerandotherthirdpartysellthroughandmarketresearchdataaswellas internallygeneratedinformation salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibitunusual salesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas partoftheaccountingforsalesreturnaccrual salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthereturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarketasa percenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescreditto customersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewiththe usgaapguidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerandpharmaceuticalsegmentsarealmostexclusivelynotresalablesalesreturnsfor certainfranchisesinthemedicaldevicessegmentaretypicallyresalablebutarenotmaterialthecompanyinfrequently exchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyhasbeen approximatelyofannualnettradesalesduringthefiscalreportingyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe yearincurredcontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentiveprogramsthe redemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvaluevolumebase incentiveprogramsarebasedonestimatedsalesvolumesfortheincentiveperiodandarerecordedasproductsaresold thecompanyalsoearnsservicerevenueforcopromotionofcertainproductsforallyearspresentedservicerevenue werelessthanoftotalrevenuesandareincludedinsalestocustomersthesearrangementsareevaluatedto determinetheappropriateamountstobedeferre inadditionthecompanyentersintocollaborationarrangementsthatcontainmultiplerevenuegeneratingactivitie amountsduefromcollaborativepartnersforthesearrangementsarerecognizedaseachactivityisperformedordelivere basedontherelativefairvalueupfrontfeesreceivedaspartofthesearrangementsaredeferredandrecognizedoverthe performanceperiodseenotetotheconsolidatedfinancialstatementsforadditionaldisclosuresoncollaboration reasonablylikelychangestoassumptionsusedtocalculatetheaccrualsforrebatesreturnsandpromotionsarenot anticipatedtohaveamaterialeffectonthefinancialstatementsthecompanycurrentlydisclosestheimpactofchange toassumptionsinthequarterlyorannualfilinginwhichthereisamaterialfinancialstatementimpact johnsonjohnsonannualreportbelowaretablesthatshowtheprogressionofaccruedrebatesreturnspromotionsreservefordoubtfulaccountsand reserveforcashdiscountsbysegmentofbusinessforthefiscalyearsendeddecemberanddecember consumersegment balanceat balanceat beginningof payment endof dollarsinmillion period accrual credit period accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatdecemberandmillionatdecemberrecordedasa contraasset pharmaceutical segment balanceat balanceat beginningof payment endof dollarsinmillion period accrual credit period accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatdecemberandmillionatdecemberrecordedasa contraasset johnsonjohnsonannualreport medicaldevicessegment balanceat balanceat beginningof payment endof dollarsinmillion period accrual credit period accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatdecemberandmillionatdecemberrecordedasa contraasset incometaxesincometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludethe resultsofanydifferencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilitie thecompanyestimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesin taxlawsandratesmayaffectrecordeddeferredtaxassetsandliabilitie thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition atdecemberanddecemberthecumulativeamountsofundistributedinternationalearningswere approximatelybillionandbillionrespectivelyatdecemberanddecemberthe companysforeignsubsidiariesheldbalancesofcashandcashequivalentsintheamountsofbillionand billionrespectivelythecompanyhasnotprovideddeferredtaxesontheundistributedearningsfromcertaininternational subsidiarieswheretheearningsareconsideredtobepermanentlyreinvestedthecompanyintendstocontinueto reinvesttheseearningsininternationaloperationsifthecompanydecidedatalaterdatetorepatriatetheseearningsto theusthecompanywouldberequiredtoprovideforthenettaxeffectsontheseamountsthecompanydoesnot determinethedeferredtaxliabilityassociatedwiththeseundistributedearningsassuchdeterminationisnotpractical seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxe legalandselfinsurancecontingenciesthecompanyrecordsaccrualsforvariouscontingenciesincludinglegal proceedingsandproductliabilityclaimsastheseariseinthenormalcourseofbusinesstheaccrualsarebasedon managementsjudgmentastotheprobabilityoflossesandwhereapplicableactuariallydeterminedestimatesthe companyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyinadditiontoaccrualsintheself insuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe reasonablyestimatedadditionallythecompanyrecordsinsurancereceivableamountsfromthirdpartyinsurerswhen recoveryisprobableasappropriatereservesagainstthesereceivablesarerecordedforestimatedamountsthatmaynot becollectedfromthirdpartyinsurer thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorde whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrue johnsonjohnsonannualreportlonglivedandintangibleassetsthecompanyassesseschangesineconomicconditionsandmakesassumption regardingestimatedfuturecashflowsinevaluatingthevalueofthecompanyspropertyplantandequipmentgoodwill andintangibleassetsastheseassumptionsandestimatesmaychangeovertimeitmayormaynotbenecessaryforthe companytorecordimpairmentcharges employeebenefitplansthecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefit definedcontributionandterminationindemnityplanswhichcovermostemployeesworldwidetheseplansarebasedon assumptionsforthediscountrateexpectedreturnonplanassetsmortalityratesexpectedsalaryincreasesandhealth carecosttrendratesseenotetotheconsolidatedfinancialstatementsforfurtherdetailsontheseratesandthe effectaratechangetothehealthcarecosttrendwouldhaveonthecompanysresultsofoperation stockbasedcompensationthecompanyrecognizescompensationexpenseassociatedwiththeissuanceofequity instrumentstoemployeesfortheirservicesbasedonthetypeofequityinstrumentthefairvalueisestimatedonthedate ofgrantusingeithertheblackscholesoptionvaluationmodeloracombinationofboththeblackscholesoption valuationmodelandmontecarlovaluationmodelandisexpensedinthefinancialstatementsoverthevestingperiodthe inputassumptionsusedindeterminingfairvaluearetheexpectedlifeexpectedvolatilityriskfreerateandthedividend yieldseenotetotheconsolidatedfinancialstatementsforadditionalinformation newaccountingpronouncement refertonotetotheconsolidatedfinancialstatementsforrecentlyadoptedaccountingpronouncementsandrecently issuedaccountingpronouncementsnotyetadoptedasofdecember economicandmarketfactor thecompanyisawarethatitsproductsareusedinanenvironmentwhereformorethanadecadepolicymaker consumersandbusinesseshaveexpressedconcernsabouttherisingcostofhealthcareinresponsetotheseconcern thecompanyhasalongstandingpolicyofpricingproductsresponsiblyfortheperiodintheunitedstate theweightedaveragecompoundannualgrowthrateofthecompanysnetpriceincreasesforhealthcareproduct prescriptionandoverthecounterdrugshospitalandprofessionalproductswasbelowtheusconsumerpriceindex cpi thecompanyoperatesincertaincountrieswheretheeconomicconditionscontinuetopresentsignificantchallengesthe companycontinuestomonitorthesesituationsandtakeappropriateactionsinflationratescontinuetohaveaneffecton worldwideeconomiesandconsequentlyonthewaycompaniesoperatethecompanyhasaccountedforoperationsin venezuelaashighlyinflationaryasthepriorthreeyearcumulativeinflationratesurpassedinthefaceofincrease coststhecompanystrivestomaintainitsprofitmarginsthroughcostreductionprogramsproductivityimprovementsand periodicpriceincrease thevenezuelangovernmenthasestablishedorisintheprocessofestablishingalternativesystemsandofferingsof variousforeigncurrencyexchangesinthecompanycontinuedtohaveaccesstoanofficialgovernmentrateof bolivaresfuertestooneusdollartosettleimportsofvariousproductsintovenezuelathroughthefourthquarterof thecompanyhasprimarilyutilizedtheofficialgovernmentrateofbolivaresfuertestooneusdollarin preparingitsfinancialstatementsduringthesecondfiscalquarterthecompanyappliedtosettleanoutstandingdividend payableatoneofthealternativeforeignexchangeratesasaresultthecompanyhasappliedthisalternativeexchange ratetotranslatecertaintransactionsasappropriateasofdecemberthecompanysvenezuelansubsidiarie representedlessthanofthecompanysconsolidatedassetsliabilitiesrevenuesandprofitsthereforetheeffectof achangeintheexchangerateisnotexpectedtohaveamaterialadverseeffectonthecompanysfullyearresult thecompanyisexposedtofluctuationsincurrencyexchangeratesachangeinthevalueoftheusdollaras comparedtoallforeigncurrenciesinwhichthecompanyhadsalesincomeorexpenseinwouldhaveincreasedor decreasedthetranslationofforeignsalesbyapproximatelymillionandincomebymillion thecompanyfacesvariousworldwidehealthcarechangesthatmaycontinuetoresultinpricingpressuresthatinclude healthcarecostcontainmentandgovernmentlegislationrelatingtosalespromotionsandreimbursementofhealthcare product changesinthebehaviorandspendingpatternsofpurchasersofhealthcareproductsandservicesincludingdelaye medicalproceduresrationingprescriptionmedicationsreducingthefrequencyofphysicianvisitsandforegoinghealth careinsurancecoverageasaresultofthecurrentglobaleconomicdownturnmaycontinuetoimpactthecompany business johnsonjohnsonannualreport thecompanyalsooperatesinanenvironmentincreasinglyhostiletointellectualpropertyrightsfirmshavefile abbreviatednewdrugapplicationsorbiosimilarbiologicalproductapplicationswiththefdaorotherwisechallenge thecoverageandorvalidityofthecompanyspatentsseekingtomarketgenericorbiosimilarformsofmanyofthe companyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductsintheevent thecompanyisnotsuccessfulindefendingthepatentclaimschallengedintheresultinglawsuitsgenericorbiosimilar versionsoftheproductsatissuewillbeintroducedtothemarketresultinginthepotentialforsubstantialmarketshareand revenuelossesforthoseproductsandwhichmayresultinanoncashimpairmentchargeinanyassociatedintangible assetforfurtherinformationseethediscussiononremicaderelatedcasesandlitigationagainstfilersof abbreviatednewdrugapplicationsinnotetotheconsolidatedfinancialstatement legalproceeding johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialandothermattersgovernmentalinvestigationsandotherlegalproceedingsthatarise fromtimetotimeintheordinarycourseofbusiness thecompanyrecordsaccrualsforsuchcontingencieswhenitisprobablethataliabilitywillbeincurredandtheamount ofthelosscanbereasonablyestimatedthecompanyhasaccruedforcertainlitigationmattersandcontinuestomonitor eachrelatedlegalissueandadjustaccrualsfornewinformationandfurtherdevelopmentsinaccordancewithaccounte standardscodificationascfortheseandotherlitigationandregulatorymatterscurrentlydisclosedfor whichalossisprobableorreasonablypossiblethecompanyisunabletodetermineanestimateofthepossiblelossor rangeoflossbeyondtheamountsalreadyaccruedthesematterscanbeaffectedbyvariousfactorsincludingwhether damagessoughtintheproceedingsareunsubstantiatedorindeterminatescientificandlegaldiscoveryhasnot commencedorisnotcompleteproceedingsareinearlystagesmatterspresentlegaluncertaintiestherearesignificant factsindisputeortherearenumerouspartiesinvolve inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutioninanyreportingperiodofone ormoreofthesematterseitheraloneorintheaggregatemayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardinglegalproceeding commonstockmarketprice thecompanyscommonstockislistedonthenewyorkstockexchangeunderthesymboljnjasoffebruary therewererecordholdersofcommonstockofthecompanythecompositemarketpricerangesfor johnsonjohnsoncommonstockduringandwere high low high low firstquarter secondquarter thirdquarter fourthquarter yearendclose johnsonjohnsonannualreportcautionary factor affect future result thisannualreportcontainsforwardlookingstatementsforwardlookingstatementsdonotrelatestrictlytohistoricalor currentfactsandanticipateresultsbasedonmanagementsplansthataresubjecttouncertaintyforwardlooke statementsmaybeidentifiedbytheuseofwordssuchasplansexpectswillanticipatesestimatesandother wordsofsimilarmeaninginconjunctionwithamongotherthingsdiscussionsoffutureoperationsfinancialperformance thecompanysstrategyforgrowthproductdevelopmentregulatoryapprovalmarketpositionandexpenditure forwardlookingstatementsarebasedoncurrentexpectationsoffutureeventsthecompanycannotguaranteethatany forwardlookingstatementwillbeaccuratealthoughthecompanybelievesthatithasbeenreasonableinitsexpectation andassumptionsinvestorsshouldrealizethatifunderlyingassumptionsproveinaccurateorthatknownorunknownrisk oruncertaintiesmaterializeactualresultscouldvarymateriallyfromthecompanysexpectationsandprojectionsinvestor arethereforecautionednottoplaceunduerelianceonanyforwardlookingstatementsthecompanydoesnotundertake toupdateanyforwardlookingstatementsasaresultofnewinformationorfutureeventsordevelopment risksanduncertaintiesincludebutarenotlimitedtoeconomicfactorssuchasinterestrateandcurrencyexchangerate fluctuationscompetitionincludingtechnologicaladvancesnewproductsandpatentsattainedbycompetitor challengesinherentinnewproductdevelopmentincludingobtainingregulatoryapprovalschallengestopatentsthe impactofpatentexpirationsuncertaintyofcommercialsuccessofnewandexistingproductssignificantadverselitigation orgovernmentactionincludingrelatedtoproductliabilityclaimsimpactofbusinesscombinationsanddivestiture significantchangesincustomerrelationshipsorchangesinbehaviorandspendingpatternsorfinancialdistressof purchasersofhealthcareproductsandserviceschangestolawsandregulationsandglobalhealthcarereformstrend towardhealthcarecostcontainmentincreasedscrutinyofthehealthcareindustrybygovernmentagenciesfinancial instabilityofinternationaleconomiesandsovereignriskmanufacturingdifficultiesordelayscomplexglobalsupplychain withincreasingregulatoryrequirementsproductefficacyorsafetyconcernsresultinginproductrecallsorregulatory actiondisruptionsduetonaturaldisastersandthepotentialfailuretomeetobligationsincomplianceagreementswith governmentbodie adiscussionoftheseandotherfactorsthatcouldcauseactualresultstodiffermateriallyfromexpectationscanbefound inthisannualreportonformkforthefiscalyearendeddecemberincludinginexhibitthecompany notesthesefactorsaspermittedbytheprivatesecuritieslitigationreformactof johnsonjohnsonannualreport johnson johnson subsidiaries consolidate balance sheet atdecemberanddecember dollarsinmillionsexceptshareandpershareamountsnote asset currentasset cashandcashequivalentsnotesand marketablesecuritiesnotesand accountsreceivabletradelessallowancesfordoubtfulaccount inventoriesnotesand deferredtaxesonincomenote prepaidexpensesandotherreceivable totalcurrentassets propertyplantandequipmentnetnotesand intangibleassetsnetnotesand goodwillnotesand deferredtaxesonincomenote otherasset totalasset liabilitiesandshareholdersequity currentliabilitie loansandnotespayablenote accountspayable accruedliabilitie accruedrebatesreturnsandpromotion accruedcompensationandemployeerelatedobligation accruedtaxesonincome totalcurrentliabilities longtermdebtnote deferredtaxesonincomenote employeerelatedobligationsnotesand otherliabilitie totalliabilitie shareholdersequity preferredstockwithoutparvalueauthorizedandunissuedshare commonstockparvaluepersharenoteauthorizedsharesissue share accumulatedothercomprehensiveincomenote retainedearning lesscommonstockheldintreasuryatcostnotesharesandshare totalshareholdersequity totalliabilitiesandshareholdersequity seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreportjohnson johnson subsidiaries consolidate statement earning dollarsandsharesinmillionsexceptpershareamountsnote salestocustomer costofproductssold grossprofit sellingmarketingandadministrativeexpense researchanddevelopmentexpense inprocessresearchanddevelopment interestincome interestexpensenetofportioncapitalizednote otherincomeexpensenet earningsbeforeprovisionfortaxesonincome provisionfortaxesonincomenote netearning addnetlossattributabletononcontrollinginter netearningsattributabletojohnsonjohnson netearningspershareattributabletojohnsonjohnsonnotesand basic diluted cashdividendspershare averagesharesoutstandingnotesand basic diluted seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreport johnson johnson subsidiaries consolidate statement comprehensive income dollarsinmillionsnote netearning othercomprehensiveincomelossnetoftax foreigncurrencytranslation security unrealizedholdinggainlossarisingduringperiod reclassificationstoearning netchange employeebenefitplans priorservicecostamortizationduringperiod priorservicecreditcostcurrentyear gainamortizationduringperiod gainlosscurrentyear effectofexchangerate netchange derivativeshedge unrealizedgainlossarisingduringperiod reclassificationstoearning netchange othercomprehensiveincomeloss comprehensiveincome comprehensivelossattributabletononcontrollinginterestnetoftax comprehensiveincomeattributabletojohnsonjohnson thetaxeffectsinothercomprehensiveincomeforthefiscalyearsendedandrespectivelysecuritie millionmillionandmillionemployeebenefitplansmillionmillionandmillion derivativeshedgesmillionmillionandmillion seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreportjohnson johnson subsidiaries consolidate statement equity dollarsinmillionsnote accumulate treasury retain comprehensive commonstock stock total earning income issuedamount balancejanuary netearningsattributabletojohnsonjohnson cashdividendspaid employeecompensationandstockoptionplans issuanceofcommonstockassociatedwiththe acquisitionofsynthesinc repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancedecember netearningsattributabletojohnsonjohnson cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancedecember netearningsattributabletojohnsonjohnson cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancedecember includesrepurchaseofcommonstockassociatedwiththeacquisitionofsynthesinc seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreport johnson johnson subsidiaries consolidate statement cash flow dollarsinmillionsnote cashflowsfromoperatingactivitie netearning adjustmentstoreconcilenetearningstocashflowsfromoperatingactivitie depreciationandamortizationofpropertyandintangible stockbasedcompensation noncontrollinginterest venezuelaadjustment assetwritedowns netgainonsaleofassetsbusinesse netgainonequityinvestmenttransaction deferredtaxprovision accountsreceivableallowance changesinassetsandliabilitiesnetofeffectsfromacquisitionsanddivestiture increaseinaccountsreceivable increaseininventorie increaseinaccountspayableandaccruedliabilitie decreaseincreaseinothercurrentandnoncurrentasset decreaseincreaseinothercurrentandnoncurrentliabilitie netcashflowsfromoperatingactivitie cashflowsfrominvestingactivities additionstopropertyplantandequipment proceedsfromthedisposalofassetsbusinessesnet acquisitionsnetofcashacquirednote purchasesofinvestment salesofinvestment otherprimarilyintangible netcashusedbyinvestingactivitie cashflowsfromfinancingactivitie dividendstoshareholder repurchaseofcommonstock proceedsfromshorttermdebt retirementofshorttermdebt proceedsfromlongtermdebt retirementoflongtermdebt proceedsfromtheexerciseofstockoptionsexcesstaxbenefit netcashusedbyfinancingactivitie effectofexchangeratechangesoncashandcashequivalent decreaseincreaseincashandcashequivalent cashandcashequivalentsbeginningofyearnote cashandcashequivalentsendofyearnote supplementalcashflowdata cashpaidduringtheyearfor interest interestnetofamountcapitalize incometaxe supplementalscheduleofnoncashinvestingandfinancingactivitie issuanceofcommonstockassociatedwiththeacquisitionofsynthesinc treasurystockissuedforemployeecompensationandstockoptionplansnetofcashproceed conversionofdebt acquisition fairvalueofassetsacquire fairvalueofliabilitiesassumedandnoncontrollinginterest netfairvalueofacquisition lessissuanceofcommonstockassociatedwiththeacquisitionofsynthesinc netcashpaidforacquisition seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreportnote consolidated financial statement summaryofsignificantaccountingpolicie principlesofconsolidation theconsolidatedfinancialstatementsincludetheaccountsofjohnsonjohnsonanditssubsidiariesthecompany intercompanyaccountsandtransactionsareeliminate descriptionofthecompanyandbusinesssegment thecompanyhasapproximatelyemployeesworldwideengagedintheresearchanddevelopmentmanufacture andsaleofabroadrangeofproductsinthehealthcarefieldthecompanyconductsbusinessinvirtuallyallcountriesof theworldanditsprimaryfocusisonproductsrelatedtohumanhealthandwellbeing thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicespreviously referredtoasmedicaldevicesanddiagnosticstheconsumersegmentincludesabroadrangeofproductsusedinthe babycareoralcareskincareoverthecounterpharmaceuticalwomenshealthandwoundcaremarketsthese productsaremarketedtothegeneralpublicandsoldbothtoretailoutletsanddistributorsthroughouttheworldthe pharmaceuticalsegmentisfocusedonfivetherapeuticareasincludingimmunologyinfectiousdiseasesneuroscience oncologyandcardiovascularandmetabolicdiseasesproductsinthissegmentaredistributeddirectlytoretailers wholesalershospitalsandhealthcareprofessionalsforprescriptionusethemedicaldevicessegmentincludesabroad rangeofproductsusedintheorthopaedicsurgicalcarespecialtysurgerycardiovascularcarediagnosticsdiabete careandvisioncaremarketswhicharedistributedtowholesalershospitalsandretailersandusedprincipallyinthe professionalfieldsbyphysiciansnurseshospitalsandclinic newaccountingpronouncement recentlyadoptedaccountingpronouncement duringthefiscalfirstquarterofthecompanyadoptedthefinancialaccountingstandardsboardfasbguidance clarifyingthereleaseofaccumulatedforeigncurrencytranslationfromothercomprehensiveincomeociintocurrent yearnetearningstheamendmentrequiresthatwhentheparentcompanyceasestohaveacontrollinginterestina subsidiaryorabusinesswithinaforeignentitytheparentistoreleaseaccumulatedforeigncurrencytranslationfrom ocithisupdatebecameeffectiveforallannualperiodsandinterimreportingperiodsbeginningafterdecember theadoptionofthisstandarddidnothaveamaterialimpactonthecompanysresultsofoperationscashflowsor financialposition duringthefiscalfirstquarterofthecompanyadoptedthefasbguidanceonthepresentationofunrecognizedtax benefitswhenvariousqualifyingtaxcreditsexisttheamendmentrequiresthatunrecognizedtaxbenefitsbepresentedon theconsolidatedbalancesheetasareductiontodeferredtaxassetscreatedbynetoperatinglossesorothertaxcredit frompriorperiodsthatoccurinthesametaxingjurisdictiontotheextentthattheunrecognizedtaxbenefitexceedsthese creditsitshallbepresentedasaliabilitythisupdatebecameeffectiveforallannualperiodsandinterimreportingperiod beginningafterdecembertheadoptionofthisstandarddidnothaveamaterialimpactonthepresentationof thecompanysfinancialposition duringthefiscalsecondquarterofthefasbissuedamendedguidanceontheuseandpresentationof discontinuedoperationsinanentitysfinancialstatementsthenewguidancerestrictsthepresentationofdiscontinue operationstobusinesscircumstanceswhenthedisposalofbusinessoperationsrepresentsastrategicshiftthathasorwill haveamajoreffectonanentitysoperationsandfinancialresultsexamplesofastrategicshiftcouldincludebutnotbe limitedtodisposalofmajorgeographicsegmentsamajorlineofbusinessorothermajorbusinesscomponentofan entitythenewguidancealsoexpandstherequireddisclosuresforentitiesthathaveassetsheldforsalebutdonotmeet thenewdefinitionofdiscontinuedoperationsthisamendmentincludesearlyadoptionprovisionsallowingthecompany toimplementthisupdateimmediatelyforthefirstquarterofthecompanyelectedtoadoptthisstandardforthefirst quarterofthebalancesandupdateddisclosuresrequiredbytheamendedguidanceareincludedinnoteinthe notestotheconsolidatedfinancialstatement duringthefiscalsecondquarterofthefasbissuedaccountingstandardsupdateaccountingfor sharebasedpaymentswhenthetermsofanawardprovidethataperformancetargetcouldbeachievedafterthe johnsonjohnsonannualreport requisiteserviceperiodthisstandardclarifiesthecurrentaccountingguidanceforentitiesthatissuesharebase paymentawardsthatrequireaspecificperformancetargetbeachievedforemployeestobecomeeligibletovestinthe awardswhichmayoccursubsequenttoarequiredserviceperiodcurrentaccountingguidancedoesnotexplicitly addresshowtoaccountforthesetypesofawardsthenewstandardprovidesexplicitguidanceandclarifiesthatthese typesofperformancetargetsshouldbetreatedasperformanceconditionstheaccountingforsharebasedawardswith performanceconditionsisalreadyspecifiedincurrentaccountingguidancethisupdateisrequiredtobeadoptedbyall publiccompaniesforallannualperiodsandinterimreportingperiodsbeginningafterdecemberearlyadoption ofthisstandardwaspermittedandthecompanyhadelectedtoadoptthisstandardforthesecondquarterofthe adoptionofthisstandarddidnothaveamaterialimpactonthecompanysresultsofoperationscashflowsorfinancial position recentlyissuedaccountingstandard notadoptedasofdecember duringthefiscalsecondquarterofthefasbissuedaccountingstandardsupdaterevenuefrom contractswithcustomersthisstandardreplacessubstantiallyallcurrentrevenuerecognitionaccountingguidancethis updateisrequiredtobeadoptedbyallpubliccompaniesforallannualperiodsandinterimreportingperiodsbeginning afterdecemberearlyadoptionofthisstandardisnotpermittedthecompanyiscurrentlyassessingtheimpact ofthefutureadoptionofthisstandardonitsfinancialstatement duringthefiscalsecondquarterofthefasbissuedamendedguidanceaccountingstandardsupdateno developmentstageentitieseliminationofcertainfinancialreportingrequirementsincludinganamendmentto variableinterestentityguidanceintopicconsolidationthechangeinthecurrentguidancewillrequirethe companytodetermineifitshouldconsolidateoneoftheseentitiesbasedonthechangeintheconsolidationanalysis thisupdatetotheconsolidationanalysiswillbecomeeffectiveforallannualperiodsandinterimreportingperiod beginningafterdecembertheadoptionofthisstandardisnotexpectedtohaveamaterialimpactonthe presentationofthecompanysresultsofoperationscashflowsorfinancialposition duringthefiscalthirdquarterofthefasbissuedaccountingstandardsupdatenodisclosureof uncertaintiesaboutanentitysabilitytocontinueasagoingconcernthisstandardrequiresmanagementtoevaluate foreachannualandinterimreportingperiodwhetherthereareconditionsandeventsconsideredintheaggregatethat raisesubstantialdoubtaboutanentitysabilitytocontinueasagoingconcernwithinoneyearafterthedatethefinancial statementsareissuedorareavailabletobeissuedifsubstantialdoubtisraisedadditionaldisclosuresaround managementsplantoalleviatethesedoubtsarerequiredthisupdatewillbecomeeffectiveforallannualperiodsand interimreportingperiodsbeginningafterdecemberthisstandardisnotexpectedtohaveanyimpactoncurrent disclosuresinthefinancialstatement cashequivalent thecompanyclassifiesallhighlyliquidinvestmentswithstatedmaturitiesofthreemonthsorlessfromdateofpurchase ascashequivalentsandallhighlyliquidinvestmentswithstatedmaturitiesofgreaterthanthreemonthsfromthedateof purchaseascurrentmarketablesecuritiesthecompanyhasapolicyofmakinginvestmentsonlywithcommercial institutionsthathaveatleastanaorequivalentcreditratingthecompanyinvestsitscashprimarilyinreverse repurchaseagreementsrrasgovernmentsecuritiesandobligationscorporatedebtsecuritiesandmoneymarket fund rrasarecollateralizedbydepositsintheformofgovernmentsecuritiesandobligationsforanamountnotlessthan oftheirvaluethecompanydoesnotrecordanassetorliabilityasthecompanyisnotpermittedtosellor repledgetheassociatedcollateralthecompanyhasapolicythatthecollateralhasatleastanaorequivalentcredit ratingthecompanyutilizesathirdpartycustodiantomanagetheexchangeoffundsandensurethatcollateralreceivedis maintainedatofthevalueoftherrasonadailybasisrraswithstatedmaturitiesofgreaterthanthreemonth fromthedateofpurchaseareclassifiedasmarketablesecuritie investment shorttermmarketablesecuritiesarecarriedatcostwhichapproximatesfairvalueinvestmentsclassifiedasavailablefor salearecarriedatestimatedfairvaluewithunrealizedgainsandlossesrecordedasacomponentofaccumulatedother comprehensiveincomelongtermdebtsecuritiesthatthecompanyhastheabilityandintenttoholduntilmaturityare carriedatamortizedcostmanagementdeterminestheappropriateclassificationofitsinvestmentindebtandequity johnsonjohnsonannualreportsecuritiesatthetimeofpurchaseandreevaluatessuchdeterminationateachbalancesheetdatethecompany periodicallyreviewsitsinvestmentsinequitysecuritiesforimpairmentandadjuststheseinvestmentstotheirfairvalue whenadeclineinmarketvalueisdeemedtobeotherthantemporaryiflossesonthesesecuritiesareconsideredtobe otherthantemporarythelossisrecognizedinearning propertyplantandequipmentanddepreciation propertyplantandequipmentarestatedatcostthecompanyutilizesthestraightlinemethodofdepreciationoverthe estimatedusefullivesoftheasset buildingandbuildingequipment year landandleaseholdimprovement year machineryandequipment year thecompanycapitalizescertaincomputersoftwareanddevelopmentcostsincludedinmachineryandequipmentwhen incurredinconnectionwithdevelopingorobtainingcomputersoftwareforinternalusecapitalizedsoftwarecostsare amortizedovertheestimatedusefullivesofthesoftwarewhichgenerallyrangefromtoyears thecompanyreviewslonglivedassetstoassessrecoverabilityusingundiscountedcashflowswhencertaineventsor changesinoperatingoreconomicconditionsoccuranimpairmentassessmentmaybeperformedontherecoverabilityof thecarryingvalueoftheseassetsiftheassetisdeterminedtobeimpairedthelossismeasuredbasedonthedifference betweentheassetsfairvalueanditscarryingvalueifquotedmarketpricesarenotavailablethecompanywillestimate fairvalueusingadiscountedvalueofestimatedfuturecashflow revenue recognition thecompanyrecognizesrevenuefromproductsaleswhenthegoodsareshippedordeliveredandtitleandriskofloss passtothecustomerprovisionsforcertainrebatessalesincentivestradepromotionscouponsproductreturnsand discountstocustomersareaccountedforasreductionsinsalesinthesameperiodtherelatedsalesarerecorde productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingpriceschargedbycompetitorsrebateswhichincludemedicaidareestimatedbase oncontractualtermshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsinthevarious marketsservedthecompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarilythroughthe analysisofwholesalerandotherthirdpartysellthroughandmarketresearchdataaswellasinternallygenerated information salesreturnsaregenerallyestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibit unusualsalesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedand analyzedaspartoftheaccountingforsalesreturnsaccrual salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthereturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarketasa percenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescreditto customersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewithusgaap guidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsalesvaluesales returnsintheconsumerandpharmaceuticalsegmentsarealmostexclusivelynotresalablesalesreturnsforcertain franchisesinthemedicaldevicessegmentaretypicallyresalablebutarenotmaterialthecompanyinfrequently exchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyhasbeen approximatelyofannualsalestocustomersduringthefiscalreportingyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe yearincurredcontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentiveprogramsthe redemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvaluevolumebase incentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedasproductsare soldthecompanyalsoearnsservicerevenueforcopromotionofcertainproductsandincludesitinsalestocustomer thesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferre johnsonjohnsonannualreport shippingandhandle shippingandhandlingcostsincurredweremillionmillionandmillioninand respectivelyandareincludedinsellingmarketingandadministrativeexpensetheamountofrevenuereceivedfor shippingandhandlingislessthanofsalestocustomersforallperiodspresente inventory inventoriesarestatedatthelowerofcostormarketdeterminedbythefirstinfirstoutmethod intangibleassetsandgoodwill theauthoritativeliteratureonusgaaprequiresthatgoodwillandintangibleassetswithindefinitelivesbeassesse annuallyforimpairmentthecompanycompletedtheannualimpairmenttestforinthefiscalfourthquarterfuture impairmenttestswillbeperformedannuallyinthefiscalfourthquarterorsoonerifwarrantedpurchasedinprocess researchanddevelopmentisaccountedforasanindefinitelivedintangibleassetuntiltheunderlyingprojectiscomplete atwhichpointtheintangibleassetwillbeaccountedforasadefinitelivedintangibleassetorabandonedatwhichpoint theintangibleassetwillbewrittenofforpartiallyimpaire intangibleassetsthathavefiniteusefullivescontinuetobeamortizedovertheirusefullivesandarereviewedfor impairmentwhenwarrantedbyeconomicconditionsseenoteforfurtherdetailsonintangibleassetsandgoodwill financialinstrument asrequiredbyusgaapallderivativeinstrumentsarerecordedonthebalancesheetatfairvaluefairvalueistheexit pricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbasedmeasurement determinedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitytheauthoritativeliterature establishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluewithlevelhavingthehighest priorityandlevelhavingthelowestchangesinthefairvalueofderivativesarerecordedeachperiodincurrentearning orothercomprehensiveincomedependingonwhetherthederivativeisdesignatedaspartofahedgetransactionandif sothetypeofhedgetransaction thecompanydocumentsallrelationshipsbetweenhedgeditemsandderivativestheoverallriskmanagementstrategy includesreasonsforundertakinghedgetransactionsandenteringintoderivativestheobjectivesofthisstrategyare minimizeforeigncurrencyexposuresimpactonthecompanysfinancialperformanceprotectthecompanyscash flowfromadversemovementsinforeignexchangeratesensuretheappropriatenessoffinancialinstrumentsand managetheenterpriseriskassociatedwithfinancialinstitutionsseenoteforadditionalinformationonfinancial instrument productliability accrualsforproductliabilityclaimsarerecordedonanundiscountedbasiswhenitisprobablethataliabilityhasbeen incurredandtheamountoftheliabilitycanbereasonablyestimatedbasedonexistinginformationtheaccrualsare adjustedperiodicallyasadditionalinformationbecomesavailablethecompanyaccruesanestimateofthelegaldefense costsneededtodefendeachmatterthisisreferredtoasdefensecostsinconnectionwithproductliabilitylitigationin certainmattersanindemnityamountisalsorecordedthisisreferredtoasproductliabilityaccrual asaresultofcostandavailabilityfactorseffectivenovemberthecompanyceasedpurchasingthirdparty productliabilityinsurancethecompanyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyin additiontoaccrualsintheselfinsuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesare probableandamountscanbereasonablyestimatedbasedontheavailabilityofpriorcoveragereceivablesforinsurance recoveriesrelatedtoproductliabilityclaimsarerecordedonanundiscountedbasiswhenitisprobablethatarecoverywill berealizedasappropriatereservesagainstthesereceivablesarerecordedforestimatedamountsthatmaynotbe collectedfromthirdpartyinsurer concentrationofcreditrisk globalconcentrationofcreditriskwithrespecttotradeaccountsreceivablescontinuestobelimitedduetothelarge numberofcustomersgloballyandadherencetointernalcreditpoliciesandcreditlimitseconomicchallengesinitaly spaingreeceandportugalthesoutherneuropeanregionhaveimpactedcertainpaymentpatternswhichhave johnsonjohnsonannualreporthistoricallybeenlongerthanthoseexperiencedintheusandotherinternationalmarketsthetotalnettradeaccount receivablebalanceinthesoutherneuropeanregionwasapproximatelybillionasofdecemberand approximatelybillionasofdecemberapproximatelybillionasofdecemberand approximatelybillionasofdecemberofthesoutherneuropeanregionnettradeaccountsreceivable balancerelatedtothecompanysconsumervisioncareanddiabetescarebusinessesaswellascertain pharmaceuticalandmedicaldevicescustomerswhichareinlinewithhistoricalcollectionpattern theremainingbalanceofnettradeaccountsreceivableinthesoutherneuropeanregionhasbeennegativelyimpacte bythetimingofpaymentsfromcertaingovernmentownedorsupportedhealthcarecustomersaswellascertain distributorsofthepharmaceuticalandmedicaldeviceslocalaffiliatesthetotalnettradeaccountsreceivablebalancefor thesecustomerswereapproximatelybillionatdecemberandbillionatdecemberthe companycontinuestoreceivepaymentsfromthesecustomersandinsomecaseslatepaymentpremiumsforcustomer wherepaymentisexpectedoverperiodsoftimelongerthanoneyearrevenueandtradereceivableshavebeen discountedovertheestimatedperiodoftimeforcollectionallowancesfordoubtfulaccountshavebeenincreasedfor thesecustomersbuthavebeenimmaterialtodatethecompanywillcontinuetoworkcloselywiththesecustomerson paymentplansmonitortheeconomicsituationandtakeappropriateactionsasnecessary researchanddevelopment researchanddevelopmentexpensesareexpensedasincurredupfrontandmilestonepaymentsmadetothirdpartiesin connectionwithresearchanddevelopmentcollaborationsareexpensedasincurreduptothepointofregulatoryapproval paymentsmadetothirdpartiessubsequenttoregulatoryapprovalarecapitalizedandamortizedovertheremaininguseful lifeoftherelatedproductamountscapitalizedforsuchpaymentsareincludedinotherintangiblesnetofaccumulate amortization thecompanyentersintocollaborativearrangementstypicallywithotherpharmaceuticalorbiotechnologycompaniesto developandcommercializedrugcandidatesorintellectualpropertythesearrangementstypicallyinvolvetwoormore partieswhoareactiveparticipantsinthecollaborationandareexposedtosignificantrisksandrewardsdependentonthe commercialsuccessoftheactivitiesthesecollaborationsusuallyinvolvevariousactivitiesbyoneormorepartie includingresearchanddevelopmentmarketingandsellinganddistributionoftenthesecollaborationsrequireupfront milestoneandroyaltyorprofitsharepaymentscontingentupontheoccurrenceofcertainfutureeventslinkedtothe successoftheassetindevelopmentamountsduefromcollaborativepartnersrelatedtodevelopmentactivitiesare generallyreflectedasareductionofresearchanddevelopmentexpensebecausetheperformanceofcontract developmentservicesisnotcentraltothecompanysoperationsingeneraltheincomestatementpresentationforthese collaborationsisasfollow naturetypeofcollaboration statementofearningspresentation thirdpartysaleofproduct salestocustomer royaltiesmilestonespaidtocollaborativepartner costofproductssold postregulatoryapproval royaltiesreceivedfromcollaborativepartner otherincomeexpensenet upfrontpaymentsmilestonespaidtocollaborativepartner researchanddevelopmentexpense preregulatoryapproval researchanddevelopmentpaymentstocollaborative researchanddevelopmentexpense partner researchanddevelopmentpaymentsreceivedfrom reductionofresearchanddevelopmentexpense collaborativepartner milestonesarecapitalizedasintangibleassetsandamortizedtocostofgoodssoldovertheusefullife forallyearspresentedtherewasnoindividualprojectthatrepresentedgreaterthanofthetotalannualconsolidate researchanddevelopmentexpense advertising costsassociatedwithadvertisingareexpensedintheyearincurredandareincludedinsellingmarketingand administrativeexpensesadvertisingexpensesworldwidewhichcomprisedtelevisionradioprintmediaandinternet advertisingwerebillionbillionandbillioninandrespectively johnsonjohnsonannualreport incometaxe incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludetheresultsofany differencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilitiesthecompany estimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesintaxlawsand ratesmayaffectrecordeddeferredtaxassetsandliabilitiesinthefuture thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition atdecemberanddecemberthecumulativeamountsofundistributedinternationalearningswere approximatelybillionandbillionrespectivelyatdecemberanddecemberthe companysforeignsubsidiariesheldbalancesofcashandcashequivalentsintheamountsofbillionand billionrespectivelythecompanyhasnotprovideddeferredtaxesontheundistributedearningsfromcertaininternational subsidiarieswheretheearningsareconsideredtobepermanentlyreinvestedthecompanyintendstocontinueto reinvesttheseearningsininternationaloperationsifthecompanydecidedatalaterdatetorepatriatetheseearningsto theusthecompanywouldberequiredtoprovideforthenettaxeffectsontheseamountsthecompanydoesnot determinethedeferredtaxliabilityassociatedwiththeseundistributedearningsassuchdeterminationisnotpractical seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxe netearningspershare basicearningspershareiscomputedbydividingnetearningsavailabletocommonshareholdersbytheweightedaverage numberofcommonsharesoutstandingfortheperioddilutedearningspersharereflectsthepotentialdilutionthatcould occurifsecuritieswereexercisedorconvertedintocommonstockusingthetreasurystockmethod useofestimate thepreparationofconsolidatedfinancialstatementsinconformitywithaccountingprinciplesgenerallyacceptedinthe usrequiresmanagementtomakeestimatesandassumptionsthataffecttheamountsreportedestimatesareusedwhen accountingforsalesdiscountsrebatesallowancesandincentivesproductliabilitiesincometaxesdepreciation amortizationemployeebenefitscontingenciesandintangibleassetandliabilityvaluationsactualresultsmayormaynot differfromthoseestimate thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorde whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrue annualclosingdate thecompanyfollowstheconceptofafiscalyearwhichendsonthesundaynearesttotheendofthemonthof decembernormallyeachfiscalyearconsistsofweeksbuteveryfiveorsixyearsthefiscalyearconsistsofweeks aswasthecaseinandisthecaseagainin reclassification certainpriorperiodamountshavebeenreclassifiedtoconformtocurrentyearpresentation johnsonjohnsonannualreport cashcashequivalentsandcurrentmarketablesecuritie attheendofandcashcashequivalentsandcurrentmarketablesecuritieswerecomprisedof dollarsinmillion cash governmentsecuritiesandobligation reverserepurchaseagreement corporatedebtsecuritie moneymarketfund timedeposit totalcashcashequivalentsandcurrentmarketablesecuritie theestimatedfairvalueapproximatedcostasofdecemberanddecember asofdecembercurrentmarketablesecuritiesconsistedofmillionandmillionofgovernment securitiesandobligationsandcorporatedebtsecuritiesrespectivelywithnoreverserepurchaseagreement asofdecembercurrentmarketablesecuritiesconsistedofmillionmillionandmillionof governmentsecuritiesandobligationsreverserepurchaseagreementsandcorporatedebtsecuritiesrespectively fairvalueofgovernmentsecuritiesandobligationsandcorporatedebtsecuritieswereestimatedusingquotedbroker pricesandsignificantotherobservableinput thecompanyinvestsitsexcesscashinbothdepositswithmajorbanksthroughouttheworldandotherhighquality moneymarketinstrumentsthecompanyhasapolicyofmakinginvestmentsonlywithcommercialinstitutionsthathaveat leastanaorequivalentcreditrate inventory attheendofandinventorieswerecomprisedof dollarsinmillion rawmaterialsandsupplie goodsinprocess finishedgood totalinventorie propertyplantandequipment attheendofandpropertyplantandequipmentatcostandaccumulateddepreciationwere dollarsinmillion landandlandimprovement buildingsandbuildingequipment machineryandequipment constructioninprogress totalpropertyplantandequipmentgross lessaccumulateddepreciation totalpropertyplantandequipmentnet thecompanycapitalizesinterestexpenseaspartofthecostofconstructionoffacilitiesandequipmentinterestexpense capitalizedinandwasmillionmillionandmillionrespectively johnsonjohnsonannualreport depreciationexpenseincludingtheamortizationofcapitalizedinterestinandwasbillion billionandbillionrespectively uponretirementorotherdisposalofpropertyplantandequipmentthecostsandrelatedamountsofaccumulate depreciationoramortizationareeliminatedfromtheassetandaccumulateddepreciationaccountsrespectivelythe differenceifanybetweenthenetassetvalueandtheproceedsarerecordedinearning intangibleassetsandgoodwill attheendofandthegrossandnetamountsofintangibleassetswere dollarsinmillion intangibleassetswithdefinitelive patentsandtrademarksgross lessaccumulatedamortization patentsandtrademarksnet customerrelationshipsandotherintangiblesgross lessaccumulatedamortization customerrelationshipsandotherintangiblesnet intangibleassetswithindefinitelive trademark purchasedinprocessresearchanddevelopment totalintangibleassetswithindefinitelive totalintangibleassetsnet goodwillasofdecemberanddecemberasallocatedbysegmentofbusinesswasasfollow dollarsinmillion consumer pharmaceutical meddevice total goodwillatdecember goodwillrelatedtoacquisition goodwillrelatedtodivestitures currencytranslationother goodwillatdecember goodwillrelatedtoacquisition goodwillrelatedtodivestitures currencytranslationother goodwillatdecember theweightedaverageamortizationperiodsforpatentsandtrademarksandcustomerrelationshipsandotherintangible assetsareyearsandyearsrespectivelytheamortizationexpenseofamortizableassetsincludedincostof productssoldwasmillionmillionandmillionbeforetaxforthefiscalyearsendeddecember decemberanddecemberrespectivelytheestimatedamortizationexpenseforthefive succeedingyearsapproximatesmillionbeforetaxperyear seenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtoacquisitionsanddivestiture fairvaluemeasurement thecompanyusesforwardforeignexchangecontractstomanageitsexposuretothevariabilityofcashflowsprimarily relatedtotheforeignexchangeratechangesoffutureintercompanyproductandthirdpartypurchasesofmaterial denominatedinaforeigncurrencythecompanyusescrosscurrencyinterestrateswapstomanagecurrencyrisk primarilyrelatedtoborrowingsbothtypesofderivativesaredesignatedascashflowhedge johnsonjohnsonannualreportadditionallythecompanyusesinterestrateswapsasaninstrumenttomanageinterestrateriskrelatedtofixedrate borrowingsthesederivativesaretreatedasfairvaluehedgesthecompanymayuseforwardforeignexchangecontract designatedasnetinvestmenthedgesadditionallythecompanyusesforwardforeignexchangecontractstooffsetit exposuretocertainforeigncurrencyassetsandliabilitiestheseforwardforeignexchangecontractsarenotdesignatedas hedgesandthereforechangesinthefairvaluesofthesederivativesarerecognizedinearningstherebyoffsettingthe currentearningseffectoftherelatedforeigncurrencyassetsandliabilitie thecompanydoesnotenterintoderivativefinancialinstrumentsfortradingorspeculativepurposesorthatcontaincredit riskrelatedcontingentfeaturesorrequirementstopostcollateralonanongoingbasisthecompanymonitor counterpartycreditratingsthecompanyconsiderscreditnonperformancerisktobelowbecausethecompanyenters intoagreementswithcommercialinstitutionsthathaveatleastanaorequivalentcreditratingasofdecember thecompanyhadnotionalamountsoutstandingforforwardforeignexchangecontractscrosscurrencyinterest rateswapsandinterestrateswapsofbillionbillionandbillionrespectively allderivativeinstrumentsarerecordedonthebalancesheetatfairvaluechangesinthefairvalueofderivativesare recordedeachperiodincurrentearningsorothercomprehensiveincomedependingonwhetherthederivativeis designatedaspartofahedgetransactionandifsothetypeofhedgetransaction thedesignationasacashflowhedgeismadeattheentrancedateofthederivativecontractatinceptionallderivative areexpectedtobehighlyeffectivechangesinthefairvalueofaderivativethatisdesignatedasacashflowhedgeandis highlyeffectivearerecordedinaccumulatedothercomprehensiveincomeuntiltheunderlyingtransactionaffectsearning andarethenreclassifiedtoearningsinthesameaccountasthehedgedtransactiongainsandlossesassociatedwith interestrateswapsarerecordedtointerestexpenseintheperiodinwhichtheyoccurgainsandlossesonnetinvestment hedgesareaccountedforthroughthecurrencytranslationaccountandareinsignificantonanongoingbasisthe companyassesseswhethereachderivativecontinuestobehighlyeffectiveinoffsettingchangesofhedgeditemsifand whenaderivativeisnolongerexpectedtobehighlyeffectivehedgeaccountingisdiscontinuedhedgeineffectivenessif anyisincludedincurrentperiodearningsinotherincomeexpensenetforforwardforeignexchangecontractsand crosscurrencyinterestrateswapsforinterestrateswapsdesignatedasfairvaluehedgeshedgeineffectivenessifany isincludedincurrentperiodearningswithininterestexpenseforthecurrentreportingperiodhedgeineffectiveness associatedwithinterestrateswapsarenotmaterial asofdecemberthebalanceofdeferrednetgainsonderivativesincludedinaccumulatedothercomprehensive incomewasmillionaftertaxforadditionalinformationseetheconsolidatedstatementsofcomprehensiveincome andnotethecompanyexpectsthatsubstantiallyalloftheamountsrelatedtoforwardforeignexchangecontractswill bereclassifiedintoearningsoverthenextmonthsasaresultoftransactionsthatareexpectedtooccuroverthat periodthemaximumlengthoftimeoverwhichthecompanyishedgingtransactionexposureismonthsexclude interestratecontractstheamountultimatelyrealizedinearningsmaydifferasforeignexchangerateschangerealize gainsandlossesareultimatelydeterminedbyactualexchangeratesatmaturityofthederivative thefollowingtableisasummaryoftheactivityrelatedtoderivativesdesignatedascashflowhedgesforthefiscalyear endeddecemberanddecember gainloss gainloss gainloss reclassifiedfrom recognizedin recognizedin accumulatedoci dollarsinmillion accumulatedoci intoincome incomeexpense cashflowhedgesbyincomestatementcaption salestocustomer costofproductssold researchanddevelopmentexpense interestincomeinterestexpensenet otherincomeexpensenet total allamountsshowninthetableabovearenetoftax effectiveportion ineffectiveportion forwardforeignexchangecontract crosscurrencyinterestrateswap johnsonjohnsonannualreport forthefiscalyearsendeddecemberanddecemberagainofmillionandagainofmillion respectivelywasrecognizedinotherincomeexpensenetrelatingtoforwardforeignexchangecontractsnot designatedashedginginstrument fairvalueistheexitpricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbase measurementdeterminedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitythe authoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevel withinthehierarchyaredescribedbelowwithlevelhavingthehighestpriorityandlevelhavingthelow thefairvalueofaderivativefinancialinstrumentieforwardforeignexchangecontractsinterestratecontractsisthe aggregationbycurrencyofallfuturecashflowsdiscountedtoitspresentvalueattheprevailingmarketinterestratesand subsequentlyconvertedtotheusdollaratthecurrentspotforeignexchangeratethecompanydoesnotbelievethat fairvaluesofthesederivativeinstrumentsmateriallydifferfromtheamountsthatcouldberealizeduponsettlementor maturityorthatthechangesinfairvaluewillhaveamaterialeffectonthecompanysresultsofoperationscashflowsor financialpositionthecompanyalsoholdsequityinvestmentswhichareclassifiedaslevelbecausetheyaretradedin anactiveexchangemarketthecompanydidnothaveanyothersignificantfinancialassetsorliabilitieswhichwould requirerevisedvaluationsunderthisstandardthatarerecognizedatfairvalue thefollowingthreelevelsofinputsareusedtomeasurefairvalue levelquotedpricesinactivemarketsforidenticalassetsandliabilitie levelsignificantotherobservableinput levelsignificantunobservableinput thecompanyssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofdecemberand decemberwereasfollow dollarsinmillion level level level total total derivativesdesignatedashedginginstrument asset forwardforeignexchangecontract interestratecontract total liability forwardforeignexchangecontract interestratecontract total derivativesnotdesignatedashedginginstrument asset forwardforeignexchangecontract liability forwardforeignexchangecontract otherinvestment assetsandliabilitiesareallclassifiedaslevelwiththeexceptionofotherinvestmentsofmillionwhichareclassifiedas level includesmillionandmillionofnoncurrentassetsforthefiscalyearsendingdecemberanddecember respectively includesmillionandmillionofnoncurrentliabilitiesforthefiscalyearsendingdecemberanddecember respectively includescrosscurrencyinterestrateswapsandinterestrateswap classifiedasnoncurrentotherasset seenotesandforfinancialassetsandliabilitiesheldatcarryingamountontheconsolidatedbalancesheet johnsonjohnsonannualreport borrowing thecomponentsoflongtermdebtareasfollow effective effective dollarsinmillion rate rate monthliborfrndue notesdue notesdue monthliborfrndue notesdue debenturesdue notesdue debenturesdue notesdue notesduebeurobeuro notesdue zerocouponconvertiblesubordinateddebenturesdue debenturesdue notesdue notesdue debenturesdue notesdue notesduemmgbpmmgbp notesdue debenturesdue notesdue notesdue debenturesdue debenturesdue notesdue notesdue subtotal lesscurrentportion totallongtermdebt weightedaverageeffectiverate translationrateatdecember translationrateatdecember theexcessofthefairvalueoverthecarryingvalueofdebtwasbillioninandbillionin includesthereopeningoftheseissue fairvalueofthenoncurrentdebtwasestimatedusingmarketpriceswhichwerecorroboratedbyquotedbrokerprice andsignificantotherobservableinput thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementsisbasedoneitherbid providedbybankstheprimerateorlondoninterbankofferedratesliborplusapplicablemarginscommitmentfee undertheagreementsarenotmaterial johnsonjohnsonannualreport throughoutthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarketshortterm borrowingsandthecurrentportionoflongtermdebtamountedtoapproximatelybillionattheendofofwhich billionwasborrowedunderthecommercialpaperprogramtheremainderprincipallyrepresentslocalborrowingby internationalsubsidiarie thecompanyhasashelfregistrationwiththeussecuritiesandexchangecommissionthatenablesthecompanyto issuedebtsecuritiesandwarrantstopurchasedebtsecuritiesonatimelybasisthecompanyissuedbondsinnovember foratotalofbillionforgeneralcorporatepurposesthisincludedthereopeningoftheandbond issuedindecember aggregatematuritiesoflongtermobligationscommencinginare dollarsinmillion incometaxe theprovisionfortaxesonincomeconsistsof dollarsinmillion currentlypayable ustaxe internationaltaxe totalcurrentlypayable defer ustaxe internationaltaxe totaldeferre provisionfortaxesonincome acomparisonofincometaxexpenseattheusstatutoryrateofinandtothecompany effectivetaxrateisasfollow dollarsinmillion international earningsbeforetaxesonincome taxrate usstatutoryrate internationaloperationsexcludingireland irelandandpuertoricooperation researchandorphandrugtaxcredit usstateandlocal usmanufacturingdeduction ustaxoninternationalincome ustaxbenefitonassetbusinessdisposal allother effectivetaxrate johnsonjohnsonannualreporttheincreaseintheeffectivetaxrateascomparedtowasattributabletothefollowingthedivestitureofthe orthoclinicaldiagnosticsbusinessatanapproximateeffectivetaxratelitigationaccrualsatlowtaxratesthemixof earningsintohighertaxjurisdictionsprimarilytheustheaccrualofanadditionalyearofthebrandedprescriptiondrug feewhichisnottaxdeductibleandadditionalustaxexpenserelatedtoaplannedincreaseindividendsfromcurrent yearforeignearningsascomparedtotheprioryeartheseincreasestotheeffectivetaxratewerepartiallyoffsetby ataxbenefitofbillionassociatedwiththeconormedsystemsdivestiture theeffectivetaxratewasreducedbyataxbenefitassociatedwiththewriteoffofassetsfortaxpurpose associatedwithsciosincandtheinclusionofboththeandbenefitfromtheresearchanddevelopmenttax creditandthecontrolledforeigncorporationlookthroughprovisionsbecausethoseprovisionswereenactedintolawin januaryandwereretroactivetojanuary theeffectivetaxratewasalsoreducedasthecompanyadjusteditsunrecognizedtaxbenefitsasaresultofithe federalappealscourtsdecisioninomjpharmaceuticalsincslitigationregardingcreditsunderformersectionof theinternalrevenuecodeseenotetotheconsolidatedfinancialstatementsforadditionalinformationandiia settlementofsubstantiallyallissuesrelatedtothecompanysusinternalrevenueserviceauditoftaxyear theimpactofthesettlementisreflectedintheustaxoninternationalincomeandtheallotherlineitemswithin theabovereconciliation theitemsnotedabovereflectthekeydriversoftheratereconciliation thecompanyhassubsidiariesoperatinginpuertoricoundervarioustaxincentive temporarydifferencesandcarryforwardsforandwereasfollow deferredtax deferredtax dollarsinmillion asset liability asset liability employeerelatedobligation stockbasedcompensation depreciation nondeductibleintangible internationalrdcapitalizedfortax reservesliabilitie incomereportedfortaxpurpose netoperatinglosscarryforwardinternational miscellaneousinternational miscellaneousus totaldeferredincometaxe themillioninwasnetofavaluationallowancerelatedtobelgiumofmillionthemillioninwasnet ofavaluationallowancerelatedtobelgiumofmillion thedifferencebetweenthenetdeferredtaxonincomeperthebalancesheetandthenetdeferredtaxaboveisincludedin taxesonincomeonthebalancesheetthecompanyhaswhollyownedinternationalsubsidiariesthathavecumulativenet lossesthecompanybelievesthatitismorelikelythannotthatthesesubsidiarieswillrealizefuturetaxableincome sufficienttoutilizethesedeferredtaxasset thefollowingtablesummarizestheactivityrelatedtounrecognizedtaxbenefit dollarsinmillion beginningofyear increasesrelatedtocurrentyeartaxposition increasesrelatedtopriorperiodtaxposition decreasesrelatedtopriorperiodtaxposition settlement lapseofstatuteoflimitation endofyear johnsonjohnsonannualreport theunrecognizedtaxbenefitsofbillionatdecemberifrecognizedwouldaffectthecompanysannual effectivetaxratethecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxaudit inprogresswithanumberoftaxauthoritiestheirshascompleteditsauditforthetaxyearsthroughhowever therearealimitednumberofissuesremainingopenforpriortaxyearsgoingbacktoinothermajorjurisdiction wherethecompanyconductsbusinesstheyearsremainopengenerallybacktotheyearthecompanybelievesit ispossiblethatauditsmaybecompletedbytaxauthoritiesinsomejurisdictionsoverthenexttwelvemonthshoweverthe companyisnotabletoprovideareasonablyreliableestimateofthetimingofanyotherfuturetaxpaymentsrelatingto uncertaintaxposition thecompanyclassifiesliabilitiesforunrecognizedtaxbenefitsandrelatedinterestandpenaltiesaslongtermliabilitie interestexpenseandpenaltiesrelatedtounrecognizedtaxbenefitsareclassifiedasincometaxexpensethecompany recognizedaftertaxinterestexpenseofmillionmillionandmillioninandrespectively thetotalamountofaccruedinterestwasmillionandmillioninandrespectively employeerelatedobligation attheendofandemployeerelatedobligationsrecordedontheconsolidatedbalancesheetswere dollarsinmillion pensionbenefit postretirementbenefit postemploymentbenefit deferredcompensation totalemployeeobligation lesscurrentbenefitspayable employeerelatedobligationsnoncurrent prepaidemployeerelatedobligationsofmillionandmillionforandrespectivelyareincludedin otherassetsontheconsolidatedbalancesheet pensionsandotherbenefitplan thecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefitdefinedcontributionand terminationindemnityplanswhichcovermostemployeesworldwidethecompanyalsoprovidespostretirement benefitsprimarilyhealthcaretoalleligibleusretiredemployeesandtheirdependent manyinternationalemployeesarecoveredbygovernmentsponsoredprogramsandthecosttothecompanyisnot significant retirementplanbenefitsforemployeeshiredbeforejanuaryareprimarilybasedontheemployeescompensation duringthelastthreetofiveyearsbeforeretirementandthenumberofyearsofserviceinthecompanyannounce thattheusdefinedbenefitplanwasamendedtoadoptanewbenefitformulaeffectiveforemployeeshiredonorafter januarythebenefitsarecalculatedusinganewformulabasedonemployeecompensationovertotalyearsof serviceinternationalsubsidiarieshaveplansunderwhichfundsaredepositedwithtrusteesannuitiesarepurchase undergroupcontractsorreservesareprovided thecompanydoesnotfundretireehealthcarebenefitsinadvanceandhastherighttomodifytheseplansinthefuture thecompanyusesthedateofitsconsolidatedfinancialstatementsdecemberanddecember respectivelyasthemeasurementdateforallusandinternationalretirementandotherbenefitplan johnsonjohnsonannualreportnetperiodicbenefitcostsforthecompanysdefinedbenefitretirementplansandotherbenefitplansforand includethefollowingcomponent retirementplan otherbenefitplan dollarsinmillion servicecost interestcost expectedreturnonplanasset amortizationofpriorservicecostcredit amortizationofnettransitionobligation recognizedactuariallosse curtailmentsandsettlement netperiodicbenefitcost amountsexpectedtoberecognizedinnetperiodicbenefitcostinthecomingyearforthecompanysdefinedbenefit retirementplansandotherpostretirementplans dollarsinmillion amortizationofnettransitionobligation amortizationofnetactuariallosse amortizationofpriorservicecredit unrecognizedgainsandlossesfortheuspensionplansareamortizedovertheaverageremainingfutureserviceforeach planforplanswithnoactiveemployeestheyareamortizedovertheaveragelifeexpectancytheamortizationofgain andlossesfortheotherusbenefitplansisdeterminedbyusingacorridorofthegreaterofthemarketvalueof assetsortheprojectedbenefitobligationtotalunamortizedgainsandlossesinexcessofthecorridorareamortizedover theaverageremainingfutureservice priorservicecostsbenefitsfortheuspensionplansareamortizedovertheremainingfutureserviceofplanparticipant atthetimeoftheplanamendmentpriorservicecostbenefitfortheotherusbenefitplansisamortizedovertheaverage remainingservicetofulleligibilityageofplanparticipantsatthetimeoftheplanamendment theweightedaverageassumptionsinthefollowingtablerepresenttheratesusedtodeveloptheactuarialpresentvalue ofprojectedbenefitobligationfortheyearlistedandalsothenetperiodicbenefitcostforthefollowingyear retirementplan otherbenefitplan worldwidebenefitplans discountrate expectedlongtermrateofreturnonplanasset rateofincreaseincompensationlevel thecompanysdiscountratesaredeterminedbyconsideringcurrentyieldcurvesrepresentinghighqualitylongterm fixedincomeinstrumentstheresultingdiscountratesareconsistentwiththedurationofplanliabilitie theexpectedratesofreturnonplanassetassumptionsrepresentthecompanysassessmentoflongtermreturnson diversifiedinvestmentportfoliosgloballytheassessmentisdeterminedusingprojectionsfromexternalfinancialsource longtermhistoricalaveragesactualreturnsbyassetclassandthevariousassetclassallocationsbymarket formeasurementofusretirementbenefitobligationsthemortalityassumptionwasupdatedtoanewlyestablishe mortalitytableresultinginanincreasetotheprojectedbenefitobligation thefollowingtabledisplaystheassumedhealthcarecosttrendratesforallindividual healthcareplan healthcarecosttrendrateassumedfornextyear ratetowhichthecosttrendrateisassumedtodeclineultimatetrend yeartheratereachestheultimatetrendrate johnsonjohnsonannualreport aonepercentagepointchangeinassumedhealthcarecosttrendrateswouldhavethefollowingeffect onepercentage onepercentage dollarsinmillion pointincrease pointdecrease healthcareplan totalinterestandservicecost postretirementbenefitobligation thefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatyearend andforthecompanysdefinedbenefitretirementplansandotherpostretirementplan otherbenefit retirementplan plan dollarsinmillion changeinbenefitobligation projectedbenefitobligationbeginningofyear servicecost interestcost planparticipantcontribution amendment actuarialgainslosse divestituresacquisition curtailmentssettlementsrestructure benefitspaidfromplan effectofexchangerate projectedbenefitobligationendofyear changeinplanasset planassetsatfairvaluebeginningofyear actualreturnonplanasset companycontribution planparticipantcontribution settlement divestituresacquisition benefitspaidfromplanasset effectofexchangerate planassetsatfairvalueendofyear fundedstatusendofyear amountsrecognizedinthecompanysbalancesheetconsistofthefollowe noncurrentasset currentliabilitie noncurrentliabilitie totalrecognizedintheconsolidatedbalancesheetendofyear amountsrecognizedinaccumulatedothercomprehensiveincomeconsistof thefollowe netactuarialloss priorservicecostcredit unrecognizednettransitionobligation totalbeforetaxeffect accumulatedbenefitobligationsendofyear johnsonjohnsonannualreportotherbenefit retirementplan plan dollarsinmillion changesinplanassetsandbenefitobligationsrecognizedinother comprehensiveincome netperiodicbenefitcost netactuarialgainloss amortizationofnetactuarialloss priorservicecostcredit amortizationofpriorservicecostcredit effectofexchangerate totalrecognizedinothercomprehensiveincomebeforetax totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome thecompanyplanstocontinuetofunditsusqualifiedplanstocomplywiththepensionprotectionactof internationalplansarefundedinaccordancewithlocalregulationsadditionaldiscretionarycontributionsaremadewhen deemedappropriatetomeetthelongtermobligationsoftheplansforcertainplansfundingisnotacommonpracticea fundingprovidesnoeconomicbenefitconsequentlythecompanyhasseveralpensionplansthatarenotfunde inthecompanycontributedmillionandmilliontoitsusandinternationalpensionplansrespectively thefollowingtabledisplaysthefundedstatusofthecompanysusqualifiednonqualifiedpensionplansand internationalfundedandunfundedpensionplansatdecemberanddecemberrespectively usplans internationalplans qualifiedplan nonqualifiedplans fundedplan unfundedplan dollarsinmillion planasset projectedbenefitobligation accumulatedbenefitobligation overunderfundedstatus projectedbenefitobligation accumulatedbenefitobligation planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligationprojected benefitobligationandplanassetsofbillionbillionandbillionrespectivelyattheendofand billionbillionandbillionrespectivelyattheendof thefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromthecompanysretirementandotherbenefitplan dollarsinmillion projectedfuturebenefitpayment retirementplan otherbenefitplan thefollowingtabledisplaystheprojectedfutureminimumcontributionstotheunfundedretirementplanstheseamount donotincludeanydiscretionarycontributionsthatthecompanymayelecttomakeinthefuture dollarsinmillion projectedfuturecontribution eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationand investmentofthepensionplansindetermininginvestmentpoliciesstrategiesandgoalseachcommitteeorboard considersfactorsincludinglocalpensionrulesandregulationslocaltaxregulationsavailabilityofinvestmentvehicle separateaccountscommingledaccountsinsurancefundsetcfundedstatusoftheplansratioofactivestoretiree johnsonjohnsonannualreport durationofliabilitiesandotherrelevantfactorsincludingdiversificationliquidityoflocalmarketsandliquidityofbase currencyamajorityofthecompanyspensionfundsareopentonewentrantsandareexpectedtobeongoingplan permittedinvestmentsareprimarilyliquidandorlistedwithlittlerelianceonilliquidandnontraditionalinvestmentssuch ashedgefund thecompanysretirementplanassetallocationattheendofandandtargetallocationsforareas follow percentof target planasset allocation worldwideretirementplan equitysecuritie debtsecuritie totalplanasset determinationoffairvalueofplanasset theplanhasanestablishedandwelldocumentedprocessfordeterminingfairvaluesfairvalueisbaseduponquote marketpriceswhereavailableiflistedpricesorquotesarenotavailablefairvalueisbaseduponmodelsthatprimarily useasinputsmarketbasedorindependentlysourcedmarketparametersincludingyieldcurvesinterestratesvolatilitie equityordebtpricesforeignexchangeratesandcreditcurve whiletheplanbelievesitsvaluationmethodsareappropriateandconsistentwithothermarketparticipantstheuseof differentmethodologiesorassumptionstodeterminethefairvalueofcertainfinancialinstrumentscouldresultinadifferent estimateoffairvalueatthereportingdate valuationhierarchy theauthoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevel withinthehierarchyaredescribedinthetablebelowwithlevelhavingthehighestpriorityandlevelhavingthelowest afinancialinstrumentscategorizationwithinthevaluationhierarchyisbaseduponthelowestlevelofinputthatis significanttothefairvaluemeasurement followingisadescriptionofthevaluationmethodologiesusedfortheinvestmentsmeasuredatfairvalue shortterminvestmentscashandquotedshortterminstrumentsarevaluedattheclosingpriceortheamountheld ondepositbythecustodianbankotherinvestmentsarethroughinvestmentvehiclesvaluedusingthenetassetvalue navprovidedbytheadministratorofthefundthenavisbasedonthevalueoftheunderlyingassetsownedbythe fundminusitsliabilitiesandthendividedbythenumberofsharesoutstandingthenavisaquotedpriceinamarket thatisnotactiveandclassifiedaslevel governmentandagencysecuritiesalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedon themajormarketonwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarket theinvestmentsareclassifiedwithinlevelofthevaluationhierarchyifquotedmarketpricesarenotavailableforthe specificsecuritythenfairvaluesareestimatedbyusingpricingmodelsquotedpricesofsecuritieswithsimilar characteristicsordiscountedcashflowswhenquotedmarketpricesforasecurityarenotavailableinanactivemarket theyareclassifiedaslevel debtinstrumentsalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedonthemajormarket onwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarkettheinvestmentsare classifiedaslevelifquotedmarketpricesarenotavailableforthespecificsecuritythenfairvaluesareestimatedby usingpricingmodelsquotedpricesofsecuritieswithsimilarcharacteristicsordiscountedcashflowsandareclassifie aslevelleveldebtinstrumentsarepricedbasedonunobservableinput equitysecuritiescommonstocksarevaluedattheclosingpricereportedonthemajormarketonwhichtheindividual securitiesaretradedsubstantiallyallcommonstockisclassifiedwithinlevelofthevaluationhierarchy commingledfundstheseinvestmentvehiclesarevaluedusingthenavprovidedbythefundadministratorthenav isbasedonthevalueoftheunderlyingassetsownedbythefundminusitsliabilitiesandthendividedbythenumberof sharesoutstandingassetsinthelevelcategoryhaveaquotedmarketpriceinamarketthatisnotactive johnsonjohnsonannualreport insurancecontractstheinstrumentsareissuedbyinsurancecompaniesthefairvalueisbasedonnegotiatedvalue andtheunderlyinginvestmentsheldinseparateaccountportfoliosaswellasconsideringthecreditworthinessofthe issuertheunderlyinginvestmentsaregovernmentassetbackedandfixedincomesecuritiesingeneralinsurance contractsareclassifiedaslevelastherearenoquotedpricesnorotherobservableinputsforprice otherassetsotherassetsarerepresentedprimarilybylimitedpartnershipsandrealestateinvestmentsaswellas commercialloansandcommercialmortgagesthatarenotclassifiedascorporatedebtotherassetsthatareexchange listedandactivelytradedareclassifiedaslevelwhileinactivelytradedassetsareclassifiedaslevelmostlimite partnershipsrepresentinvestmentsinprivateequityandsimilarfundsthatarevaluedbythegeneralpartnerscertainof theselimitedpartnershipsaswellasanyotherassetsvaluedusingunobservableinputsareclassifiedaslevel thefollowingtablesetsforththeretirementplansinvestmentsmeasuredatfairvalueasofdecemberand december quotedprice significant inactive significant marketsfor observable unobservable identicalasset input input level level level totalasset dollarsinmillion shortterminvestmentfund governmentandagencysecuritie debtinstrument equitysecuritie commingledfund insurancecontract otherasset investmentsatfairvalue thecompanysotherbenefitplansareunfundedexceptforuscommingledfundslevelofmillionand millionatdecemberanddecemberrespectivelyandmillionandmillionofusshortterm investmentfundslevelatdecemberanddecemberrespectively thefairvalueofjohnsonjohnsoncommonstockdirectlyheldinplanassetswasmillionoftotalplan assetsatdecemberandmillionoftotalplanassetsatdecember levelgainsandlosses thetablebelowsetsforthasummaryofchangesinthefairvalueoftheplanslevelassetsfortheyearsende decemberanddecember debt equity commingle insurance total dollarsinmillion instrument security fund contract asset level balancedecember realizedgainslosse unrealizedgainslosse purchasessalesissuancesandsettlementsnet balancedecember realizedgainslosse unrealizedgainslosse purchasessalesissuancesandsettlementsnet transfersinoutandexchangeratechange balancedecember johnsonjohnsonannualreport savingsplan thecompanyhasvoluntaryksavingsplansdesignedtoenhancetheexistingretirementprogramscoveringeligible employeesthecompanymatchesapercentageofeachemployeescontributionsconsistentwiththeprovisionsofthe planforwhichhesheiseligibletotalcompanymatchingcontributionstotheplansweremillionmillionand millioninandrespectively capitalandtreasurystock changesintreasurystockwere treasurystock amountsinmillionsexcepttreasurystocksharesinthousand share balanceatjanuary employeecompensationandstockoptionplans issuanceofcommonstockassociatedwiththeacquisitionofsynthesinc repurchaseofcommonstock balanceatdecember employeecompensationandstockoptionplans repurchaseofcommonstock balanceatdecember employeecompensationandstockoptionplans repurchaseofcommonstock balanceatdecember includesrepurchaseofcommonstockassociatedwiththeacquisitionofsynthesinc aggregatesharesofcommonstockissuedwereapproximatelysharesattheendofand cashdividendspaidwerepershareincomparedwithdividendsofpershareinandper sharein onjulythecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogramauthorizing thecompanytopurchaseuptobillionofthecompanyssharesofcommonstockasofdecember billionhasbeenrepurchasedundertheprogramsharerepurchaseswilltakeplaceontheopenmarketfromtimetotime basedonmarketconditionstherepurchaseprogramhasnotimelimitandmaybesuspendedforperiodsordiscontinue atanytimeanysharesacquiredwillbeavailableforgeneralcorporatepurposesthecompanyintendstofinancethe sharerepurchaseprogramthroughavailablecash accumulatedothercomprehensiveincome componentsofothercomprehensiveincomelossconsistofthefollowing gain total gain loss accumulate foreign loss employee currency benefit derivative comprehensive dollarsinmillion translation security plan hedge incomeloss january netchange december netchange december netchange december johnsonjohnsonannualreportamountsinaccumulatedothercomprehensiveincomearepresentednetoftherelatedtaximpactforeigncurrency translationisnotadjustedforincometaxeswhereitrelatestopermanentinvestmentsininternationalsubsidiariesfor additionaldetailsoncomprehensiveincomeseetheconsolidatedstatementsofcomprehensiveincome detailsonreclassificationsoutofaccumulatedothercomprehensiveincome gainlossonsecuritiesreclassificationsreleasedtootherincomeexpensenet employeebenefitplansreclassificationsareincludedinnetperiodicbenefitcostseenoteforadditional detail gainlossonderivativeshedgesreclassificationstoearningsarerecordedinthesameaccountasthe hedgedtransactionseenoteforadditionaldetail internationalcurrencytranslation fortranslationofitssubsidiariesoperatinginnonusdollarcurrenciesthecompanyhasdeterminedthatthelocal currenciesofitsinternationalsubsidiariesarethefunctionalcurrenciesexceptthoseinhighlyinflationaryeconomieswhich aredefinedasthosewhichhavehadcompoundcumulativeratesofinflationoformoreduringthepastthreeyear orwhereasubstantialportionofitscashflowsarenotinthelocalcurrency inconsolidatinginternationalsubsidiariesbalancesheetcurrencyeffectsarerecordedasacomponentofaccumulate othercomprehensiveincomethisequityaccountincludestheresultsoftranslatingcertainbalancesheetassetsand liabilitiesatcurrentexchangeratesandsomeaccountsathistoricalratesexceptforthoselocatedinhighlyinflationary economiesthetranslationofbalancesheetaccountsforhighlyinflationaryeconomiesarereflectedintheoperate result arollforwardofthechangesduringandforforeigncurrencytranslationadjustmentsisincludedin note netcurrencytransactiongainsandlossesincludedinotherincomeexpensewerelossesofmillionmillion andmillioninandrespectively earningspershare thefollowingisareconciliationofbasicnetearningspersharetodilutednetearningspershareforthefiscalyearsende decemberdecemberanddecember inmillionsexceptpershareamount basicnetearningspershareattributabletojohnsonjohnson averagesharesoutstandingbasic potentialsharesexercisableunderstockoptionplans lesssharesrepurchasedundertreasurystockmethod convertibledebtshare acceleratedsharerepurchaseprogram adjustedaveragesharesoutstandingdilute dilutednetearningspershareattributabletojohnsonjohnson thedilutednetearningspersharecalculationincludedthedilutiveeffectofconvertibledebtthatisoffsetbytherelate reductionininterestexpenseofmillionaftertaxforandmillionforyearsand thedilutedearningspersharecalculationforandincludedallsharesrelatedtostockoptionsastheexercise priceofalloptionswaslessthantheaveragemarketvalueofthecompanysstockdilutednetearningspersharefor excludedmillionsharesrelatedtostockoptionsastheexercisepriceoftheseoptionswasgreaterthantheir averagemarketvaluewhichwouldresultinanantidilutiveeffectondilutedearningspershare thedilutedearningspersharecalculationforthefiscalyearsendeddecemberanddecember includedthedilutiveeffectofmillionsharesandmillionsharesrespectivelyrelatedtotheacceleratedshare repurchaseprogramassociatedwiththeacquisitionofsynthesincseenotetotheconsolidatedfinancial statementsforadditionaldetail johnsonjohnsonannualreport rentalexpenseandleasecommitment rentalsofspacevehiclesmanufacturingequipmentandofficeanddataprocessingequipmentunderoperatinglease wereapproximatelymillionmillionandmillioninandrespectively theapproximateminimumrentalpaymentsrequiredunderoperatingleasesthathaveinitialorremainingnoncancelable leasetermsinexcessofoneyearatdecemberare dollarsinmillion total commitmentsundercapitalleasesarenotsignificant commonstockstockoptionplansandstockcompensationagreement atdecemberthecompanyhadstockbasedcompensationplansthesharesoutstandingareforcontract underthecompanysstockoptionplanthelongtermincentiveplanandthelongtermincentive planthelongtermincentiveplanexpiredaprilalloptionsandrestrictedsharesgrantedsubsequentto thatdatewereunderthelongtermincentiveplanunderthelongtermincentiveplanthecompanymay issueuptomillionsharesofcommonstockplusanysharescanceledexpiredforfeitedornotissuedfromthe longtermincentiveplansubsequenttoaprilsharesavailableforfuturegrantsunderthelongterm incentiveplanweremillionattheendof thecompensationcostthathasbeenchargedagainstincomefortheseplanswasmillionmillionand millionforandrespectivelythetotalincometaxbenefitrecognizedintheincomestatementfor sharebasedcompensationcostswasmillionmillionandmillionforand respectivelythetotalunrecognizedcompensationcostwasmillionmillionandmillionfor andrespectivelytheweightedaverageperiodforthiscosttoberecognizedwasyearsyearsand yearsforandrespectivelysharebasedcompensationcostscapitalizedaspartofinventorywere insignificantinallperiod thecompanysettlesemployeebenefitequityissuanceswithtreasurysharestreasurysharesarereplenishedthroughout theyearforthenumberofsharesusedtosettleemployeebenefitequityissuance stockoption stockoptionsexpireyearsfromthedateofgrantandvestoverserviceperiodsthatrangefrommonthstoyearsall optionsaregrantedattheaverageofthehighandlowpricesofthecompanyscommonstockonthenewyorkstock exchangeonthedateofgrant thefairvalueofeachoptionawardwasestimatedonthedateofgrantusingtheblackscholesoptionvaluationmodel thatusestheassumptionsnotedinthefollowingtableexpectedvolatilityrepresentsablendedrateofyeardaily historicalaveragevolatilityrateandaweekaverageimpliedvolatilityratebasedonatthemoneytradedjohnson johnsonoptionswithalifeofyearshistoricaldataisusedtodeterminetheexpectedlifeoftheoptiontheriskfreerate wasbasedontheustreasuryyieldcurveineffectatthetimeofgrant theaveragefairvalueofoptionsgrantedwasandinandrespectivelythefair valuewasestimatedbasedontheweightedaverageassumptionsof riskfreerate expectedvolatility expectedlifeinyear dividendyield johnsonjohnsonannualreportasummaryofoptionactivityundertheplanasofdecemberdecemberanddecemberand changesduringtheyearsendingonthosedatesispresentedbelow aggregate intrinsic weight value outstanding average dollarsin sharesinthousand share exerciseprice millions sharesatjanuary optionsgrante optionsexercised optionscanceledforfeite sharesatdecember optionsgrante optionsexercised optionscanceledforfeite sharesatdecember optionsgrante optionsexercised optionscanceledforfeite sharesatdecember thetotalintrinsicvalueofoptionsexercisedwasmillionmillionandmillioninand respectively thefollowingtablesummarizesstockoptionsoutstandingandexercisableatdecember sharesinthousand outstanding exercisable average average average exercise exercise exercisepricerange option life price option price averagecontractualliferemaininginyear stockoptionsoutstandingatdecemberanddecemberwereandanaveragelifeofyear andandanaveragelifeofyearsrespectivelystockoptionsexercisableatdecemberand decemberwereatanaveragepriceofandatanaveragepriceofrespectively restrictedshareunitsandperformance shareunit thecompanygrantsrestrictedshareunitswhichvestoverserviceperiodsthatrangefrommonthstoyearsthe companyalsograntsperformanceshareunitswhicharepaidinsharesofjohnsonjohnsoncommonstockafterthe endofathreeyearperformanceperiodwhetheranyperformanceshareunitsvestandtheamountthatdoesvestistied tothecompletionofserviceperiodsthatrangefrommonthstoyearsandtheachievementoverathreeyearperiodof threeequallyweightedgoalsthatdirectlyalignwithorhelpdrivelongtermtotalshareholderreturnsalesadjuste operationalearningspershareandrelativetotalshareholderreturnthenumberofsharesactuallyearnedattheendof thethreeyearperiodwillvarybasedonlyonactualperformancefromtoofthetargetnumberofperformance shareunitsgrante johnsonjohnsonannualreport asummaryoftherestrictedshareunitsandperformanceshareunitsactivityundertheplansasofdecemberis presentedbelow outstanding outstanding restricted performance sharesinthousand shareunit shareunit sharesatjanuary grant issue canceledforfeite sharesatdecember grant issue canceledforfeite sharesatdecember grant issue canceledforfeite sharesatdecember theaveragefairvalueoftherestrictedshareunitsgrantedwasandinand respectivelyusingthefairmarketvalueatthedateofgrantthefairvalueofrestrictedshareunitswasdiscountedfor dividendswhicharenotpaidontherestrictedshareunitsduringthevestingperiodthefairvalueofrestrictedshareunit issuedwasmillionmillionandmillioninandrespectively theweightedaveragefairvalueoftheperformanceshareunitsgrantedwasandin andcalculatedusingtheweightedaveragefairmarketvalueforeachofthethreecomponentgoalsatthedateof grant thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedonthedateof grantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividendswhicharenotpaidonthe performanceshareunitsduringthevestingperiodthefairvaluefortherelativetotalshareholderreturngoalofeach performanceshareunitwasestimatedonthedateofgrantusingthemontecarlovaluationmodelthefairvalueof performanceshareunitsissuedinwasmillionduetoacceleratedvestinginaccordancewiththeplan documentnoperformanceshareunitsvestedinand segmentsofbusinessandgeographicarea salestocustomer dollarsinmillion consumer unitedstate international total pharmaceutical unitedstate international total medicaldevice unitedstate international total worldwidetotal johnsonjohnsonannualreportpretaxprofit identifiableasset dollarsinmillion consumer pharmaceutical medicaldevice total lessexpensenotallocatedtosegment generalcorporate worldwidetotal additionstoproperty depreciationand plantequipment amortization dollarsinmillion consumer pharmaceutical medicaldevice segmentstotal generalcorporate worldwidetotal salestocustomer longlivedasset dollarsinmillion unitedstate europe westernhemisphereexcludingus asiapacificafrica segmentstotal generalcorporate othernonlonglivedasset worldwidetotal seenoteforadescriptionofthesegmentsinwhichthecompanyoperate exportsalesarenotsignificantinthecompanyhadonewholesalerdistributingproductsforallthreesegmentsthatrepresente approximatelyofthetotalconsolidatedrevenuesinandthecompanydidnothaveacustomerthatrepresente oftotalrevenue amountsnotallocatedtosegmentsincludeinterestincomeexpensenoncontrollinginterestsandgeneralcorporateincome expenseincludescurrencyrelatedexpenseofbillionassociatedwiththeacquisitionofsynthesincin generalcorporateincludescashcashequivalentsandmarketablesecurities includesnetlitigationexpenseofmillioncomprisedofmillionmillionandmillioninthemedicaldevice pharmaceuticalandconsumersegmentsrespectivelyincludesmillionofinprocessresearchanddevelopmentexpense comprisedofmillionandmillioninthepharmaceuticalandmedicaldevicessegmentsrespectivelythemedicaldevice segmentincludesanetgainofmillionfromthedivestitureoftheorthoclinicaldiagnosticsbusinesssynthesintegration costsofmillionandmillionexpenseforthecostassociatedwiththedepuyasrhipprogramincludesanadditional yearofthebrandedprescriptiondrugfeeofmillioninthepharmaceuticalsegment includesmillionofnetlitigationexpensecomprisedofmillionandmillioninthemedicaldevicesand pharmaceuticalsegmentsrespectivelyincludesmillionofsynthesintegrationtransactioncostsinthemedicaldevice segmentincludesmillionofinprocessresearchanddevelopmentexpensecomprisedofmillionandmillioninthe pharmaceuticalandmedicaldevicessegmentsrespectivelythemedicaldevicessegmentalsoincludesmillionexpensefor thecostassociatedwiththedepuyasrtmhipprogramincludesmillionofincomerelatedtootheradjustmentscomprisedof millionandmillionintheconsumerandpharmaceuticalsegmentsrespectively includesmillionofnetlitigationexpensecomprisedofmillionandmillioninthepharmaceuticalandmedical devicessegmentsrespectivelyincludesmillionofinprocessresearchanddevelopmentexpensecomprisedof millionandmillioninthepharmaceuticalandmedicaldevicessegmentsrespectivelyincludesmillionofsynthe integrationtransactioncostsinthemedicaldevicessegmentincludesmillionofassetwritedownsandotheradjustment comprisedofmillionmillionandmillioninthepharmaceuticalconsumerandmedicaldevicessegment respectivelythemedicaldevicessegmentalsoincludesmillionexpenseforthecostassociatedwiththedepuyasrhip program longlivedassetsincludepropertyplantandequipmentnetforandofand respectivelyandintangibleassetsandgoodwillnetforandofandrespectively johnsonjohnsonannualreport selectedquarterlyfinancialdataunaudite selectedunauditedquarterlyfinancialdatafortheyearsandaresummarizedbelow dollarsinmillionsexceptpershare second fourth second fourth datum quarter quarter quarter quarter quarter quarter quarter quarter segmentsalestocustomer consumer pharmaceutical medicaldevice totalsale grossprofit earningsbeforeprovisionfortaxeson income netearningsattributabletojohnson johnson basicnetearningspershareattributable tojohnsonjohnson dilutednetearningspershare attributabletojohnsonjohnson thefirstquarterofincludessynthesintegrationcostsofmillionaftertaxmillionbeforetaxandamilliontax benefitassociatedwithconormedsystem thesecondquarterofincludeslitigationexpenseofmillionaftertaxmillionbeforetaxandsynthesintegration costsofmillionaftertaxmillionbeforetax thethirdquarterofincludesanadditionalyearofthebrandedprescriptiondrugfeeofmillionafterandbeforetax litigationexpenseofmillionaftertaxmillionbeforetaxsynthesintegrationcostsofmillionaftertaxmillion beforetaxandmillionaftertaxmillionbeforetaxforcostsassociatedwiththedepuyasrhipprogramadditionally thefiscalthirdquarterofincludesanetgainofbillionaftertaxbillionbeforetaxforthedivestitureoftheortho clinicaldiagnosticsbusiness thefourthquarterofincludeslitigationexpenseprimarilyrelatedtoproductliabilityandpatentlitigationofmillionafter taxmillionbeforetaxsynthesintegrationcostsofmillionaftertaxmillionbeforetaxandmillionaftertax millionbeforetaxfromimpairmentofinprocessresearchanddevelopment thefirstquarterofincludessynthesintegrationtransactioncostsofmillionaftertaxmillionbeforetaxandnet litigationexpenseofmillionaftertaxmillionbeforetax thesecondquarterofincludesnetlitigationexpenseofmillionaftertaxmillionbeforetaxandsynthe integrationtransactioncostsofmillionaftertaxmillionbeforetax thethirdquarterofincludesnetlitigationexpenseofmillionaftertaxmillionbeforetaxsynthesintegration transactioncostsofmillionaftertaxmillionbeforetaxandmillionaftertaxmillionbeforetaxfrom impairmentofinprocessresearchanddevelopment thefourthquarterofincludesnetlitigationexpenseofmillionaftertaxmillionbeforetaxsynthesintegration transactioncostsmillionaftertaxmillionbeforetaxmillionaftertaxmillionbeforetaxfromimpairmentof inprocessresearchanddevelopmentandmillionaftertaxmillionbeforetaxforcostsassociatedwiththedepuyasr hipprogramandamilliontaxbenefitassociatedwithsciosinc businesscombinationsanddivestitures certainbusinesseswereacquiredformillionincashandmillionofliabilitiesassumedduringthese acquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeeninclude inthefinancialstatementsfromtheirrespectivedatesofacquisition theacquisitionsincludedcovagenagaprivatelyheldbiopharmaceuticalcompanyspecializinginthe developmentofmultispecificproteintherapeuticsthroughthefynomabtechnologyplatformaliosbiopharmainca privatelyheldclinicalstagebiopharmaceuticalcompanyfocusedondevelopingtherapiesforviraldiseasesandthe orslelectrolytereadytodrinkbrandfromjagdaleindustriesltdtheexcessofpurchasepriceovertheestimatedfair valueoftangibleassetsacquiredamountedtomillionandhasbeenassignedtoidentifiableintangibleasset johnsonjohnsonannualreportwithanyresidualrecordedtogoodwillofthisamountapproximatelymillionhasbeenidentifiedasthevalueof iprdassociatedwiththeacquisitionsofcovagenagandaliosbiopharmaincthevalueoftheiprdwascalculate usingcashflowprojectionsdiscountedfortheinherentriskintheproject theiprdrelatedtotheacquisitionofaliosbiopharmaincaliosofmillionisassociatedwithalioslead compoundalanorallyadministeredantiviraltherapyfortreatmentofinfantswithrespiratorysyncytialvirusrsv aprobabilityofsuccessfactorofwasusedtoreflectinherentclinicalandregulatoryriskthediscountrateapplie wastheiprdrelatedtotheacquisitionofcovagenagofmillionisassociatedwithcovagenslead compoundcovacurrentlyinphasebstudyforpsoriasisandholdingpotentialasatreatmentforabroadrangeof inflammatorydiseasesincludingrheumatoidarthritisaprobabilityofsuccessfactorofwasusedtoreflectinherent clinicalandregulatoryriskthediscountrateappliedwas certainbusinesseswereacquiredformillionincashandmillionofliabilitiesassumedduringthese acquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeeninclude inthefinancialstatementsfromtheirrespectivedatesofacquisition theassumedliabilitiesprimarilyrepresentthefairvalueofthecontingentconsiderationwhichmaybepayablerelatedto theacquisitionofaragonpharmaceuticalsincaspertermsoftheagreementadditionalpaymentsofuptomillion maybepaidinthefuturebasedonreachingpredeterminedmilestone theacquisitionsincludedflexiblestentingsolutionsincaleadingdeveloperofinnovativeflexibleperipheral arterialvenousandbiliarystentsshanghaielskermotherbabycoltdababycarecompanyinchinaandaragon pharmaceuticalsincaprivatelyheldpharmaceuticaldiscoveryanddevelopmentcompanyfocusedondrugstotreat hormonallydrivencancer theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtomillionandha beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwillofthisamountapproximately millionhasbeenidentifiedasthevalueofiprdassociatedwiththeacquisitionsofaragonpharmaceuticalsincand flexiblestentingsolutionsinc theiprdrelatedtotheacquisitionofaragonpharmaceuticalsincofmillionisassociatedwitharagon androgenreceptorantagonistprogramfortreatmentofhormonallydrivencancersthevalueoftheiprdwascalculate usingcashflowprojectionsdiscountedfortheinherentriskinsuchprojectsprobabilityofsuccessfactorsrangingfrom wereusedtoreflectinherentclinicalandregulatoryriskthediscountrateappliedwastheiprd relatedtotheacquisitionofflexiblestentingsolutionsincofmillionisassociatedwiththeapprovalforperipheral vascularindicationsincludingthesuperficialfemoralarteryindicationaprobabilityofsuccessfactorofwasuse andadiscountraterangingbetweenwasapplied certainbusinesseswereacquiredformillionincashandstockandmillionofliabilitiesassumeddure theseacquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshave beenincludedinthefinancialstatementsfromtheirrespectivedatesofacquisition theacquisitionsincludedsynthesincaglobaldeveloperandmanufactureroforthopaedicsdevicesguangzhou biosealbiotechcoltdadeveloperofbiologiccombinationsaddressingmoderatetoseverehemostasisangiotech pharmaceuticalsincintellectualpropertyandknowhowrelatedtothequilltmknotlesstissueclosuredevice corimmungmbhadeveloperofaphaseiitreatmentforchfcalibramedicalincadeveloperofauniquewearable threedayinsulinpatchforconvenientanddiscreetmealtimedosingforpeoplewithdiabeteswhotakemultipledaily injectionsofinsulinspectrumvisionllcafullservicedistributorofcontactlensesservingrussiawithfacilitiesinthe ukraineandkazakhstanandmarketingauthorizationstrademarksandpatentsextendingzyrtecrelatedmarketright inaustraliaandcanada theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtomillionand hasbeenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwillofthisamountapproximately millionhasbeenidentifiedasthevalueofiprdassociatedwiththeacquisitionsofcorimmungmbhandsynthe inc theiprdrelatedtotheacquisitionofsynthesincofmillionisassociatedwithorthopaedicdevicesandtheiprd associatedwithcorimmunofmillionisrelatedtoachftreatmenttheseiprdvalueswerecalculatedusingthe cashflowprojectionsdiscountedfortheriskinherentinsuchprojectssynthesinchadaprobabilityofsuccessfactorof discountedusingaratecorimmunhadaprobabilityofsuccessfactorofdiscountedusingarate duringthecompanyrecordedachargeofbillionfortheimpairmentoftheinprocessresearchand developmentassociatedwithcorimmun johnsonjohnsonannualreport duringthefiscalsecondquarterofthecompanycompletedtheacquisitionofsynthesincaglobaldeveloperand manufactureroforthopaedicsdevicesforapurchasepriceofbillionincashandstockthenetacquisitioncostof thetransactionwasbillionbasedoncashonhandatclosingofbillion underthetermsoftheagreementeachshareofsynthesinccommonstockwasexchangedforchfincashand sharesofjohnsonjohnsoncommonstockbasedonthecalculatedexchangeratiotheexchangeratiowa calculatedonjuneandbasedontherelevantexchangerateandclosingpriceofjohnsonjohnsoncommon stockonthatdatethetotalfairvalueofconsiderationtransferredwasbillionwhentheacquisitionwascomplete onjunebasedontherelevantexchangerateandclosingpriceofjohnsonjohnsoncommonstockonthat datethetotalfairvalueoftheconsiderationtransferredwasbillionjanssenpharmaceuticalacompanyorganize underthelawsofirelandandawhollyownedsubsidiaryofjohnsonjohnsonusedcashonhandtosatisfythecash portionofthemergerconsideration thestockportionofthemergerconsiderationconsistedofsharesofjohnsonjohnsoncommonstockpurchasedby janssenpharmaceuticalfromtwobankspursuanttotwoacceleratedsharerepurchaseasragreementsdatedjune onjunejanssenpharmaceuticalpurchasedanaggregateofapproximatelymillionsharesof johnsonjohnsoncommonstockataninitialpurchasepriceofbillionundertheasragreementswithallofthe sharesdeliveredtojanssenpharmaceuticalonjuneduringthefiscalthirdquarterofthecompany settledtheremainingliabilitiesundertheasragreementsforbillionincashwhichwasrecordedasareductionto equity inadditionwhilethecompanybelievesthatthetransactionsundereachasragreementandaseriesofrelatedinternal transactionswereconsummatedinataxefficientmannerinaccordancewithapplicablelawitispossiblethattheinternal revenueservicecouldassertoneormorecontrarypositionstochallengethetransactionsfromataxperspectiveif challengedanamountuptothetotalpurchasepriceforthesynthessharescouldbetreatedassubjecttoapplicableus taxatapproximatelythestatutoryratetothecompanyplusinter thefollowingtablesummarizestheconsiderationtransferredtoacquiresynthesincvaluedontheacquisitiondateof june dollarsinmillion cashmultiplychfbysharesofsynthescommonstockoutstandingbytheexchangeratea commonstockmultiplybysharesofsynthescommonstockoutstandingbyjjstockpriceb totalfairvalueofconsiderationtransferred synthescommonstockoutstandingofmillionsharesasoftheacquisitiondateandchfusdexchangerateof johnsonjohnsonclosingstockpriceonthenewyorkstockexchangeasofacquisitiondateofpershare thecompanycontinuestoexecutetheintegrationplanstocombinebusinessessalesorganizationssystemsand locationsasaresultofwhichthecompanyhasandwillcontinuetoincurintegrationcosts theoperatingresultsofsyntheswerereportedinthecompanysfinancialstatementsbeginningonjunetotal salesandnetearningsforsynthesforthefiscalyearendeddecemberweremillionandmillion respectively thefollowingtableprovidesproformaresultsofoperationsforthefiscalyearendeddecemberasifsynthe inchadbeenacquiredasofthebeginningoftheperiodpresentedtheproformaresultsincludetheeffectofdivestitures andcertainpurchaseaccountingadjustmentssuchastheestimatedchangesindepreciationandamortizationexpenseon theacquiredtangibleandintangibleassetshoweverproformaresultsdonotincludeanyanticipatedcostsavingsor othereffectsoftheintegrationofsynthesincaccordinglysuchamountsarenotnecessarilyindicativeoftheresultsifthe acquisitionhadoccurredonthedatesindicatedorwhichmayoccurinthefuture unauditedproforma consolidatedresult dollarsinmillionsexceptpershareamount netsale netearningsattributabletojohnsonjohnson dilutednetearningspershareattributabletojohnsonjohnson johnsonjohnsonannualreportthecompanyrecordedacquisitionrelatedcostsbeforetaxofmillionmillionandmillionin andrespectivelywhichwererecordedinotherincomeexpenseandcostofproductssold inconnectionwiththesynthesacquisitiondepuyorthopaedicsincagreedtodivestcertainrightsandassetsrelatedto itstraumabusinesstobiometincandcompletedtheinitialclosingforthistransactioninthefiscalsecondquarterof includingthosecountriesthatrepresentedthemajorityofsalesasofdecemberthetransactionhad closedworldwide withtheexceptionofthesynthesincacquisitionsupplementalproformainformationforandin accordancewithusgaapstandardsrelatedtobusinesscombinationsandgoodwillandotherintangibleassetsisnot providedastheimpactoftheaforementionedacquisitionsdidnothaveamaterialeffectonthecompanysresultsof operationscashflowsorfinancialposition duringthecompanydivestituresincludedtheorthoclinicaldiagnosticsbusinesstothecarlylegrouptheky brandtoreckittbenckisergroupplcintheusandcertainothermarketsandthebenecolbrandtoraisioplcin thegainsonthedivestituresofbusinesseswereapproximatelybillionthecompanycompletedthedivestiture ofitsorthoclinicaldiagnosticsbusinesstothecarlylegroupforapproximatelybillionandthecompanyrecorde apretaxnetgainofapproximatelybillionorthoclinicaldiagnosticsresultsareincludedinthecompanysmedical devicessegmentpretaxprofitasofdecembertheassetsclassifiedasheldforsalerelatingtotheortho clinicaldiagnosticscompaniesincountriesthathavenotcompletelyclosedduetolocalregulatoryrequirementswere millionofinventoryclassifiedasprepaidexpensesandotherontheconsolidatedbalancesheetandmillionof propertyplantandequipmentclassifiedasotherassetsontheconsolidatedbalancesheet duringthecompanydivestituresincludedwomenssanitaryprotectionproductsintheuscanadaandthe caribbeantoenergizerholdingsincrolaidstochattemincdoribaxrightstoshionogiandthesaleofcertain consumerbrandsandcertainpharmaceuticalproductsinthegainsonthedivestituresofbusinesseswere billionduringthecompanydivestituresincludedbystolicnebivololiprightstoforestlaboratoriesincthe traumabusinessofdepuyorthopaedicsinctobiometincthetherakosbusinesstoanaffiliateofgorescapital partnersiiilpthesaleofcertainconsumerbrandsandtherhogambusinessinthegainsonthedivestiture ofbusinesseswerebillion injanuaryadefinitiveagreementwasannouncedtodivesttheuslicenserightstonucyntatapentadol nucyntaertapentadolextendedreleasetabletsandnucyntatapentadoloralsolutionforapproximately billionthetransactionisexpectedtocloseinthefiscalsecondquarterofsubjecttocustomaryclosingcondition andcompletionoffinancing legalproceeding johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialandothermattersgovernmentalinvestigationsandotherlegalproceedingsthatarise fromtimetotimeintheordinarycourseoftheirbusiness thecompanyrecordsaccrualsforsuchcontingencieswhenitisprobablethataliabilitywillbeincurredandtheamount ofthelosscanbereasonablyestimatedasofdecemberthecompanyhasdeterminedthattheliabilitie associatedwithcertainlitigationmattersareprobableandcanbereasonablyestimatedthecompanyhasaccruedfor thesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsasmightbewarrantedbasedon newinformationandfurtherdevelopmentsinaccordancewithascfortheseandotherlitigationand regulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossiblethecompanyisunableto determineanestimateofthepossiblelossorrangeoflossbeyondtheamountsalreadyaccruedthesematterscanbe affectedbyvariousfactorsincludingwhetherdamagessoughtintheproceedingsareunsubstantiatedorindeterminate scientificandlegaldiscoveryhasnotcommencedorisnotcompleteproceedingsareinearlystagesmatterspresent legaluncertaintiestherearesignificantfactsindisputeortherearenumerouspartiesinvolvedamountsaccruedforlegal contingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyon estimatesandassumption inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutioninanyreportingperiodofone ormoreofthesematterseitheraloneorintheaggregatemayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod johnsonjohnsonannualreport productliability certainsubsidiariesofjohnsonjohnsonareinvolvedinnumerousproductliabilityclaimsandlawsuitsinvolvingmultiple productsclaimantsinthesecasesseeksubstantialcompensatoryandwhereavailablepunitivedamageswhilethese subsidiariesbelievetheyhavesubstantialdefensesitisnotfeasibletopredicttheultimateoutcomeoflitigationthe companyhasestablishedproductliabilityaccrualsincompliancewithascbasedoncurrentlyavailable informationwhichinsomecasesmaybelimitedinadditionproductliabilityaccrualscanrepresentprojectedproduct liabilityforthousandsofclaimsaroundtheworldeachindifferentlitigationenvironmentsandwithdifferentfactpattern changestotheaccrualsmayberequiredinthefutureasadditionalinformationbecomesavailable themostsignificantofthesecasesincludethedepuyasrxlacetabularsystemanddepuyasrhipresurface systemthepinnacleacetabularcupsystempelvicmeshesandrisperdalasofdecemberinthe ustherewereapproximatelyplaintiffswithdirectclaimsinpendinglawsuitsregardinginjuriesallegedlydueto theasrxlacetabularsystemanddepuyasrhipresurfacingsystemwithrespecttothepinnacle acetabularcupsystemwithrespecttopelvicmeshesandwithrespecttorisperdal inaugustdepuyorthopaedicsincdepuyannouncedaworldwidevoluntaryrecallofitsasrxlacetabular systemanddepuyasrhipresurfacingsystemusedinhipreplacementsurgeryclaimsforpersonalinjuryhavebeen madeagainstdepuyandjohnsonjohnsonthenumberofpendinglawsuitsisexpectedtofluctuateascertainlawsuit aresettledordismissedandadditionallawsuitsarefiledcasesfiledinfederalcourtsintheunitedstateshavebeen organizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthenortherndistrictofohiolitigationhas alsobeenfiledincountriesoutsideoftheunitedstatesprimarilyintheunitedkingdomcanadaandaustraliain novemberdepuyreachedanagreementwithacourtappointedcommitteeoflawyersrepresentingasrhip systemplaintiffstoestablishaprogramtosettleclaimswitheligibleasrhippatientsintheunitedstateswhohad surgerytoreplacetheirasrhipsknownasrevisionsurgeryasofaugustthissettlementcovere approximatelypatientsinfebruarydepuyreachedanadditionalagreementsubjecttofinaldocumentation whichwouldeffectivelyextendtheexistingsettlementprogramtoasrhippatientswhohadrevisionsurgeriesafter augustandpriortofebruarythissecondagreementisestimatedtocoverapproximately additionalpatientstheestimatedcostoftheseagreementsiscoveredbyexistingaccrualsthissettlementprogramis expectedtobringtoaclosesignificantasrhiplitigationactivityintheushowevermanylawsuitsintheuswill remainandthesettlementprogramdoesnotaddresslitigationoutsideoftheusthecompanycontinuestoreceive informationwithrespecttopotentialcostsassociatedwiththisrecallonaworldwidebasisthecompanyhasestablishe accrualsforthecostsassociatedwiththedepuyasrhipprogramandrelatedproductliabilitylitigationupdatesto theseaccrualsmayberequiredinthefutureasadditionalinformationbecomesavailable claimsforpersonalinjuryhavealsobeenmadeagainstdepuyandjohnsonjohnsonrelatingtodepuyspinnacle acetabularcupsystemusedinhipreplacementsurgerythenumberofpendingproductliabilitylawsuitscontinuesto increaseandthecompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberof casescasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamultidistrictlitigationintheunite statesdistrictcourtforthenortherndistrictoftexaslitigationhasalsobeenfiledincountriesoutsideoftheunite statesprimarilyintheunitedkingdomthecompanyhasestablishedanaccrualtocoverdefensecostsinconnection withproductliabilitylitigationassociatedwithdepuyspinnacleacetabularcupsystemchangestothisaccrualmay berequiredinthefutureasadditionalinformationbecomesavailable claimsforpersonalinjuryhavebeenmadeagainstethiconincethiconandjohnsonjohnsonarisingoutofethicon pelvicmeshdevicesusedtotreatstressurinaryincontinenceandpelvicorganprolapsethenumberofpendingproduct liabilitylawsuitscontinuestoincreaseandthecompanycontinuestoreceiveinformationwithrespecttopotentialcosts andtheanticipatednumberofcasescasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamulti districtlitigationintheunitedstatesdistrictcourtforthesoutherndistrictofwestvirginiainadditionclassactionsand individualpersonalinjurycasesorclaimshavebeencommencedinaustraliabelgiumcanadaenglandisraelitalythe netherlandsscotlandandvenezuelaseekingdamagesforallegedinjuryresultingfromethiconspelvicmeshdevice thecompanyhasestablishedanaccrualwithrespecttoproductliabilitylitigationassociatedwithethiconspelvicmesh productschangestothisaccrualmayberequiredinthefutureasadditionalinformationbecomesavailable claimsforpersonalinjuryhavebeenmadeagainstjanssenpharmaceuticalsincandjohnsonjohnsonarisingoutoftheuse ofrisperdalindicatedforthetreatmentofschizophreniaacutemanicormixedepisodesassociatedwithbipolaridisorder andirritabilityassociatedwithautismandrelatedcompoundsthenumberofpendingproductliabilitylawsuitscontinuesto increaseandthecompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberof casesthecompanyhasestablishedanaccrualtocoverdefensecostsinconnectionwithproductliabilitylitigationassociate withrisperdalchangestothisaccrualmayberequiredinthefutureasadditionalinformationbecomesavailable johnsonjohnsonannualreportintellectualproperty certainsubsidiariesofjohnsonjohnsonaresubjectfromtimetotimetolegalproceedingsandclaimsrelatedto patenttrademarkandotherintellectualpropertymattersarisingoutoftheirbusinessesmanyofthesemattersinvolve challengestothecoverageandorvalidityofthepatentsonvariousproductsalthoughthesesubsidiariesbelievethatthey havesubstantialdefensestothesechallengeswithrespecttoallmaterialpatentstherecanbenoassuranceastothe outcomeofthesemattersandalossinanyofthesecasescouldpotentiallyadverselyaffecttheabilityofthese subsidiariestoselltheirproductsorrequirethepaymentofpastdamagesandfutureroyaltiesthemostsignificantof thesemattersaredescribedbelow medicaldevice injanuarytycohealthcaregrouplptycoandussurgicalcorporationnowcovidienplcfiledalawsuit againstethiconendosurgeryinceesintheunitedstatesdistrictcourtforthedistrictofconnecticutallegingthat eessharmonicshearsinfringedthreetycopatentsthecasewastriedinjulyandinmarchthecourt ruledthatsomeofeessharmonicshearsinfringedtycospatentsandorderedeestopaydamagesof approximatelymillionbutdeclinedtoorderinjunctivereliefeesappealedandindecembertheunite statescourtofappealsforthefederalcircuitreversedthedistrictcourtsrulingandfoundalltheassertedclaim invalidinjanuarytycofiledamotionforrehearinginjulycovidienfiledanotherpatentinfringementlawsuit againsteesintheunitedstatesdistrictcourtforthedistrictofconnecticutseekingdamagesandapreliminary injunctionallegingthateessnewestversionofitsharmonicscalpelstheharmonicaceshearsandthe harmonicaceshearsinfringedthethreetycopatentsassertedinthepreviouscasecovidienbroughtamotionfor apreliminaryinjunctionagainsttheharmonicaceshearsandinoctoberthedistrictcourtgranted covidiensmotionforapreliminaryinjunctioneesappealedandthecourtofappealsforthefederalcircuitgrantedee aninterimstayoftheinjunctiontheclaimsassertedbycovidieninthiscasearethesameclaimsthatweredeclared invalidindecemberbythecourtofappealsinthetycocasediscussedabove innovemberrochediagnosticsoperationsincetalrochefiledapatentinfringementlawsuitagainstlifescan inclifescanintheunitedstatesdistrictcourtforthedistrictofdelawarealleginglifescansonetouchlineof bloodglucosemonitoringsystemsinfringetwopatentsrelatedtotheuseofmicroelectrodesensorsrocheisseeke monetarydamagesandinjunctivereliefinseptemberlifescanobtainedafavorablerulingonclaimconstruction thatprecludedafindingofinfringementthecourtenteredjudgmentagainstrocheinjulyandrocheappeale thecourtofappealsreversedthedistrictcourtsrulingonclaimconstructionandremandedthecasetothedistrict courtfornewfindingsontheissueindecemberthedistrictcourtruledinlifescansfavorandreinstatedthe originalclaimconstructioninfebruaryrocheappealedtherule injunerembrandtvisiontechnologieslprembrandtfiledapatentinfringementlawsuitagainstjohnson johnsonvisioncareincjjvcintheunitedstatesdistrictcourtfortheeasterndistrictoftexasallegingthatjjvcs manufactureandsaleofitsacuvueadvanceandacuvueoasyshydrogelcontactlensesinfringetheirus patentnothechangpatentrembrandtisseekingmonetaryreliefthecasewastransferredtotheunite statesdistrictcourtforthemiddledistrictoffloridainmaythejuryreturnedaverdictholdingthatneitherofthe accusedlensesinfringesthepatentrembrandtappealedandinaugusttheunitedstatescourtofappeal forthefederalcircuitaffirmedthedistrictcourtsjudgmentrembrandtaskedthedistrictcourttograntitanewtrial basedonallegednewevidenceandinjulythedistrictcourtdeniedrembrandtsmotionrembrandthasappealed thedistrictcourtsdenialofitsmotionforanewtrial indecemberthestateofisraelfiledalawsuitinthedistrictcourtintelavivjaffaagainstomrix biopharmaceuticalsincandvariousaffiliatesomrixinthelawsuitthestateclaimsthatanemployeeofagovernment ownedhospitalwastheinventoronseveralpatentsrelatedtofibringluetechnologythattheemployeedevelopedwhilehe wasagovernmentemployeethestateclaimsthathehadnorighttotransferanyintellectualpropertytoomrixbecauseit belongstothestatethestateisseekingdamagesplusroyaltiesonquixilandevicelproductsoralternatively transferofthepatentstothestatethecaseremainsactivebutnotrialdatehasbeenset inseptemberlifescaninclifescanfiledalawsuitagainstshastatechnologiesinstacarecorpandconductive technologiescollectivelyshastaintheunitedstatesdistrictcourtforthenortherndistrictofcaliforniaforpatent infringementforthemakingandmarketingofastripforuseinlifescansonetouchbloodglucosemetersshastaha allegedthatthethreelifescanpatentsinsuitareinvalidshastaalsochallengedthevalidityoftheassertedpatentsinthe unitedstatespatentandtrademarkofficeusptoandthepatentinfringementcasehasbeenstayedpendingthe outcomeoftheusptoproceedingsthevalidityoftwoofthepatentswasconfirmedbytheusptoandinaugust johnsonjohnsonannualreport theusptodeterminedthatthethirdpatentuspatentnothepatentisinvalidlifescanisappeale thatdecisionthepatentcasehasresumedonthetwootherpatentsinaprilshastabroughtcounterclaimsfor allegedantitrustviolationsandfalseadvertisingandthoseclaimshavebeenstayedpendingresolutionofthepatent infringementcaseinmaylifescanfiledapatentinfringementlawsuitagainstunistriptechnologiesllcunistrip intheunitedstatesdistrictcourtforthedistrictofnorthcarolinaallegingthatthemakingandmarketingofunistrips stripsinfringethesamepatentsassertedagainstshastaabovethatcasehasbeenstayedpendingtheoutcomeofthe appealoftheusptosdecisiononthevalidityofthepatentinjulyunistripbroughtalawsuitagainst lifescanintheunitedstatesdistrictcourtfortheeasterndistrictofpennsylvaniaallegingantitrustviolationsrelatingto marketingpracticesforlifescansstrip innovemberhowmedicaosteonicscorphowmedicaandstrykerirelandltdstrykerfiledapatent infringementlawsuitagainstdepuyorthopaedicsincdepuyintheunitedstatesdistrictcourtforthedistrictofnew jerseyalleginginfringementbydepuyspinnacleacetabularcupsystemandduralocacetabularcupsystemof apatentrelatingtoaduallockingmechanismfeatureinanacetabularcupsystemhowmedicaandstrykersought monetarydamagesandinjunctivereliefdepuyfiledacounterclaiminfebruaryassertingthatstrykerstrident acetabularhipsysteminfringesdepuysuspatentnodepuysoughtdamagesandinjunctivereliefinjune thecasewassettledanddismisse inmaymedtronicminimedincmedtronicpuertoricooperationscoandminimeddistributioncorp collectivelymedtronicminimedfiledapatentinfringementlawsuitagainstanimascorporationanimasintheunite statesdistrictcourtforthecentraldistrictofcaliforniaallegingthatanimassonetouchpingglucosemanagement systemandtheirirandirinsulinpumpsinfringenineoftheirpatentsmedtronicminimedsince withdrewtwoofthepatentsfromthelawsuitandisseekingmonetarydamagesandinjunctivereliefwithrespecttothe remainingpatentsinjulyanimasenteredintoasettlementofthislawsuit inseptemberbonuttiskeletalinnovationsllcbonuttianonpracticingentityfiledapatentinfringementlawsuit againstdepuymitekllcthedepuyinstitutellcnowdepuysynthesinstitutellcdepuyincnowdepuy synthesincanddepuyorthopaedicsinccollectivelydepuyintheunitedstatesdistrictcourtforthedistrictof massachusettsallegingthatdepuysmanufacturesaleandormethodofusingthesigmafamilyofpartialandtotal kneesystemsandthelcscompletekneesystemwillfullyinfringethreeofbonuttispatentsbonuttialsoallege thatthemethodofusingcertainofdepuyssutureanchorswillfullyinfringefourofbonuttisotherpatentsinaugust thepartiesenteredintoasettlementoftheportionofthelawsuitrelatingtosutureanchor inmarchmedinolltdmedinolfiledapatentinfringementlawsuitagainstcordiscorporationcordisand johnsonjohnsonintheunitedstatesdistrictcourtforthesoutherndistrictofnewyorkallegingthatallofcordiss salesofthecypherandcypherselectstentsmadeintheunitedstatessincewillfullyinfringedfourof medinolspatentsdirectedtothegeometryofarticulatedstentsmedinolisseekingdamagesandattorneysfeesafter trialinjanuarythedistrictcourtdismissedthecasefindingmedinolunreasonablydelayedbringingitsclaimsand medinoldidnotappealthedecisioninseptemberthedistrictcourtdeniedamotionbymedinoltovacatethe judgmentandgrantitanewtrialmedinolisappealingthisdecision injanuarybaxterinternationalincbaxterhealthcarecorporationandbaxterhealthcaresacollectivelybaxter filedalawsuitagainstjohnsonjohnsonethiconincethiconferrosanmedicaldevicesasandpackaging coordinatorsincintheunitedstatesdistrictcourtforthenortherndistrictofillinoisallegingthatthemanufacture importationsaleandoruseofethiconssurgiflohemostaticmatrixfamilyofproductsinfringessixofbaxter patentsbaxterisseekingmonetarydamagesandinjunctivereliefinfebruarybaxteralsofiledacomplaintbefore theunitedstatesinternationaltradecommissionitcagainstthesamedefendantsallegingthattheimportationintothe unitedstatesofethiconssurgiflohemostaticmatrixfamilyofproductsviolatessectionofthetariffactof duetotheallegedinfringementoffourofitsproductsandisseekinganexclusionordertoenjointheimportation intotheunitedstatesofsuchproductsthedistrictcourtcasehasbeenstayedpendingtheoutcomeoftheitccase allthepatentsexpireinaugusttheitccasewastriedinjanuaryandthepartiesareawaitingadecision injunemyhealthincmyhealthfiledapatentinfringementlawsuitagainstlifescaninclifescanintheunite statesdistrictcourtfortheeasterndistrictoftexasalleginglifescansonetouchverioiqbloodglucose monitoringsysteminfringesmyhealthspatentrelatedtoamethodformonitoringandtreatingpatientsmyhealthis seekingmonetarydamagesandinjunctivereliefinaugustlifescanfiledamotiontodismissthelawsuitinoctober lifescanfiledaninterpartesreviewproceedingintheunitedstatespatentandtrademarkofficeseekingto invalidatemyhealthspatentindecemberlifescanmovedtostaythelawsuitpendingadecisionintheinter partesreviewproceeding johnsonjohnsonannualreportindecemberbonuttiskeletalinnovationsllcbonuttisueddepuysynthessalesincanddepuysynthe productsincintheunitedstatesdistrictcourtforthedistrictofmassachusettsallegingthatdepuysynthessproduct lineofspineimplantsinfringessixpatentsownedbybonuttigenerallycoveringwedgeimplantsandtheirmethodsof implantation pharmaceutical inmayabbottbiotechnologyltdabbottfiledapatentinfringementlawsuitagainstcentocorinccentocor nowjanssenbiotechincjbiintheunitedstatesdistrictcourtforthedistrictofmassachusettsallegingthat simponiinfringesabbottsuspatentnosandthesalfeldpatentsabbottwasseeke monetarydamagesandinjunctivereliefthepartieshavesettledthecase inaugustabbottgmbhcoabbottgmbhandabbottbioresearchcentercollectivelynowreferredtoas abbviefiledapatentinfringementlawsuitagainstcentocornowjbiintheunitedstatesdistrictcourtforthedistrictof massachusettsallegingthatstelarainfringestwounitedstatespatentsassignedtoabbottgmbhtrialwasheldin septemberandajuryreturnedaverdictinfavorofjbiinvalidatingabbviespatentclaimsabbvieappealedandin julythecourtofappealsforthefederalcircuitaffirmedthelowercourtsrulingalsoinaugustabbott gmbhandabbottlaboratorieslimitedcollectivelynowreferredtoasabbviebroughtapatentinfringementlawsuitin thefederalcourtofcanadaallegingthatstelarainfringesabbottgmbhscanadianpatentatrialwasheldin decemberinthecanadiancaseandthecourtruledinfavorofabbviefindingthattheassertedclaimswerevalid andinfringedbystelarajbiappealedthatdecisioninmayabbviesmotionforaninjunctionwasgrantedin partandjbialsoappealedthatdecisioninoctobertheappellatecourtoverturnedthefindingofliabilityremande thecasetothetrialcourtforretrialandliftedtheinjunctioninadditiontotheusandcanadianlitigationsinaugust abbviefiledpatentinfringementlawsuitsrelatedtostelarainthenetherlandsswitzerlandandgermanythe partieshavesettledallofthecasesdiscussedaboverelatedtostelara inandnoramcoincnoramcoasubsidiaryofjohnsonjohnsonmovedtointerveneinseveralpatent infringementlawsuitsfiledintheunitedstatesdistrictcourtforthesoutherndistrictofnewyorkbypurduepharmalp andotherspurdueagainstnoramcooxycodonecustomersimpaxlaboratoriesincimpaxtevapharmaceuticalsusa inctevaandamnealpharmaceuticalsllcamnealwatsonlaboratoriesincfloridawatsonandandrxlabsllc andrxthelawsuitsareinresponsetothedefendantsrespectiveabbreviatednewdrugapplicationsseekingapproval tomarketgenericextendedreleaseoxycodoneproductsbeforetheexpirationofcertainpurduepatentsthreeofthe assertedpatentsrelatetooxycodoneandprocessesformakingoxycodoneandnoramcohasagreedtodefendthe lawsuitsonbehalfofimpaxtevaamnealwatsonandandrxinaprilwatsonandandrxenteredintoasettlement withpurduethetrialagainstimpaxandtevaaswellastwopartiesnotdefendedbynoramcotookplaceinseptember andnoramcodefendedtevaandimpaxinnovemberimpaxenteredintoasettlementwithpurduein januarythecourtissuedadecisioninvalidatingtherelevantpurduepatentsandsubsequentlydismissedthe lawsuitagainstamnealandotherpartiesnotdefendedbynoramcopurduehasappealedthecourtsdecisionin decembertevaenteredintoaconfidentialsettlementwithpurdueandtevasubsequentlymovedtohavethe appealdismissedasmootinviewofthesettlementpurduehasopposedtevasmotion inaugustdrjamesmswansonfiledalawsuitagainstalzacorporationalzainthenortherndistrictof californiaseekingtobeaddedasaninventoronthreealzaownedpatentsrelatingtoconcertaalternatively drswansonhasallegedthatthepatentsinsuitareinvalidasaresultofalzasallegedomissionofdrswansonasa namedinventorthelawsuitalsoincludesclaimsoffraudbreachoffiduciarydutyandunfaircompetitiondrswansonis seekingdamagesandanawardofunjustenrichmentalzafiledamotiontodismissdrswansonsclaimsaswellas counterclaimsforbreachofcontractandnegligentmisrepresentationthecourtgrantedthemotioninpartanddeniedit inpartalzafiledamotionforsummaryjudgmentontheissueofinventorshipandahearingwasheldinfebruary thepartiesareawaitingadecision johnsonjohnsonacquiredtheprostatecancerbusinessofaragonpharmaceuticalsincaragonincludingarn acompoundbeingtestedfortreatmentofprostatecancerinseptemberpriortotheacquisitioninmay medivationincmedivationhadsuedaragonandtheuniversityofcaliforniaseekingrightstoarnindecember thestatecourtgrantedsummaryjudgmenttoaragononmedivationsclaimsawardingtherightsofthearn compoundtoaragonandinjanuarythecourtdismissedthecaseagainstaragonmedivationhasappeale remicaderelatedcase inmarchhospirahealthcarecorporationhospirafiledanimpeachmentproceedingagainstthekennedyinstitute ofrheumatologykennedychallengingthevalidityofacanadianpatentrelatedtoremicadeafeldmanpatent johnsonjohnsonannualreport whichisexclusivelylicensedtojanssenbiotechincjbiinoctoberkennedyalongwithjbijanssenincand cilaggmbhinternationalbothaffiliatesofjbifiledacounterclaimforinfringementagainstcelltrionhealthcarecoltd celltrioninctogethercelltrionandhospirathecounterclaimallegesthattheproductsdescribedincelltrionsand hospirasmarketingapplicationstohealthcanadafortheirsubsequententrybiologicssebtoremicadewould infringethefeldmanpatentsownedbykennedydiscoveryinthepatentactionisongoingtrialhasbeenscheduledfor september injanuaryhealthcanadaapprovedcelltrionssebtoremicadeallowingcelltriontomarketitsbiosimilar versionofremicadeincanadaregardlessofthependingpatentactioninjunehospirareceivedapprovalfor itssebtoremicadeinjulyjanssenincjanssenfiledalawsuittocompelthecanadianministerofhealthto withdrawthenoticeofcomplianceforhospirassebbecausehospiradidnotserveanoticeofallegationonjanssento addressthepatentlistedbyjanssenonthepatentregisterifthenoticeofcomplianceiswithdrawnhospirawouldhave toserveanoticeofallegationandjanssencouldcommenceanapplicationtoprohibitissuanceofthenoticeof complianceuntilexpiryoftherelevantpatentahearinghasbeenscheduledformarch inseptemberjbiandnyulangonemedicalcenternyumedicalcenterreceivedanofficeactionfromthe unitedstatespatentandtrademarkofficeusptorejectingtheclaimsinuspatentnorelatingto remicadethepatentinareexaminationproceedinginstitutedbyathirdpartythepatentiscoownedby jbiandnyumedicalcenterandnyumedicalcentergrantedjbianexclusivelicensetonyumedicalcentersrights underthepatentcurrentlythepatentintheunitedstatesexpiresinseptemberjbirespondedtothat rejectionindecemberandinaugustjbiandnyumedicalcenterreceivedafurtherrejectionjbiresponde totherejectionbyfilingafurtheramendmentandinnovemberjbispetitiontoentertheamendmentwasgrante theapplicationwasreturnedtotheexaminerforissuanceofanewofficeactionwhichoccurredinfebruaryfurther rejectingthepatentjbihassixtydaystorespondtotherejectionjbibelievesthepatentisvalidwillrespondtothe latestofficeactiontodefendthepatentandifnecessaryjbiwillpursueallavailableappeal inmarchcelltrionfiledadeclaratoryjudgmentlawsuitagainstjbiintheunitedstatesdistrictcourtforthedistrict ofmassachusettsseekingtoinvalidatethepatentandtwootheruspatentsthatrelatetoremicadeandareco ownedbyjbiandnyumedicalcenterandexclusivelylicensedtojbicollectivelythelepatentsjbimovedtodismiss thecaseforlackofjurisdictionandcelltrionvoluntarilydismisseditslawsuitalsoinmarchcelltrionfiledalawsuit intheunitedstatesdistrictcourtforthesoutherndistrictofnewyorkagainstkennedyseekingtoinvalidatethree patentsownedbykennedythefeldmanpatentsthefeldmanpatentsarelicensedtojbiandalsorelateto remicadekennedymovedtodismissthecaseforlackofjurisdictionincludingfailuretocomplywiththeprocedural requirementsofthebiologicspricecompetitionandinnovationactthebpciaindecemberthecourtgrante themotion inaugusthospirainchospirafiledalawsuitintheunitedstatesdistrictcourtforthesoutherndistrictofnew yorkagainstjbinewyorkuniversitynyunyumedicalcenterandkennedyseekingtoinvalidatethefeldman patentshospiraallegesthatithasexclusiverightstomarketcelltrionsbiosimilarversionofremicadeintheunite statesifitisapprovedbythefdainoctoberjbinyuandnyumedicalcentermovedtodismissthiscasefor lackofjurisdictionincludingfailuretocomplywiththeproceduralrequirementsofthebpciaindecemberthe courtgrantedthemotion inaugustcelltrionfiledforfdaapprovaltomakeandsellitsownbiosimilarversionofremicadeinfebruary jbireceivedanoticeofcommercialmarketingfromcelltrioninaccordancewiththebpcianotifyingjbithat celltrionandorhospiraintendtobegincommercialmarketingofabiosimilarproductasearlyasdaysfromthedate ofthenoticethepartiesareproceedingwiththepatentresolutionproceduressetforthinthebpciajbibelievesthe patentsarevalidandwillenforcetherelevantpatent ifanyoftheleorfeldmanpatentsisfoundtobeinvalidanysuchpatentcouldnotbereliedupontopreventthe introductionofbiosimilarversionsofremicadethetimingofthepossibleintroductionofabiosimilarversionof remicadeintheunitedstateswouldbesubjecttoapprovalbythefdalossofexclusivitywilllikelyresultina reductioninsalesasbiosimilarversionsofremicadeareintroducedtothemarket litigationagainstfilersofabbreviatednewdrugapplicationsandas thefollowingsummarizeslawsuitspendingagainstgenericcompaniesthathavefiledabbreviatednewdrugapplications andaswiththefdaorundertakensimilarregulatoryprocessesoutsideoftheunitedstatesseekingtomarketgeneric formsofproductssoldbyvarioussubsidiariesofjohnsonjohnsonpriortoexpirationoftheapplicablepatentscovere thoseproductstheseandastypicallyincludeallegationsofnoninfringementinvalidityandunenforceabilityofthe johnsonjohnsonannualreportapplicablepatentsintheeventthesubsidiariesarenotsuccessfulintheseactionsorthestatutorymonthstaysofthe andasexpirebeforetheunitedstatesdistrictcourtrulingsareobtainedthethirdpartycompaniesinvolvedwillhavethe abilityuponapprovalofthefdatointroducegenericversionsoftheproductsatissuetothemarketresultinginthe potentialforsubstantialmarketshareandrevenuelossesforthoseproductsandwhichmayresultinanoncash impairmentchargeinanyassociatedintangibleasset prezista anumberofgenericcompanieshavefiledandasseekingapprovaltomarketgenericversionsofprezistain novembertibotecincnowtibotecllcandtibotecpharmaceuticalsnowjanssenrdirelandcollectively tibotecfiledapatentinfringementlawsuitagainstlupinltdlupinpharmaceuticalsinccollectivelylupinmylaninc andmylanpharmaceuticalsinccollectivelymylanintheunitedstatesdistrictcourtforthedistrictofnewjerseyin responsetolupinsandmylansrespectiveandasseekingapprovaltomarketgenericversionsoftibotecsprezista productbeforetheexpirationoftibotecspatentrelatingtoprezistalupinandmylaneachfiledcounterclaim allegingnoninfringementandinvalidityinjulytibotecfiledanotherpatentinfringementlawsuitagainstlupininthe unitedstatesdistrictcourtforthedistrictofnewjerseyinresponsetolupinssupplementtoitsandatoaddnew dosagestrengthsforitsproposedproductinaugusttibotecandgdsearlecompanygdsearlefileda patentinfringementlawsuitagainstlupinandmylaninresponsetotheirnoticelettersadvisingthattheirandasare seekingapprovaltomarketgenericversionsoftibotecsprezistaproductbeforetheexpirationoftwoadditional patentsrelatingtoprezistathattibotecexclusivelylicensesfromgdsearleinseptemberthecourt consolidatedtheabovelawsuitsreferredtohereasthefirstconsolidatedaction theapprovednewdrugapplicationforprezistawastransferredfromtibotecinctojanssenproductslpin decemberinandjanssenproductslpandjanssenrdirelandcollectivelyjanssenaddedseveral patentsthattheyownorexclusivelylicensefromgdsearletothefirstconsolidatedactionagainstmylanandlupinin junejanssenandgdsearledismissedtheirclaimsrelatingtothepatentsownedbygdsearleagainstlupin andmylanbasedonthosepartiesagreementnottoseekfdaapprovaloftheirrespectiveandasuntilthenovember expirationofthegdsearlepatentsafteratrialregardingtheremainingpatentsinthefirstconsolidatedaction thecourtissuedadecisioninaugustinfavorofjanssenholdingthattheassertedpatentsarevalidandwouldbe infringedbylupinsandmylansmarketingoftheirproposedproductslupinfiledanappeal inmaylupinnotifiedjanssenthatitfiledanandaseekingapprovaltomarketanewdosagestrengthofitsgeneric versionofprezistainresponsejanssenfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthe districtofnewjerseyallegingthatlupinsnewdosagestrengthwouldinfringethesamepatentsthatjanssenisasserting againstlupinintheoriginalactioninmarchjanssenfiledapatentinfringementlawsuitagainstlupinintheunite statesdistrictcourtforthedistrictofnewjerseyalleginginfringementofunitedstatespatentnoinjanuary thecourtconsolidatedtheselawsuitsreferredtohereasthesecondconsolidatedactionandstayedthem pendinglupinsappealofthecourtsdecisioninthefirstconsolidatedaction janssenfiledapatentinfringementlawsuitagainstheterodrugsltdunitiiiandheterousaincinmarchinthe unitedstatesdistrictcourtforthedistrictofnewjerseyalleginginfringementofunitedstatespatentnos anddiscoveryinthiscaseisongoingandatrialdateissetforoctober janssenandgdsearlealsofiledpatentinfringementlawsuitsagainsttevapharmaceuticalsusaincandteva pharmaceuticalsltdcollectivelytevaintheunitedstatesdistrictcourtforthedistrictofnewjerseyinresponseto tevasandaseekingapprovaltomarketagenericversionofprezistabeforetheexpirationofcertainpatentsrelating toprezistathatjansseneitherownsorexclusivelylicensesfromgdsearleinmarchthepartiesenteredintoa settlementagreementandthelawsuitsagainsttevaweredismisse injulyjanssenfiledapatentinfringementlawsuitagainstmylanintheunitedstatesdistrictcourtforthedistrictof newjerseyalleginginfringementofunitedstatespatentnodiscoveryinthecaseinongoe inaugustjanssenfiledpatentinfringementlawsuitsagainstciplaltdandciplausainccollectivelyciplainthe unitedstatesdistrictcourtsforthedistrictsofnewjerseyanddelawareinresponsetociplasandaseekingapproval tomarketagenericversionofjanssensprezistaproductbeforetheexpirationofcertainofjanssenspatentsrelating toprezistaciplafiledcounterclaimsseekingdeclarationsofnoninfringementandinvalidityofthepatentsinsuit discoveryisongoe inresponsetoitsnoticeofallegationseekingapprovaltomarketagenericversionofprezistaincanadabeforethe expirationofcanadianpatentnojanssenincandjanssenrdirelandfiledanoticeofapplicationagainst mylanpharmaceuticalsulcinjulyindecemberjanssenrdirelandtransferreditsprezistapatentsto johnsonjohnsonannualreport janssensciencesirelanducandjanssensciencesirelanducwassubstitutedforjanssenrdirelandasplaintiffinthe abovereferencedactionsinjanuaryjanssenincandjanssensciencesirelanducfiledanoticeofapplication againsttevacanadalimitedinresponsetoitsnoticeofallegationseekingapprovaltomarketagenericversionof prezistabeforetheexpirationofcanadianpatentno ineachoftheabovelawsuitsjanssensoughtorisseekinganorderenjoiningthedefendantsfrommarketingtheirgeneric versionsofprezistabeforetheexpirationoftherelevantpatent concerta injunealzacorporationalzaandjanssenpharmaceuticalsincjpifiledpatentinfringementlawsuitsinthe unitedstatesdistrictcourtforthedistrictofdelawareagainstparpharmaceuticalsincparosmoticakereskedelmie szolgaltatokftosmoticaandnorwichpharmaceuticalsincnorwichinresponsetothosepartiesandasseeke approvaltomarketagenericversionofconcertabeforetheexpirationofunitedstatespatentnothe patentinadditioninseptemberparandosmoticafiledcounterclaimsagainstalzaandjpiseeking declarationsofinvalidityandnoninfringementofthepatentinsuitandnorwichfiledamotiontodismissnorwichwa dismissedfromthecaseinoctoberbasedonitsagreementtobeboundbytheoutcomeofthecasewith osmoticainmarchalzaandjpiamendeditscomplaintagainstparandosmoticatoassertinfringementofnewly issuedunitedstatespatentnothepatentinjunealzajpiandosmoticaenteredintoa settlementoftheactionandinseptemberalzajpiandparenteredintoasettlement inmayalzaandjpifiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofw virginiaagainstmylanincandmylanpharmaceuticalsincmylaninresponsetoitsandaseekingapprovaltomarketa genericversionofconcertabeforetheexpirationofthepatentmylanfiledcounterclaimsseekingdeclaration ofinvalidityandnoninfringementofthepatentsinsuit injunealzaandjpifiledapatentinfringementlawsuitinthedistrictofdelawareagainstsandozincinresponse toitsandaseekingapprovaltomarketagenericversionofconcertabeforetheexpirationoftheand patentssandozfiledcounterclaimsseekingdeclarationsofinvalidityunenforceabilityandnoninfringementofthepatent insuitindecemberthepartiesenteredintoasettlementagreementandthelawsuitwasdismisse indecemberjanssenincandalzafiledanoticeofapplicationagainstactavispharmacompanyactavisin responsetoitsnoticeofallegationseekingapprovaltomarketagenericversionofconcertabeforetheexpirationof canadianpatentno ineachoftheabovelawsuitsalzaandorjpiareseekinganorderenjoiningthedefendantsfrommarketingtheirgeneric versionsofconcertabeforetheexpirationoftheandorpatent nucyntaandnucyntaer injulyjanssenpharmaceuticalsincjpifiledpatentinfringementlawsuitsintheunitedstatesdistrictcourtfor thedistrictofnewjerseyagainstactaviselizabethllcactavisincandactavisllccollectivelyactavisaswellas alkemlaboratorieslimitedandascendlaboratoriesllccollectivelyalkemthepatentinfringementclaimsagainst actavisandalkemrelatetotheirrespectiveandasseekingapprovaltomarketagenericversionofnucyntaer beforetheexpirationofunitedstatesreissuepatentnothepatentunitedstatespatentno thepatentandastoactavisonlyunitedstatespatentnothepatentthelawsuitalsoincludes apatentinfringementclaimagainstalkeminresponsetoitsandaseekingapprovaltomarketagenericversionof nucyntabeforetheexpirationoftheandpatentsindecemberjpifiledanadditionalcomplaintinthe districtcourtofnewjerseyagainstalkemassertingunitedstatespatentnorelatedtoitsandaseeke approvaltomarketagenericversionofnucyntaerinaugustjpiamendedthecomplaintagainstalkemtoadd additionaldosagestrength inoctoberjpireceivedaparagraphivnoticefromsandozincsandozwithrespecttonucyntarelatedto thepatentandaparagraphivnoticefromroxanelaboratoriesincroxanewithrespecttonucyntarelatedto theandpatentsinresponsetothosenoticesjpifiledanadditionalcomplaintintheunitedstatesdistrict courtforthedistrictofnewjerseyagainstroxaneandsandozassertingthepatentagainstsandozandthe andpatentsagainstroxaneinapriljpiandsandozenteredintoajointstipulationofdismissalofthecase againstsandozbasedonsandozsagreementnottoenterthemarketpriortotheexpirationoftheassertedpatentsin juneinresponsetoaparagraphivnoticefromroxanewithrespecttonucyntaerjpifiledacomplaint assertingtheandpatentsagainstroxane johnsonjohnsonannualreportinjulyinresponsetoaparagraphivnoticefromwatsonlaboratoriesincwatsonwithrespecttothe nucyntaoralsolutionproductandtheandpatentsjpifiledalawsuitintheunitedstatesdistrictcourtfor thedistrictofnewjerseyassertingtheandpatentsagainstwatson ineachoftheabovelawsuitsjpiisseekinganorderenjoiningthedefendantsfrommarketingtheirgenericversionsof nucyntaerandnucyntabeforetheexpirationoftheassertedpatent governmentproceeding likeothercompaniesinthepharmaceuticalandmedicaldevicesindustriesjohnsonjohnsonandcertainofit subsidiariesaresubjecttoextensiveregulationbynationalstateandlocalgovernmentagenciesintheunitedstatesand othercountriesinwhichtheyoperateasaresultinteractionwithgovernmentagenciesisongoingthemostsignificant litigationbroughtbyandinvestigationsconductedbygovernmentagenciesarelistedbelowitispossiblethatcriminal chargesandsubstantialfinesandorcivilpenaltiesordamagescouldresultfromgovernmentinvestigationsorlitigation averagewholesalepriceawplitigation johnsonjohnsonandseveralofitspharmaceuticalsubsidiariesthejjawpdefendantsalongwithnumerousother pharmaceuticalcompaniesaredefendantsinaseriesoflawsuitsinstateandfederalcourtsinvolvingallegationsthatthe pricingandmarketingofcertainpharmaceuticalproductsamountedtofraudulentandotherwiseactionableconduct becauseamongotherthingsthecompaniesallegedlyreportedaninflatedaveragewholesalepriceawpforthedrug atissuepayorsallegedthattheyusedthoseawpsincalculatingproviderreimbursementlevelsmanyofthesecase bothfederalactionsandstateactionsremovedtofederalcourtwereconsolidatedforpretrialpurposesinamultidistrict litigationmdlintheunitedstatesdistrictcourtforthedistrictofmassachusetts theplaintiffsinthesecasesincludedthreeclassesofprivatepersonsorentitiesthatpaidforanyportionofthepurchase ofthedrugsatissuebasedonawpandstategovernmententitiesthatmademedicaidpaymentsforthedrugsatissue basedonawpinjuneafteratrialonthemeritsthemdlcourtdismissedtheclaimsoftwooftheplaintiffclasse againstthejjawpdefendantsinmarchthecourtdismissedtheclaimsofthethirdclassagainstthejjawp defendantswithoutprejudice awpcasesbroughtbyvariousattorneysgeneralhaveproceededtotrialagainstothermanufacturersseveralstate casesagainstcertainsubsidiariesofjohnsonjohnsonhavebeensettledincludingthecaseinalaskawhichsettledin aprilandcasesarestillpendinginillinoisnewjerseywisconsinutahandpennsylvaniathecasesinillinoisnew jerseyandwisconsinhavenotyetproceededtotrialinutahtheclaimsbroughtbytheattorneygeneralweredismissed bythecourtinbutthestatemayappealthedismissalaftertheconclusionofsimilarpendingmattersagainstother defendantstheawpcaseagainstthejjawpdefendantsbroughtbytheattorneygeneralofthecommonwealthof pennsylvaniawastriedincommonwealthcourtinthecourtfoundinthecommonwealthsfavorwithregardto certainofitsclaimsunderthepennsylvaniaunfairtradepracticesandconsumerprotectionlawutplenteredan injunctionandawardedmillioninrestitutionandmillionincivilpenaltiesthecourtfoundinthejjawp defendantsfavoronthecommonwealthsclaimsofunjustenrichmentmisrepresentationfraudcivilconspiracyandon certainofthecommonwealthsclaimsundertheutplthejjawpdefendantsappealedthecommonwealthcourt utplrulingandinjunethepennsylvaniasupremecourtvacatedthejudgmententeredbythecommonwealth courtandremandedthecaseforfurtherproceedingsonremandinjanuarythecommonwealthcourtdismisse themonetaryawardsagainstthejjawpdefendantswhichmaybeappealed risperdal innovemberjohnsonjohnsonanditssubsidiaryjanssenpharmaceuticalsincjpifinalizedpreviously disclosedsettlementagreementswiththeunitedstatesdepartmentofjusticeandfortyfivestatesresolvingfederal investigationsandstatemedicaidclaimsrelatedtopastpromotionalpracticesofrisperdalfromthrough andothermattersjpihadalsosettledallegedconsumerfraudclaimsinconnectionwiththesaleandmarketingof risperdalwiththirtysixstatesandthedistrictofcolumbiainseptemberinadditiontotheseactionsthe attorneysgeneralofseveralstatesbroughtactionsagainstjpirelatedtothesaleandmarketingofrisperdal seekingoneormoreofthefollowingremediesreimbursementofmedicaidorotherpublicfundsforrisperdal prescriptionswrittenforofflabelusecompensationfortreatingtheircitizensforallegedadversereactionsto risperdalcivilfinesorpenaltiesforviolationsofstatefalseclaimsactsorconsumerfraudstatutespunitivedamage orotherreliefrelatingtoallegedunfairbusinesspracticescertainoftheseactionsalsosoughtinjunctivereliefrelatingto thepromotionofrisperdalmanyoftheactionsandclaimsbroughtbythestateattorneysgeneralhavebeensettle eitherindividuallyoraspartofthesettlementsdescribedabove johnsonjohnsonannualreport fourstateshaveremainingclaimsinlitigationrelatedtorisperdaloneclaimisonremandinarkansasthecasein southcarolinaisonappealinkentuckyatrialhasbeensetforaprilandinmississippithecasehasnot progressedtotrialthecompanyhasnotaccruedanamountequaltothejudgmentobtainedinsouthcarolinatothe extentanystatehasanoutstandingmedicaidrelatedclaimnotresolvedbythesettlementsreferencedabovethe companyhasaccruedanamountapproximatelyequaltowhatthatstatewouldhavereceivedifithadparticipatedinthe relevantfederalsettlementstatecasesthatwenttojudgmentaftertrialarediscussedbelow intheattorneygeneralofwestvirginiacommencedalawsuitagainstjanssenpharmaceuticaincnowjpibase onclaimsofallegedconsumerfraudastoduragesicaswellasrisperdaljpiwasfoundliableanddamage wereassessedatmillionjpifiledanappealandinnovemberthewestvirginiasupremecourtofappeal reversedthetrialcourtsdecisionindecembertheattorneygeneralofwestvirginiadismissedthecaseasit relatedtorisperdalwithoutanypaymentthereafterjpisettledthecaseinsofarasitrelatedtoduragesic intheattorneygeneraloflouisianafiledamulticountcomplaintagainstjanssenpharmaceuticaincnowjpi johnsonjohnsonwaslateraddedasadefendantthecasewastriedinoctobertheissuetriedtothejurywa whetherjohnsonjohnsonorjpihadviolatedthestatesmedicalassistanceprogramintegritylawtheactthrough misrepresentationsallegedlymadeinthemailingofanovemberdearhealthcareprofessionalletterregarde risperdalthejuryreturnedaverdictthatjpiandjohnsonjohnsonhadviolatedtheactandawarde millionindamagesthetrialjudgesubsequentlyawardedtheattorneygeneralcounselfeesandexpensesintheamount ofmillioninjanuarythelouisianasupremecourtreversedthedistrictcourtsjudgmentinfavorofthe attorneygeneralandrenderedjudgmentinfavorofjohnsonjohnsonandjpiinaprilthelouisianasupreme courtdeniedtheattorneygeneralspetitionseekingarehearingoftheappellateargumentsresultinginfinaldismissalof thecase intheofficeofgeneralcounselofthecommonwealthofpennsylvaniafiledalawsuitagainstjanssen pharmaceuticaincnowjpionamulticountcomplaintrelatedtojanssenpharmaceuticassaleofrisperdaltothe commonwealthsmedicaidprogramthetrialoccurredinjunethetrialjudgedismissedthecaseafterthecloseof theplaintiffsevidencethecommonwealthfiledanappealandinjulythepennsylvaniaappealscourtupheldthe dismissalofthecommonwealthscase intheattorneygeneralofsouthcarolinafiledalawsuitagainstjohnsonjohnsonandjanssenpharmaceutica incnowjpionseveralcountsinmarchthematterwastriedtoajuryonliabilityonlyatwhichtimethelawsuit waslimitedtoclaimsofviolationofthesouthcarolinaunfairtradepracticesactincludingamongothersquestionsof whetherjohnsonjohnsonorjpiengagedinunfairordeceptiveactsorpracticesintheconductofanytradeor commercebydistributingthenovemberdearhealthcareprofessionalletterregardingrisperdalorintheiruse oftheproductsfdaapprovedlabelthejuryfoundinfavorofjohnsonjohnsonandagainstjpiinjunethe courtawardedcivilpenaltiesofapproximatelymillionagainstjpijpihasappealedthisjudgmentandthe companybelievesithasstrongargumentssupportingtheappealoralargumentontheappealtookplacebeforethe southcarolinasupremecourtinmarchandthepartiesareawaitingadecision inaprilinthelawsuitbroughtbytheattorneygeneralofarkansasthejuryfoundagainstbothjpiandjohnson johnsonandthecourtimposedpenaltiesintheamountofapproximatelybillioninjanuarythetrialcourt awardedattorneyfeesofapproximatelymillionjpiandjohnsonjohnsonappealedbothawardstothearkansas supremecourtandinmarchthearkansassupremecourtdismissedthestatesclaimunderthearkansas medicaidfraudfalseclaimsactaswellastheapproximatelybillioninpenaltiesandreversedandremandeda claimunderthearkansasdeceptivetradepracticesactinaprilthearkansassupremecourtrejectedapetition bythestateforrehearingonthecasetrialontheremandofthecaseisscheduledforjune mcneilconsumerhealthcare startinginjunemcneilconsumerhealthcaredivisionofmcneilppcincmcneilconsumerhealthcareand certainaffiliatesincludingjohnsonjohnsonthecompaniesreceivedgrandjurysubpoenasfromtheunitedstate attorneysofficefortheeasterndistrictofpennsylvaniarequestingdocumentsbroadlyrelatingtorecallsofvarious productsofmcneilconsumerhealthcareandthefdainspectionsofthefortwashingtonpennsylvaniaandlancaster pennsylvaniamanufacturingfacilitiesaswellascertaindocumentsrelatingtorecallsofasmallnumberofproductsof othersubsidiariesinadditioninfebruarythegovernmentservedmcneilppcincmcneilppcwithacivil investigativedemandseekingrecordsrelevanttoitsinvestigationtodetermineiftherewasaviolationofthefederalfalse claimsactthegrandjuryandfalseclaimsinvestigationsarecontinuingthecompaniesarecooperatingwiththe unitedstatesattorneysofficeinrespondingtotheseinvestigation johnsonjohnsonannualreportthecompanieshavealsoreceivedcivilinvestigativedemandsfrommultiplestateattorneysgeneralofficesbroadly relatingtothemcneilrecallissuesthecompaniescontinuetocooperatewiththeseinquirieswhicharebee coordinatedthroughamultistatecoalitionifaresolutioncannotbereachedwiththismultistatecoalitionitispossible thatindividualstateattorneysgeneralofficesmayfilecivilmonetaryclaimsagainstthecompaniesinjanuarythe oregonattorneygeneralfiledacivilcomplaintagainstjohnsonjohnsonmcneilppcandmcneilhealthcarellcin statecourtallegingcivilviolationsoftheoregonunlawfultradepracticesactrelatingtoanearlierrecallofamcneilotc productinnovemberthestatecourtgrantedamotionbythecompaniestodismissoregonscomplaintinit entiretywithprejudiceindecemberoregonfiledanoticeofappealinthecourtofappealsofthestateof oregonoralargumenttookplaceinjulyandthepartiesareawaitingadecision opioidslitigation alongwithotherpharmaceuticalcompaniesjanssenpharmaceuticalsincjpihasbeennamedinanumberoflawsuit allegingclaimsrelatedtoopioidmarketingpracticesinmaysantaclaraandorangecountiesincaliforniathe countiesfiledacomplaintinstatecourtinorangecountycaliforniaagainstnumerouspharmaceuticalmanufacturer includingjpiallegingclaimsrelatedtoopioidmarketingpracticesincludingfalseadvertisingunfaircompetitionand publicnuisanceinjunethecityofchicagofiledacomplaintincookcountycircuitcourtagainstseveral pharmaceuticalmanufacturersincludingjpialleginganumberofclaimsrelatedtoopioidmarketingpracticesinclude consumerfraudviolationsandfalseclaimsthecasewaslaterremovedtotheunitedstatesdistrictcourtforthe northerndistrictofillinoisandindecemberdefendantsfiledamotiontodismissthecityofchicagosfirst amendedcomplaintforfailuretostateaclaiminseptemberthetennesseeattorneygeneraldivisionof consumeraffairsissuedarequestforinformationtojpirelatedtoopioidsmarketingpractice inseptembersynthesincsynthesreceivedacivilinvestigativedemandissuedpursuanttothefalseclaimsact fromtheunitedstatesattorneysofficefortheeasterndistrictofpennsylvaniathedemandsoughtinformation regardingallegationsthatfellowshipshadbeenofferedtohospitalsinexchangeforagreementstopurchaseproduct syntheshasproduceddocumentsandinformationinresponsetothedemandandiscooperatingwiththeinquiry inmayacclarentincacclarentreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsrequestingdocumentsbroadlyrelatingtothesalesmarketingandallegedofflabelpromotionbyacclarent ofrelievastratusmicroflowspacerproductstheinvestigationiscontinuingandacclarentiscooperatingwiththe unitedstatesattorneysofficeinrespondingtothesubpoena inaugustdepuyorthopaedicsincdepuyincnowdepuysynthesincandjohnsonjohnsonservicesinc thecompaniesreceivedaninformalrequestfromtheunitedstatesattorneysofficeforthedistrictofmassachusetts andthecivildivisionoftheunitedstatesdepartmentofjusticetheunitedstatesfortheproductionofmaterialsrelate totheasrxlhipdeviceinjulytheunitedstatesnotifiedtheunitedstatesdistrictcourtforthedistrictof massachusettsthatithaddeclinedtointerveneinaquitamcasefiledpursuanttothefalseclaimsactagainstthe companiesthedistrictcourtissuedanorderinaugustthatpubliclyunsealedtheunitedstatesdeclination noticehoweverthecomplaintinthematterremainsundersealinadditioninoctoberagroupofstateattorney generalissuedcivilinvestigativedemandsrelatingtothedevelopmentsalesandmarketingofseveralofdepuy orthopaedicsincshipproductsinjulytheoregondepartmentofjusticewhichwasinvestigatingthesematter independentlyoftheotherstatesannouncedasettlementofitsasrxlhipdeviceinvestigationforatotalpaymentof milliontothestateoforegon inoctoberjohnsonjohnsonwascontactedbythecaliforniaattorneygeneralsofficeregardingamultistate attorneygeneralinvestigationofthemarketingofsurgicalmeshproductsforherniaandurogynecologicalpurposesby johnsonjohnsonssubsidiaryethiconincethiconjohnsonjohnsonandethiconhavesinceenteredintoaserie oftollingagreementswiththestatesandthedistrictofcolumbiaparticipatinginthemultistateinvestigationandhave respondedtocivilinvestigativedemandsservedbycertainoftheparticipatingstate indecembertherakosinctherakosformerlyasubsidiaryofjohnsonjohnsonandpartoftheorthoclinical diagnosticsincocdfranchisereceivedaletterfromthecivildivisionoftheunitedstatesattorneysofficeforthe easterndistrictofpennsylvaniainformingtherakosthattheunitedstatesattorneysofficewasinvestigatingthesale andmarketingofuvadexmethoxsalenandtheuvarxtssystemduringtheperiodtothepresenttheunite statesattorneysofficerequestedthatocdandjohnsonjohnsonpreservedocumentsthatcouldrelatetothe investigationtherakoswassubsequentlyacquiredbyanaffiliateofgorescapitalpartnersiiilpinjanuaryocd andjohnsonjohnsonretaincertainliabilitiesthatmayresultfromtheinvestigationforactivitythatoccurredpriortothe johnsonjohnsonannualreport saleoftherakosinmarchtheunitedstatesattorneysofficerequestedthatjohnsonjohnsonproducecertain documentsandjohnsonjohnsoniscooperatingwiththerequestfollowingthedivestitureofocdjohnsonjohnson retainsocdsportionofanyliabilitythatmayresultfromtheinvestigationforactivitythatoccurredpriortothesaleof therakos inmayjanssenpharmaceuticalsincjpireceivedasubpoenafromtheatlantaregionalofficeofthedepartment ofhealthandhumanservicesofficeofinspectorgeneralseekingproductionofdocumentsandinformationregarde thesalesmarketingandpromotionalpracticesincludingtheremunerationofhealthcareprovidersrelatedto nucyntairandnucyntaerandanystudiesreportsandorcomplaintsregardingthesafetyandoractualor potentialsideeffectsofnucyntairandnucyntaerinoctobertheunitedstatesdepartmentofjustice dojinformedjpithatthegovernmentsinvestigationstemmedfromthefilingofaquitamcomplaintthatthedojhad formallydeclinedtointerveneinthequitamactionandthatthedojwasclosingitsinvestigationrelatedtonucynta irandnucyntaertheplaintiffinthequitamcomplaintfiledanoticeofdismissalandthecourtdismissedthequi tamactionindecember inrecentyearsjohnsonjohnsonhasreceivednumerousrequestsfromavarietyofunitedstatescongressional committeestoproduceinformationrelevanttoongoingcongressionalinquiriesitisthepolicyofjohnsonjohnsonto cooperatewiththeseinquiriesbyproducingtherequestedinformation generallitigation inseptemberjohnsonjohnsonfiledalawsuitagainstguidantcorporationguidantintheunitedstatesdistrict courtforthesoutherndistrictofnewyorkallegingthatguidantbreachedprovisionsofamergeragreementbetween johnsonjohnsonandguidantinjuneguidantfiledamotionforsummaryjudgmentandinjulythejudge deniedguidantsmotionthetrialconcludedinjanuaryandinfebruarybeforeadecisionwasissuedbythe courtjohnsonjohnsonandguidantenteredintoasettlementagreementpursuanttowhichguidantagreedtopay johnsonjohnsonmillionandagreedthatitwillnotsuejohnsonjohnsonoritsaffiliatesforpatentinfringement regardingcertainstentproductsjohnsonjohnsonwilldismissitsactionagainstguidantwithprejudicethecompany willrecordthistransactioninfiscalyear injunefollowingthepublicannouncementthatorthoclinicaldiagnosticsincocdhadreceivedagrandjury subpoenafromtheunitedstatesdepartmentofjusticeantitrustdivisioninconnectionwithaninvestigationthatha sincebeenclosedmultipleclassactioncomplaintswerefiledagainstocdbydirectpurchasersseekingdamagesfor allegedpricefixingthesecaseswereconsolidatedforpretrialpurposesintheunitedstatesdistrictcourtforthe easterndistrictofpennsylvaniaasinrebloodreagentantitrustlitigationinaugustthedistrictcourtgranteda motionfiledbyplaintiffsforclasscertificationinoctobertheunitedstatescourtofappealsforthethirdcircuit grantedocdspetitionforinterlocutoryreviewoftheclasscertificationrulingoralargumentontheappealwasheldin februaryandthepartiesareawaitingadecisionfollowingthedivestitureofocdjohnsonjohnsonretainsany liabilitythatmayresultfromthesecase inseptemberashareholderronaldmonkfiledalawsuitintheunitedstatesdistrictcourtforthedistrictofnew jerseyseekingclasscertificationandallegingthatjohnsonjohnsonandcertainindividualsincludingexecutiveofficer andemployeesofjohnsonjohnsonfailedtodisclosethatanumberofmanufacturingfacilitiesfailedtomaintaincurrent goodmanufacturingpracticesandthatasaresultthepriceofthecompanysstockdeclinedsignificantlyplaintiffsought topursueremediesunderthesecuritiesexchangeactoftorecoverhisallegedeconomiclossesindecember amotionbyjohnsonjohnsontodismisswasgrantedinpartanddeniedinpartinseptemberplaintifffile asecondamendedcomplaintandjohnsonjohnsonandtheindividualdefendantsmovedtodismissplaintiffssecond amendedcomplaintinpartfollowingmediationthepartiesreachedanagreementinprincipletosettlethecaseandin julyfiledforpreliminaryapprovaloftheproposedsettlementinnovemberthecourtapprovedthe settlementthreepartiesthathadobjectedtothesettlementappealedthecourtsapprovalorderspriortothemediation fortheappealthepartiesagreedtodismisstheappealwithprejudiceandwithoutcostsagainstanypartytheunite statescourtofappealsforthethirdcircuitdismissedthecaseinapril inaprilomjpharmaceuticalsincomjprfiledalawsuitagainsttheunitedstatesinunitedstatesdistrictcourt forthedistrictofpuertoricoallegingoverpaymentoffederalincometaxesforthetaxyearsendednovember andnovemberomjprallegedthattheinternalrevenueserviceerroneouslycalculatedomjprstaxcredit undersectionofthetaxcodeomjprfiledamotionforsummaryjudgmentandtheunitedstatesfiledacross motionforsummaryjudgmentinoctoberthecourtgrantedamotionbytheunitedstatesforsummaryjudgment anddeniedamotionbyomjprforsummaryjudgmentomjprappealedthisdecisioninjunetheappellatecourt reversedthetrialcourtsdecisionandinstructedthetrialcourttoentersummaryjudgmentinfavorofomjpr johnsonjohnsonannualreportinseptemberjohnsonjohnsonjohnsonjohnsonincandmcneilconsumerhealthcaredivisionofjohnson johnsonincreceivedanoticeofcivilclaimfiledbynickfieldinthesupremecourtofbritishcolumbiacanadathe bccivilclaimthebccivilclaimisaputativeclassactionbroughtonbehalfofpersonswhoresideinbritishcolumbia andwhopurchasedduringtheperiodbetweenseptemberandinoraboutdecemberoneormorevarious mcneilinfantsorchildrensoverthecountermedicinesthatweremanufacturedatthefortwashingtonfacilitythebc civilclaimallegesthatthedefendantsviolatedthebcbusinesspracticesandconsumerprotectionactandother canadianstatutesandcommonlawsbysellingmedicinesthatwereallegedlynotsafeandoreffectiveordidnotcomply withcanadiangoodmanufacturingpracticestheclasscertificationhearingisscheduledforoctober inaugustunitedstatescustomsandborderprotectionissuedapenaltynoticeagainstjanssenorthollc janssenorthoassessingpenaltiesfortheallegedimproperclassificationofdarunavirethanolateprezistain connectionwithitsimportationintotheunitedstatesinoctoberjanssenorthosubmittedapetitionforreliefin responsetothepenaltynotice johnsonjohnsonoritssubsidiariesarealsopartiestoanumberofproceedingsbroughtunderthecomprehensive environmentalresponsecompensationandliabilityactcommonlyknownassuperfundandcomparablestatelocalor foreignlawsinwhichtheprimaryreliefsoughtisthecostofpastandorfutureremediation shareholderderivativeaction inseptembertwoshareholderderivativelawsuitswerefiledintheunitedstatesdistrictcourtforthedistrictof newjerseybydonovanspamerandthegeorgeleonfamilytrustnamingcurrentandformerdirectorsofjohnson johnsonasdefendantsandjohnsonjohnsonasthenominaldefendanttheselawsuitsallegethatthedefendant breachedtheirfiduciarydutiesintheirdecisionswithrespecttothecompensationofthechiefexecutiveofficerdure theperiodfromthroughandthatthedefendantsmademisleadingstatementsinthecompanysannualproxy statementsbothoftheselawsuitswerevoluntarilydismissedwithoutprejudicebutasimilarlawsuitthegeorgeleon familytrustvcolemanwasrefiledinjulythatlawsuitsoughtavarietyofreliefincludingmonetarydamage injunctivereliefandcorporategovernancereformsinjunetheboardofdirectorsofjohnsonjohnsonthe boardreceivedareportpreparedbyspecialindependentcounseltotheboardwhichinvestigatedtheallegation containedinthederivativeactionsfiledbydonovanspamerandbythegeorgeleonfamilytrustandinseveral shareholderdemandlettersthattheboardreceivedinandraisingsimilarissuesthereportrecommende thatjohnsonjohnsonrejecttheshareholderdemandsandtakewhateverstepsarenecessaryorappropriatetosecure dismissalofthederivativelitigationtheboardunanimouslyadoptedthereportsrecommendation inseptemberjohnsonjohnsonmovedtodismissorinthealternativeforsummaryjudgmentinthegeorge leonfamilytrustvcolemanbasedupontheboardsdeterminationinoctobertheplaintiffintheleonlitigation filedanamendedcomplaintandjohnsonjohnsonmovedtodismisstheamendedcomplaintorinthealternativefor summaryjudgmentbasedupontheboardsdeterminationinjunethecourtgrantedsummaryjudgmentinfavorof johnsonjohnson johnsonjohnsonannualreport report independent register public accounting firm totheshareholdersandboardofdirectorsofjohnsonjohnson inouropiniontheaccompanyingconsolidatedbalancesheetsandtherelatedconsolidatedstatementsofearning statementsofcomprehensiveincomestatementsofequityandstatementsofcashflowspresentfairlyinallmaterial respectsthefinancialpositionofjohnsonjohnsonanditssubsidiariesatdecemberanddecember andtheresultsoftheiroperationsandtheircashflowsforeachofthethreeyearsintheperiodendeddecember inconformitywithaccountingprinciplesgenerallyacceptedintheunitedstatesofamericaalsoinouropinionthe companymaintainedinallmaterialrespectseffectiveinternalcontroloverfinancialreportingasofdecember basedoncriteriaestablishedininternalcontrolintegratedframeworkissuedbythecommitteeofsponsore organizationsofthetreadwaycommissioncosothecompanysmanagementisresponsibleforthesefinancial statementsformaintainingeffectiveinternalcontroloverfinancialreportingandforitsassessmentoftheeffectivenessof internalcontroloverfinancialreportingincludedintheaccompanyingmanagementsreportoninternalcontrolover financialreportingourresponsibilityistoexpressopinionsonthesefinancialstatementsandonthecompanysinternal controloverfinancialreportingbasedonourintegratedauditsweconductedourauditsinaccordancewiththestandard ofthepubliccompanyaccountingoversightboardunitedstatesthosestandardsrequirethatweplanandperform theauditstoobtainreasonableassuranceaboutwhetherthefinancialstatementsarefreeofmaterialmisstatementand whethereffectiveinternalcontroloverfinancialreportingwasmaintainedinallmaterialrespectsourauditsofthefinancial statementsincludedexaminingonatestbasisevidencesupportingtheamountsanddisclosuresinthefinancial statementsassessingtheaccountingprinciplesusedandsignificantestimatesmadebymanagementandevaluatingthe overallfinancialstatementpresentationourauditofinternalcontroloverfinancialreportingincludedobtainingan understandingofinternalcontroloverfinancialreportingassessingtheriskthatamaterialweaknessexistsandtesting andevaluatingthedesignandoperatingeffectivenessofinternalcontrolbasedontheassessedriskourauditsalso includedperformingsuchotherproceduresasweconsiderednecessaryinthecircumstanceswebelievethatouraudit provideareasonablebasisforouropinion acompanysinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe reliabilityoffinancialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewith generallyacceptedaccountingprinciplesacompanysinternalcontroloverfinancialreportingincludesthosepoliciesand proceduresthatipertaintothemaintenanceofrecordsthatinreasonabledetailaccuratelyandfairlyreflectthe transactionsanddispositionsoftheassetsofthecompanyiiprovidereasonableassurancethattransactionsare recordedasnecessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccounte principlesandthatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsof managementanddirectorsofthecompanyandiiiprovidereasonableassuranceregardingpreventionortimelydetection ofunauthorizedacquisitionuseordispositionofthecompanysassetsthatcouldhaveamaterialeffectonthefinancial statement becauseofitsinherentlimitationsinternalcontroloverfinancialreportingmaynotpreventordetectmisstatementsalso projectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequate becauseofchangesinconditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate pricewaterhousecoopersllp florhamparknewjersey february johnsonjohnsonannualreportmanagement report internal control financial reporting undersectionofthesarbanesoxleyactofmanagementisrequiredtoassesstheeffectivenessofthe companysinternalcontroloverfinancialreportingasoftheendofeachfiscalyearandreportbasedonthatassessment whetherthecompanysinternalcontroloverfinancialreportingiseffective managementofthecompanyisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancial reportingthecompanysinternalcontroloverfinancialreportingisdesignedtoprovidereasonableassuranceastothe reliabilityofthecompanysfinancialreportingandthepreparationofexternalfinancialstatementsinaccordancewith generallyacceptedaccountingprinciple internalcontrolsoverfinancialreportingnomatterhowwelldesignedhaveinherentlimitationsthereforeinternalcontrol overfinancialreportingdeterminedtobeeffectivecanprovideonlyreasonableassurancewithrespecttofinancial statementpreparationandmaynotpreventordetectallmisstatementsmoreoverprojectionsofanyevaluationof effectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequatebecauseofchangesin conditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate thecompanysmanagementhasassessedtheeffectivenessofthecompanysinternalcontroloverfinancialreportingas ofdecemberinmakingthisassessmentthecompanyusedthecriteriaestablishedbythecommitteeof sponsoringorganizationsofthetreadwaycommissioncosoininternalcontrolintegratedframework thesecriteriaareintheareasofcontrolenvironmentriskassessmentcontrolactivitiesinformationandcommunication andmonitoringthecompanysassessmentincludedextensivedocumentingevaluatingandtestingthedesignand operatingeffectivenessofitsinternalcontrolsoverfinancialreporting basedonthecompanysprocessesandassessmentasdescribedabovemanagementhasconcludedthatasof decemberthecompanysinternalcontroloverfinancialreportingwaseffective theeffectivenessofthecompanysinternalcontroloverfinancialreportingasofdecemberhasbeenauditedby pricewaterhousecoopersllpanindependentregisteredpublicaccountingfirmasstatedintheirreportwhichappear alexgorsky dominicjcaruso chairmanboardofdirector vicepresidentfinance chiefexecutiveofficer chieffinancialofficer johnsonjohnsonannualreport summary operation statistical datum dollarsinmillionsexceptpershare amount salestocustomersus salestocustomersinternational totalsale costofproductssold sellingmarketingandadministrativeexpense researchanddevelopmentexpense inprocessresearchanddevelopment interestincome interestexpensenetofportioncapitalized otherincomeexpensenet restructure earningsbeforeprovisionfortaxesonincome provisionfortaxesonincome netearning addnetlossattributabletononcontrolle interest netearningsattributabletojohnson johnson percentofsalestocustomer dilutednetearningspershareofcommon stock percentreturnonaverageshareholdersequity percentincreasedecreaseoverprevious year salestocustomer dilutednetearningspershare supplementarybalancesheetdata propertyplantandequipmentnet additionstopropertyplantandequipment totalasset longtermdebt operatingcashflow commonstockinformation dividendspaidpershare shareholdersequitypershare marketpricepershareyearendclose averagesharesoutstandingmillion basic diluted employeesthousand attributabletojohnsonjohnson johnsonjohnsonannualreportshareholder return performance graph setforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnonthecompanyscommonstockfor periodsoffiveyearsandtenyearsendingdecemberagainstthecumulativetotalreturnofthestandard poorsstockindexthestandardpoorspharmaceuticalindexandthestandardpoorshealthcareequipment indexthegraphsandtablesassumethatwasinvestedondecemberanddecemberineachof thecompanyscommonstockthestandardpoorsstockindexthestandardpoorspharmaceuticalindexand thestandardpoorshealthcareequipmentindexandthatalldividendswerereinveste year shareholder return performance indices johnson johnson index pharmaceucidcal index healthcare equipment index year cagr pharm equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex year shareholder return performance indices johnson johnson index pharmaceucidcal index healthcare equipment index year cagr pharm equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex johnsonjohnsonannualreport reconciliationofnongaapfinancialmeasure thetablesthatfollowareprovidedtoreconcilecertainfinancialdisclosuresinthechairmansletterandbusiness highlight change dollarsinmillionsexceptpersharedata earningsbeforeprovisionfortaxesonincomeasreported orthoclinicaldiagnosticsdivestiturenetgain litigationexpense synthesintegrationtransactioncostsandcurrencyrelate additionalyearofbrandedprescriptiondrugfee inprocessresearchanddevelopment depuyasrhipprogram intangibleassetwritedowns earningsbeforeprovisionfortaxesonincomeasadjuste netearningsattributabletojohnsonjohnsonasreporte orthoclinicaldiagnosticsdivestiturenetgain litigationexpense synthesintegrationtransactioncostsandcurrencyrelate additionalyearofbrandedprescriptiondrugfee inprocessresearchanddevelopment depuyasrhipprogram taxbenefitassociatedwithconormedsystem sciostaxbenefit intangibleassetwritedown netearningsattributabletojohnsonjohnsonasadjuste dilutednetearningspershareattributabletojohnsonjohnsonasreporte orthoclinicaldiagnosticsdivestiturenetgain litigationexpense synthesintegrationtransactioncostsandcurrencyrelate additionalyearofbrandedprescriptiondrugfee inprocessresearchanddevelopment depuyasrhipprogram taxbenefitassociatedwithconormedsystem sciostaxbenefit intangibleassetwritedown dilutednetearningspershareattributabletojohnsonjohnsonasadjuste includesadjustmenttodeferredtaxassetrelatedtodeductibilitybytaxjurisdiction amountincludesinprocessresearchanddevelopmentchargeofmillionrelatedtobapineuzumabivoffsetbymillionreportedasnetloss attributabletononcontrollinginter thecompanyprovidesearningsbeforeprovisionfortaxesonincomenetearningsattributabletojohnsonjohnsonandnet earningspershareattributabletojohnsonjohnsondilutedonanadjustedbasisbecausemanagementbelievesthatthese measuresprovideusefulinformationtoinvestorsamongotherthingsthesemeasuresmayassistinvestorsinevaluatingthe costsassociatedwithacquisitionsrestructuringlitigationandchangesinapplicablelawsandregulationsincludingsignificant accountingortaxmattersthesespecialitemsmaybehighlyvariabledifficulttopredictandofasizethatsometimeshas evaluatingresultsrelativetoemployeeperformancecompensationtargetsunlikeearningsbeforeprovisionfortaxesonincome netearningsattributabletojohnsonjohnsonandnetearningspershareattributabletojohnsonjohnsondilutedprepared inaccordancewithgaapadjustedearningsbeforeprovisionfortaxesonincomeadjustednetearningsattributableto johnsonjohnsonandadjustednetearningspershareattributabletojohnsonjohnsondilutedmaynotbecomparable withthecalculationofsimilarmeasuresforothercompaniesthelimitationsofusingthesenongaapfinancialmeasuresas periodsuchastheeffectsofanacquisitiontheorthoclinicaldiagnosticsdivestiturerestructuringlitigationandchangesin applicablelawsandregulationsincludingsignificantaccountingortaxmattersanddonotprovideacomparableviewofthe measuresinadditiontoandnotasreplacementsfororsuperiortomeasuresoffinancialperformancepreparedinaccordance withgaap johnsonjohnsonannualreportoperational sale growth segment exclude acquisition divestiture consumer pharmaceutical medicaldevice total operational wwasreporte sanitaryprotection diagnostic orthoclinicaldiagnostic allotheracquisitionsanddivestiture wwopsexcludingacquisitionsanddivestiture operationalgrowthexcludestheimpactofcurrencytranslation operationalsalesgrowthexcludingthenetimpactofacquisitionsanddivestituresisanongaapfinancialmeasure investorsshouldconsidernongaapfinancialmeasuresinadditiontoandnotasreplacementsfororsuperiorto measuresoffinancialperformancepreparedinaccordancewithgaapduetothevariablenatureofacquisitionsand divestituresandtheimpacttheymayhaveontheanalysisofunderlyingbusinessperformanceandtrendsmanagement believesthatprovidingthismeasureenhancesaninvestorsunderstandingofthecompanysperformanceandmayassist intheevaluationofongoingbusinessoperationsperiodoverperiodthisnongaapfinancialmeasureispresentedto permitinvestorstomorefullyunderstandhowmanagementassessestheperformanceofthecompanyincludingfor internalevaluationoftheperformanceofthecompanysbusinessesandplanningandforecastingforfutureperiodsthe useofthisnongaapfinancialmeasureasaperformancemeasureislimitedinthatitprovidesaviewofthecompanys resultsofoperationswithoutincludingalleventsduringaperiodandmaynotprovideacomparableviewofthecompany performancetothatofothercompaniesinthehealthcareindustry johnsonjohnsonannualreport board director senior management alexgorsky alexgorsky chairmanboardofdirector chiefexecutiveofficer chairmanexecutivecommittee marysuecoleman presidentemeritauniversityofmichigan dominicjcaruso vicepresidentfinance jamesgcullen chieffinancialofficer retiredpresidentandchiefoperatingofficer memberexecutivecommittee bellatlanticcorporation douglaskchia dscottdavis corporatesecretary chairmanandformerchiefexecutiveofficer assistantgeneralcounsel unitedparcelserviceinc stephenjcosgrove ianeldavis corporatecontroller chairmanrollsroyceholdingsplcformerchairman chiefaccountingofficer andworldwidemanagingdirector mckinseycompany joaquinduato worldwidechairmanpharmaceutical susanllindquist memberandformerdirectorwhiteheadinstitutefor petermfasolo biomedicalresearchprofessorofbiology vicepresidentglobalhumanresource massachusettsinstituteoftechnology memberexecutivecommittee markbmcclellan jorgemesquita seniorfellowineconomicstudiesand worldwidechairmanconsumer directoroftheinitiativeonvalueand michelorsinger innovationinhealthcarebrookingsinstitution worldwidechairmanglobalorthopaedics annemmulcahy johnapapa formerchairmanandchiefexecutiveofficer treasurer xeroxcorporation sandraepeterson leofmullin groupworldwidechairman retiredchairmanandchiefexecutiveofficer memberexecutivecommittee deltaairlinesinc garyjpruden williamdperez worldwidechairmanglobalsurgery retiredpresidentandchiefexecutiveofficer wmwrigleyjrcompany michaelesnee vicepresidentglobalcorporateaffair charlesprince retiredchairmanandchiefexecutiveofficer paulusstoffel citigroupinc chiefscientificofficer worldwidechairmanpharmaceutical aeugenewashington memberexecutivecommittee vicechancellorofhealthsciencesdeanofthedavid geffenschoolofmedicineattheuniversityofcalifornia michaelhullmann losangelesuclachiefexecutiveofficerofthe vicepresidentgeneralcounsel uclahealthsystem memberexecutivecommittee ronaldawilliams kathrynewengel formerchairmanandchiefexecutiveofficer vicepresidentjohnsonjohnsonsupplychain aetnainc jessejwu chairmanjohnsonjohnsonchina johnsonjohnsonannualreportprincipaloffice commonstock johnsonjohnsononline onejohnsonjohnsonplaza listedonnewyorkstockexchange wwwjnjcom newbrunswicknewjersey stocksymboljnj shareholderrelationscontact wwwjnjcomournewscenter annualmeete douglaskchia theannualmeetingofshareholder corporatesecretary wwwblogjnjcom willtakeplaceonthursdayaprilat thestatetheatrelivingstonavenuenew investorrelationscontact brunswicknewjerseythemeetingwill louisemehrotra wwwfacebookcomjnj conveneatameasternall vicepresidentinvestorrelation shareholdersasoftherecorddateof wwwtwittercomjnjcare februaryarecordiallyinvitedto wwwtwittercomjnjnews attendaformalnoticeofannualmeete wwwyoutubecomjnj proxystatementandproxyhavebeenmade transferagentandregistrar availabletoshareholder questionsregardingstockholdingscertificatereplace wwwlinkedincomcompany menttransferdividendsandaddresschangesshould johnsonjohnson corporategovernance bedirectedto copiesofourannualreporton computershare formkfiledwiththesecuritiesand pobox toviewtheonlinejohnsonjohnson exchangecommissionproxy collegestationtx yearinreviewpleasegoto statementandthisannualreportare overnightcorrespondenceshouldbesentto wwwyearinreviewjnjcomorscanthis availableonlineatwwwinvestorjnjcomor computershare qrcode toshareholderswithoutchargeupon qualitycirclesuite writtenrequesttotheofficeofthe collegestationtx corporatesecretaryatourprincipal shareholderwebsite addressorbycalle wwwcomputersharecominvestor shareholderonlineinquirie onthecorporategovernancesectionofour httpswwwuscomputersharecominvestor websitewwwinvestorjnjcomshareholder contact canviewourfilingswiththesecuritiesand exchangecommissionincludingquarterly dividendreinvestmentplan reportsonformqandcurrentreport ourdividendreinvestmentplanallowsforfullor onformkrestatedcertificateof partialdividendreinvestmentandadditionalweekly incorporationbylawsprinciplesof cashinvestmentsuptoperyearin corporategovernancechartersoftheaudit johnsonjohnsoncommonstockwithoutpershare committeecompensationbenefit orservicechargesonstockpurchasesifyouare interestedinparticipatingintheplanandneedan committeenominatingcorporate enrollmentformandormoreinformationpleasecall governancecommitteeregulatory theplanadministratorcomputersharetrust compliancegovernmentaffair companynaator committeeandsciencetechnology outsidetheusorgotowwwcomputersharecom sustainabilitycommitteepolicyonbusiness investor conductforemployeescodeofbusiness conductethicsformembersoftheboard hearingimpaire ofdirectorsandexecutiveofficersandother shareholderswhohaveinquiriesregardingstock corporategovernancematerialscopiesof relatedmatterscancommunicatedirectlywith thesedocumentsareavailabletoshareholder computersharetrustcompanynaviaa telecommunicationsdevicetddthetelephone withoutchargeuponwrittenrequesttothe numberforthisserviceisor corporatesecretaryatourprincipaladdress outsidetheus undersectionofthesarbanesoxleyact electronicdeliverynotification wearerequiredtofilecertificationssignedby ourproxystatementandthisannualreportare thechiefexecutiveofficerandthechief availableonourwebsiteatwwwinvestorjnjcom financialofficerasexhibitstoourformk annualreportscfmshareholderswhoarestill orformqforeachfiscalyearorquart receivingpapercopiesofourproxystatementsand inadditionwearerequiredtosubmita annualreportsbymailcanelecttoreceiveinsteadan certificationsignedbythechiefexecutive emailthatwillprovidealinktothosedocumentson officertothenewyorkstockexchange theinternetshareholderswhoholdtheirsharesin withindaysfollowingtheannualmeete theirownnamemayenrollintheelectronicproxyand ofshareholderscopiesofthecertification annualreportaccessserviceforfutureannualmeeting filedforpreviousyearsarepostedonthe onlineatwwwcomputersharenacomgreen corporategovernancesectionofourwebsite thejohnsonjohnsonannualreport shareholderswhoholdtheirsharesbeneficiallyin andfuturecertificationswillbeposte containsmanyofthevaluabletrademarksand streetnamethatisinthenameofabankbrokeror promptlyuponfile otherholderofrecordandwishtoenrollforelectronic tradenamesownedandusedbythejohnson accessmayregisteratenrollicsdeliverycomjnj johnsonfamilyofcompaniesintheunite statesandinternationallytodistinguish productsandservicesofoutstandingquality johnsonjohnson shareholder informationcare world person time inspire unite people scan code view digital version johnson johnson annual report